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General introduction and outline of thesis
A straightforward guide to the basic science behind 
cardiovascular cell-based therapies.
Interrogating TGF-β Function and Regulation in 
Endothelial Cells.
ENDOGLIN is dispensable for vasculogenesis, but 
required for vascular endothelial growth factor-
induced angiogenesis.
Exosomes from Cardiomyocyte Progenitor 
Cells and Mesenchymal Stem Cells Stimulate 
Angiogenesis Via EMMPRIN.
Cardiac Progenitor Cell-Derived Extracellular 
Vesicles Reduce Infarct Size and Associate with 




















Cardiovascular diseases such as myocardial infarction, heart failure and stroke are the 
major cause of mortality in the world.1 In the case of a myocardial infarction, one of the 
arteries supplying the heart gets blocked, e.g. by a blood clot due to a ruptured athero-
sclerotic plaque. This blockage causes a disruption in the supply of oxygen and nutrients 
to part of the cardiac muscle, leading to ischaemia. In the affected area, oxygen sensitive 
cells start to die while cardiomyocytes try to adapt their metabolism to the hypoxic condi-
tions. Opening of the occluded blood vessel aims at containing the damage to the cardiac 
tissue, but the sudden inflow of oxygen also has a downside: it leads to the generation of 
reactive oxygen species (ROS), which are particularly harmful for the cardiomyocytes.2 
The death of cells causes the release of several chemokines and cytokines, which attracts 
inflammatory cells such as neutrophils and monocytes to the ischaemic area. During this 
inflammatory phase, granulation tissue is formed. Here, the inflammatory cells contrib-
ute by clearing the infarcted tissue from cell and matrix debris, while fibroblasts provide 
strength to the weakened cardiac wall.3,4 The initial inflammation is ‘dampened’ by the 
release of anti-inflammatory cytokines. This switch is also marked by a decrease in M1/
pro-inflammatory macrophages and an increase in M2/anti-inflammatory phenotype.5 
These macrophages also release pro-angiogenic cytokines, stimulating angiogenesis in 
the (borderzone of) the infarcted area. In this proliferative phase, endothelial cells form 
new blood vessels in order to restore the blood flow to the damaged myocardium. Due 
to the loss of cardiomyocytes and the degradation of the extracellular matrix (ECM) by 
matrix metalloproteinases (MMPs) released by the inflammatory cells, the cardiac wall is 
weakened. In an attempt to strengthen the wall and avoid rupture of the heart, cardiac 
fibroblast proliferate and deposit ECM proteins, like collagen I, at the site of infarction.
Ideally, the lost cardiomyocytes are replaced during the proliferative phase. However, the 
general consensus is that the heart is a post-mitotic organ. Progenitor cells have been 
found in the heart that are capable of differentiating to cardiomyocytes, endothelial cells 
and smooth muscle cells,6,7 but their number is too few to respond to the extensive dam-
age after a myocardial infarction. Recent research has shown that cardiomyocytes are 
capable of limited proliferation, but this too is not sufficient to repair the affected area.8 
Thus, the lost tissue is replaced by fibroblasts, which form a collagen rich scar. The reduc-
tion in contractile tissue results subsequently in an increase in load for the residual cardi-
ac tissue. The decreased contractile force is partly compensated through enlargement of 
the remaining cardiomyocytes.9  If the infarct is small enough, the heart is capable to deal 
with the changes in cardiac load. However, when the biomechanical stress is too great, 
compensatory hypertrophy is insufficient and heart failure is the result. 
Regenerative Therapies
There is little that can be done to prevent the progression to heart failure. Presently, the 
only treatment that is being offered in the clinic to aid in the occurrence of heart failure 
is a left-ventricular assist device (LVAD), which helps to relieve the left side of the heart 
of the pressure. However, this is not a long term solution and only offers support until a 




the occurrence of a MI, since this is the optimal time window to minimize the loss of cardi-
omyocytes and thereby prevent ‘later’ heart failure. Therefore, this kind of therapy would 
ideally reduce the initial damage, restore the cardiomyocytes that have been lost and last-
ly prevent the formation of a scar that would hinder cardiac function. Since this is a lot 
to be expecting from a therapy, most of the research focusses to achieve at least one of 
these requirements. Restoration of cardiac function by replacing the lost cardiomyocytes 
is a strategy explored by many different labs. Cell therapy has been a straightforward 
approach in which the cells are directly injected into the myocardium. The mode of action 
of these cells can be multifold, namely differentiation into cardiomyocytes, supporting 
endogenous regeneration, or/and protecting the affected cells.  Several different cell types 
have been studied for their regenerative potential, each with distinctive advantages and 
effects. Among these are bone marrow cells, mesenchymal stem cells and cardiac progen-
itor cells. All of these have shown positive effects on cardiac function in the preclinical 
phase and are being under investigation in clinical trials.10–15 However, even though cell 
therapy with bone marrow cells and mesenchymal stem cells has been effective to some 
point, these cells are not able to differentiate into cardiomyocytes.16,17 Induced pluripo-
tent stem cells have the potential to differentiate towards every cell type and do indeed 
increase cardiac function and vascularization, but still hold the danger of teratoma and 
tumor formation.18–21 Progenitor cells from the heart are multipotent and differentiate into 
cardiomyocytes, endothelial cells and smooth muscle cells.7,22 Injection after MI showed 
their in vivo regenerative potential, but also the progenitor cells have encountered prob-
lems.6,12,23 Cell retention and survival in the hostile environment of the infarcted heart is 
still a great challenge, as well as successful coupling to the existing myocardium. (Cell 
therapy for cardiac repair is reviewed in Chapter 2) More recently, another strategy has 
evolved in which new cardiomyocytes are formed by induction of transdifferentiation of 
fibroblasts. Initial successful transdifferentiation rate so far has been low, but it has po-
tential to introduce new cardiomyocytes even in the event of a fully formed scar.24
Even though cell therapy has not been as successful yet as had been expected, the results 
obtained so far have given more insight in how the damage in the infarcted heart can be 
treated. Bone marrow and mesenchymal stem cell do not contribute to the myocardium 
but can still have a positive effect on the heart and its function. Moreover, cardiomyocyte 
progenitor  cells also positively affect the heart without differentiation into cardiomyo-
cytes.25 Therefore, other factors from the cells affect the regenerative processes in a bene-
ficial way. In order to benefit from cell therapy, it is important to understand the regener-
ative processes and their underlying signalling pathways, as well as how cell therapy can 
influence these processes.  
Cellular processes involved in myocardial wound healing
The processes taking place after a myocardial infarction are tightly orchestrated and all 
can be targeted for a regenerative therapy. Each stage is characterized by several develop-
ments, but some overlap does exist between the stages. In order to understand the poten-
tial effects of a therapy, it is important to comprehend what mechanism can be affected at 
which time. An overview of the phases after myocardial infarction and the corresponding 




Right after occlusion of the artery, the ischemia results in apoptosis and necrosis of the 
cardiomyocytes. Programmed cells death by means of apoptosis is the main cause of death 
(in the first two days), with necrosis affecting only a fraction of the dying cells.26,27  Sur-
vival signals that signal via Akt/Pi3-kinase signalling have been found to reduce apoptosis 
and infarct size.28 Release of cellular components such as cytokines due to necrosis results 
in a pro-inflammatory environment, which results in the recruitment/homing of inflam-
matory cells at the site of infarction. 
Figure 1: Phases and processes in the cardiac tissue after MI. Healthy myocardium has an intricate 
architecture of cardiomyocytes, interstitial cells and blood vessels. After MI, the loss of oxygen 
and nutrients results in the death of cells in the ischaemic region, followed by an inflammatory 
reaction. Next, blood vessels, fibroblasts and, to a much lower rate, cardiomyocytes start to 
proliferate. Lastly, a collagen scar is formed and the remaining tissue undergoes remodelling. 
Angiogenesis
The hypoxic environment of the infarct triggers the secretion of several pro-angiogen-
ic factors, such as  vascular endothelial growth factor (VEGF), stromal derived factor 1 
(SDF1), angiopoietin 2 (ANGPT2), placental growth factor (PlGF), platelet-derived growth 
factor B (PDGFB), and stem cell factor (SCF).29 These factors trigger the activation of en-
dothelial cells when the inflammation begins to resolve. During the initial inflammatory 
phase after MI, granulation tissue is formed in which the inflammatory cells clear the 
debris and the cardiac wall is strengthened by fibroblasts. When the inflammation starts 
to resolve, a shift is made to the proliferative phase in which the regenerative processes 
are stimulated by the above mentioned factors. Of these, VEGF, is considered one of the 
most potent pro-angiogenic factor. Binding of VEGF to its corresponding receptors on 
endothelial cells activates them, upon which they start to proliferate. They start to sprout 
and form new capillary networks into the ischaemic area, thereby attempting restore the 




Another cascade that is crucially important for the formation of new blood vessels is 
transforming growth factor β (TGF-β). TGF-β is rapidly upregulated in the borderzone of 
the infarct and the infarcted area 24-48hours after myocardial infarction.31,32. Binding of 
TGF-β to the activin receptor-like kinase 1 (ALK1) and its coreceptor Endoglin activates 
signalling via Smad1/5/8. Endoglin haploinsufficiency leads to several deficiencies related 
to angiogenesis and inflammatory cells. Vascular defects such as arteriovenous malfor-
mations and recurrent nosebleeds are common in HHT patients. Endoglin null mice are 
embryonically lethal due to cardiovascular developmental defects. Thus TGFbeta mediat-
ed signalling via ALK1 is important for proper angiogenesis.
Proliferation, Migration and EndoMT
Besides endothelial cells, fibroblasts also become activated and start to proliferate.33 Con-
version to myofibroblasts is marked by expression of α-SMA. The first myofibroblasts 
are apparent in the infarcted area 4-6 days after MI and can persist for many years.34 
The conversion of fibroblasts to myofibroblasts is regulated by TGF-β, which also induces 
the proliferation of cardiac fibroblasts. TGF-β has been shown to induce upregulation of 
α-SMA, the formation of stress fibers, and changes the morphology of the cells in vitro.35 
The majority of the myofibroblasts develop from cardiac fibroblasts, but a small percent-
age potentially derives from endothelial cells. The increase of TGF-β induces the process 
of Endo-MT in endothelial cells, converting them to (myo)fibroblasts.36 Furthermore, car-
diac fibroblasts upregulate both collagen I and collagen III when stimulated with TGF-β. 
37 The upregulation of TGF-β after MI is responsible for these effects in vivo. Indeed, an 
increase is seen in the downstream mediators of TGF-β, namely Smad 2/3/4 expression, 
as well as an increase in the matrix proteins Collagen I and decorin in vivo. 38 Moreover, 
overexpression of TGF-β in mice resulted in an increase in interstitial fibrosis, while mice 
heterozygous for TGF-β show reduced fibrosis upon aging.39,40 Migration of the myofibro-
blasts into the injured area facilitate the formation of a scar, where the myofibroblasts 
deposit new collagen rich ECM.41
Differentiation of progenitor cells
During the healing process, the heart fails to replace the lost cardiomyocytes with new 
cells. It was long thought that the heart had no intrinsic regenerative capacity, but the 
finding of resident cardiac progenitor cells contradicted this notion. These cells have been 
shown to be able to differentiate into cardiomyocytes in vivo, as well as endothelial cells 
and smooth muscle cells. Injection of these cells after MI resulted in a long-term increase 
in cardiac function.6,7,22,23 This was accompanied by an increase in capillary density in the 
borderzone, showing increased angiogenesis.22,25,42 It was shown that even in the absence 
of functional differentiation, the progenitor cells were able to induce these effects after 
MI.25,42 These findings show that cardiac progenitor cells are able to positively affect car-
diac function through differentiation as well as via secreting paracrine factors that stim-
ulate the endogenous cells. Indeed, cardiac progenitor cells secrete several growth factors 
that are important in the regenerative process.42 
Further investigations have revealed that cardiac progenitor cells also secrete microvesi-
cles, which are able to contain multiple growth factors and cytokines, thereby conveying 
multiple messages at once. Since vesicles can be isolated from in vitro cell culture, they 
are an interesting method of applying paracrine factors for in vivo purposes and eventual 
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clinical therapies. Elucidating the effect of the microvesicles and their content responsible 
for these effects is therefore our goal.
Exosomes
Extracellular vesicles
How cells communicate with one another has long been thought to be restricted to mes-
sage conveyed by either secreted single agent proteins or direct communication via gap 
junctions. However, there are many more options a cell has to communicate with the rest 
of the body. A major constituent in paracrine signalling are the extracellular vesicles, a 
large group consisting of exosomes, and ectosomes or microvesicles. 
The extracellular vesicles are a diverse group with a maximum diameter of 100 µm. They 
have a bilipid membrane and the contents consist of proteins and RNAs from their donor 
cell. Communication through the vesicles can have a few distinct advantages: it is possible 
to send a bundle of proteins/RNAs at once; the recipient cell can be defined through spe-
cific proteins in the membrane of the vesicle; vesicles can act locally but also systemically. 
The differences between the individual microvesiscles are not clear yet. One group of 
microvesicles are the exosomes.  Even though a defined set of parameters is not specified, 
they are mostly seen as the smallest extra-cellular vesicle with a diameter of 30-150nm. 
They are a distinct vesicle population with specific protein content, since not all proteins 
from the cell are represented in the exosomes.43 A comparison between between cytokine 
and extracellular vesicle signalling is seen in Figure 2.
Exosome biogenesis
Exosomes are formed as part of the endosomal network in multivesicular bodies, instead 
of being shed from the plasma membrane such as ectosomes.44 It was found that fusion 
of these multivesicular bodies with the cell membrane resulted in the release of the vesi-
cles into the extracellular space.45 Thus, besides evidence of a pathway of vesicle release, 
proteins can be specifically transferred to these vesicles. The proteins and RNAs present 
in the exosomes are indeed a partial reflection of the cytoplasma of the cells, however, 
there are specific sorting mechanisms in place to control the contents. Sorting of proteins 
into exosomes can be done via two different pathways: via the ESCRT (endosomal sorting 
complexes required for transport) machinery or via sphingolipids and the formation of 
ceramides.
Fusion of the multivesicular body (MVB) with the cell membrane results in release of the 
exosomes in the intercellular space. The transport of the MVBs towards the cell mem-
brane is largely dependent on members of the RAB family. Several Rabs have been impli-
cated in the transport, such as Rab5A, Rab9A, Rab2B and Rab35, but the most prominent 
players are Rab 27A and Rab27B. Depletion of either of these proteins markedly decreased 
exosome secretion. The CD63 positive organelles with the ILVs were either retained in 
the cytoplasma and enlarged or accumulated around the nucleus as normal sized vesicles, 
depending on Rab27A or Rab27B knockdown, respectively.46,47 Subsequent fusion of the 




Proteins and RNA in exosomes
The exosomal content released by a cells is dependent on the processes present/active in 
a cell, i.e. which pathways are activated and which proteins/RNAs are present. Exosomes 
from several tumour lines which were diverse in their characteristics have been analysed 
for their proteins. The protein profiles indeed differed between the exosomes from the 
various tumour lines and represented the variances in cell behaviour, e.g. the invasiveness 
of the cells.49
Exosomes contain proteins which can directly affect the recipient cell. Interestingly, the 
protein content of the exosomes is somewhat dissimilar from the cells. It is known that 
exosomes lack for example endoplasmatic reticulum associated proteins, due to their na-
ture. However, one study has shown that especially proteins of the cytoskeleton, cell death 
associated proteins and signal proteins were more abundant in exosomes of breast cancer 
cells.50
Valadi et al have shown that exosomes also contain functional mRNAs that can be trans-
ferred to recipient cells. In these cells, the mRNA can be translated to proteins, thereby 
affecting the recipient cells. Besides mRNA, small RNAs such as miRNAs are also present, 
which, after processing by Dicer, can downregulated their targets.51 The specific compo-
sition of RNA in exosomes is to some extend similar to the composition in the cytoplasma 
Figure 2: Schematic overview of exosome signalling versus single cytokine signalling in recipient 
cells. Exosomes (left) are able to fuse with the cell membrane, thereby releasing their contents 
of proteins and RNAs, or they bind to receptors on the cell membrane upon which they are 
internalised via endocytosis. After internalisation, they fuse with the endosomal membrane and 
their content can enter the cytoplasm of the recipient cell. Cytokine signalling (right) depends on 
single cytokines to bind to their corresponding (co-)receptors on the cell membrane. After binding 
to the receptor, downward signalling is activated via, for example, kinases and phosphorylation, 
upon which the downstream effect is initiated.
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of the donor cell. However, there is specific shuttling to and from exosomes. Microarray 
data of hepatic cancer cells and their exosomes have shown that some miRNAs are more 
abundant in exosomes from all cell types, while others were only increased in some spe-
cific cell types. Thus, miRNAs can be selectively sorted into exosomes.52,53 Several miRNAs 
have been found to be exclusively in exosomes, and are not present in the parent cells.54 
The same has been shown for mRNAs; the levels present in the cytoplasm do not always 
correspond the levels found in the secreted exosomes.55
Exosomes and cardiovascular regeneration
The importance of paracrine factors has also become apparent in cardiovascular research. 
Over the last few years, exosomes from a variety of cells and conditions have been inves-
tigated for their ability to protect the heart and aid in its regeneration. One of the first 
studies to show that paracrine factors and especially microvesicles have a beneficial effect 
after myocardial infarction was done by TImmers et al. They showed that injection of me-
dium conditioned by MSCs could confer short term beneficial effects, such as a reduction 
infarct size and apoptosis, as well as long term improvement of cardiac function, capillary 
density and scar formation. Further investigation into the conditioned medium ruled out 
single proteins or growth factors, but rather pointed at the larger constituents, namely 
microvesicles.56
So far, CPCs and MSCs have been the most popular donor cells for exosome studies in 
cardiac regeneration, but also pluripotent stem cells have been investigated. Studies have 
shown that exosomes from these cells are able to reduce apoptosis in cardiomyocytes, 
showing cardioprotective effects.57–60 Furthermore, angiogenesis was stimulated in mi-
gration and tubule formation assays.61–63 When studied, proliferation was also increased 
in cardiomyocytes, endothelial cells or CPCs.58,61,62,64,65 Two studies have shown that inhibi-
tion of exosome release abrogates the affect, thereby confirming the role of exosomes.62,66 
Exosomes can not only affect several of the processes after a myocardial infarction, but 
are also modified according to the environment and state of the cell. Proliferation and 
migration has been shown to be induced by tumour exosomes, as well as cell invasion.67,68 
Angiogenesis has also been shown to be stimulated upon exosome uptake by for example 
induction of endothelial cell proliferation.55 Environmental cues such as low oxygen ten-
sion or hypoxia have been shown to increase the angiogenic potential of exosomes, among 
other effects.69 The ability to affect these processes and being able to manipulate the effect 
of the exosomes makes them highly versatile means of cardiac regenerative therapy.
Scope of this thesis
In this thesis, the processes and signalling pathways involved in cardiac repair are studied. 
Cell therapy has been an important part of regenerative research and therefore much 
effort has been put in researching the potential of various cells to repair the damaged 
myocardium. In Chapter 2, an overview is given regarding the research into cell therapies 
and their impact on cardiac regeneration. Since the cause of damage after MI is mainly 
caused by ischaemia, the formation of new blood vessels is important for restoring the 




the migration of cells into the infarcted zone. This process of angiogenesis can be studied 
in several ways in vitro, which are described in Chapter 3. Multiple signalling cascades are 
involved in the different phases of angiogenesis, among which VEGF and TGF-β. The role 
of TGF-β is ambiguous, since it can both induce and inhibit angiogenesis, depending on 
external factors and through which (co)receptors of TGF-β is signalling. How the TGF-β 
co-receptor Endoglin affects vasculogenesis and angiogenesis is investigated in Chapter 4. 
Growth factors and cytokines are not the only agents responsible for intercellular signalling. 
Cells are capable of conveying a plethora of signals via the secretion of exosomes. Since 
these exosomes can contain multiple mRNAs, miRNAs and proteins, they are capable of 
presenting an entire package of signals for the recipient cell, ranging from proliferation 
to EMT and angiogenesis. Cardiac progenitor cells are also capable of secreting these 
exosomes and in Chapter 4 we investigated how these exosomes specifically affected 
angiogenesis in vitro and in vivo. After a myocardial infarction, multiple processes take 
place such as removal of the damaged cells, reinstating the blood flow to the affected tissue 
and scar formation. In the heart, the regeneration capacity of the endogenous cells is not 
sufficient to replace all lost tissue with new working myocardium. An effective therapy 
could address this at two points: to generate new myocardial cells or reduce the damage 
done after the myocardial infarction. The most efficient course of action would be to 
address both points in the course of the healing process. Exosomes are the perfect agents 
for a rapid therapy, as they convey multiple messages and are swiftly taken up by the 
recipient cells. Therefore, in Chapter 5 we researched the short-term effect of exosomes 
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It has been over a decade since the concept of cell-based therapy was coined as a method 
to treat patients who suffered the consequences of myocardial infarction (MI). Shortly 
after promising preclinical results emerged, a rapid translation to the clinic was made 
using stem cells isolated from a variety of sources, including bone marrow mononuclear 
cells (BM-MNC), mesenchymal stem cells (MSC) and cardiac progenitor cells (CPC). The 
hypothesis was that transplanted stem cells would provide cues that enhance the wound 
healing process, and locally differentiate into new contractile cardiac tissue. However, 
although the clinical trials have been shown to be safe, only a relatively small effect on 
cardiac function has been observed. It has become clear that each cell type applied in cell-
based therapy has its own ability for cardiac repair. Basic knowledge of each cell popula-
tion’s behaviour and its ability to interfere in different stages of post-MI wound healing 
may enable us to design an optimised cell-based therapy.
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The promise of cardiovascular cell-based therapy
Myocardial infarction (MI) is the foremost cause of heart failure and successive mortal-
ity in the Western world.1 Recently developed treatments for patients suffering MI aim 
to reopen or bypass the culprit vessel to restore normal flow in the heart. While this 
has drastically prolonged life-expectancy, none of these therapies actually treat the loss 
of contractile tissue and the subsequent replacement by a stiff fibrotic scar. Both events 
will result in compensatory remodelling of the surviving tissue and a decreased cardiac 
function that will ultimately culminate in heart failure. Currently, the only real cure for a 
damaged heart is cardiac transplantation.
Since adult cardiac myocytes are unable to proliferate sufficiently to replace damaged 
tissue, cellbased therapy is being pursued as a new approach to repair the damaged heart. 
The concept being that stem or progenitor cells delivered locally to the injured area dif-
ferentiate into new cardiac tissue leading to regeneration of cardiac muscle. Moreover, 
these cells may produce cytokines or growth factors that potentially induce angiogenesis 
to reinstate blood flow and influence scar remodelling.
To date, several different sources of human cells have been explored for their regenerative 
potential. In this review, we will summarise how these clinically applicable cell popula-
tions may act to contribute to cardiac repair after MI.
The different stages of post-myocardial infarct repair
The healing response initiated after MI is recognised by different overlapping phases, each 
benefitting differently from cell injection (Figure 1). As such, it is important to understand 
the different processes encompassing these phases.
Inflammation
Upon occlusion of a coronary vessel, the tissue at the site of MI is instantly subjected to a 
severe hypoxic environment. Subsequent necrosis of cardiomyocytes triggers an inflam-
matory response leading to immune cells infiltrating the infarcted tissue that secrete addi-
tional pro-inflammatory cytokines and growth factors (Figure 1). Importantly, infiltrated 
neutrophils and macrophages aid in the clearing of dead cells and debris.2 Additionally, 
macrophages play a role in the remodelling of the extracellular matrix by producing, for 
instance, matrix metalloproteinases (MMP). Although the inflammatory response is crit-
ical for clearance of cell debris and initiation of wound healing, an exaggerated response 
can lead to devastating results such as heart rupture (reviewed in 2).
Proliferation and scar formation
After the removal of dead cells, the infarcted ventricular wall is severely weakened. Fibro-
blasts will start to proliferate and migrate towards the site of injury, where they differen-
tiate into myofibroblasts (Figure 1). Because of low oxygen levels after MI, many proan-
giogenic factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast 
growth factor (bFGF), are released leading to the generation of new vessels in the infarct/
borderzone. During the proliferation phase, a more complex capillary network is formed.3
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Figure 1: Stages in infarct healing. Healing of myocardial infarction consists of 3 overlapping 
stages, each identified by different processes. Top row shows H&E staining of a murine LV wall 
throughout the three phases after MI, at days 3, 7 and 14, respectively. Below is a magnification 
at the cellular level for each phase. Depicting from left to right: disruption of cardiac tissue and 
the influx of immune cells, thinning of the ventricular wall and proliferation of fibroblasts, infarct 
distention and the collagen scar. For each phase, the processes and cells involved are listed, 
together with the potential cell therapy has.
Late in the healing process, during the maturation phase, myofibroblasts start to pro-
duce large quantities of extracellular matrix proteins of which collagen is the main com-
ponent. As a result, the granulation tissue is slowly being replaced by a rigid fibrotic 
scar. By yet unknown processes, the myofibroblasts undergo apoptosis, leaving a mature, 
collagen-rich scar, designed to keep the ventricular wall together.3
LV remodelling
MI affects the ischemic area, as well as the entire ventricular wall. Reduced wall strength 
causes infarct expansion. The replacement of cardiomyocytes by a collagen scar increases 
the contraction forces on the remaining viable tissue. The increased ventricular wall stress 
results in late remodelling, which involves hypertrophy of surviving cardiomyocytes and 
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alterations in ventricular wall structure.4 LV remodelling is a final attempt of the heart 
to compensate for the loss of contractile tissue and the increased wall forces, leading to 
LV enlargement and wall thinning (Figure 1). LV remodelling is a time-dependent process 
and closely correlated to the histological damage at the infarct site. Although LV remodel-
ling will largely stop when the tensile strength of the scar counterbalances the distending 
forces, it will never fully compensate for the loss of cardiomyocytes.4
Cell populations used for cardiovascular cell-based therapy
In an attempt to identify a cell type that has the potential to contribute in the repair of the 
infarcted heart, several populations of human cells have been isolated and progressed into 
clinical trials. Three of the most studied cell types include bone marrow mononuclear cells 
(BM-MNC), mesenchymal stem cells (MSC), and cardiac-derived progenitor cells (CPC). 
Each of these populations has a distinct potential for cardiac repair.
Bone marrow mononuclear cells
BM-MNCs represent the most extensively studied cell population for cell-based therapy. 
BM-MNC transplantation was translated to the clinic relatively fast, and over the last few 
years, a multitude of clinical trials have shown that injection of BM-MNCs results in a 
(modestly) increased EF, smaller end-diastolic and end-systolic volumes, and a reduced 
infarct size.5
There are several explanations for this strong clinical interest in BM-MNCs; first, they 
can easily be obtained under GMP conditions by density gradient centrifugation of 
bone marrow aspirates. Second, since there is no requirement for ex vivo amplification, 
BM-MNCs allow for autologous application shortly after MI. Third, BM-MNCs represent a 
heterogeneous cell mixture containing several types of stem and progenitor cells includ-
ing haematopoietic stem cells (HSC), MSCs and endothelial progenitor cells. All these have 
been hypothesised to either have the ability to differentiate into cardiac cell types, or to 
provide paracrine signals that support the post-injury healing response (reviewed in 6).
To elucidate the mechanisms by which BM-MNCs influence cardiac function, in vitro and 
preclinical experiments were performed. The first studies in mice suggested that injection 
of bone marrow-derived HSCs shortly after MI resulted in generation of cardiac tissue via 
differentiation of HSCs into cardiomyocytes,7 and endothelial cells.8 Although subsequent 
preclinical studies failed to corroborate the reported regeneration,9,10 a small but signifi-
cant effect on cardiac function was observed.10 Interestingly, a direct cellular contribu-
tion to cardiac improvement is unlikely since the number of surviving transplanted cells 
rapidly declined within a few weeks posttransplantation.10,11 Additionally, the observation 
that injection of an extract of bone marrow cells had an equal effect on cardiac function 
compared to cell injection,12 strongly supports a role for secreted chemokines, cytokines 
and growth factors in BM-MNC-induced cardiac repair.
This ‘paracrine hypothesis’ was further substantiated by in vitro studies using human 
BM-MNCs obtained from patients after acute MI. The isolated cells stimulated the prolif-
eration and migration of coronary artery endothelial cells and enhanced tube formation. 
Furthermore, BM-MNCs protected rat cardiomyocytes from ischaemic cell death.13 
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A similar effect was observed when BM-MNCs were injected 3 days after MI; within days, 
an increase in vascular density and cardiomyocyte proliferation occurred in the border-
zone, accompanied by a decrease in apoptosis.12 Extract of bone marrow cells was shown 
to act similarly on the injured myocardium, again underpinning the importance of parac-
rine effects.12 These data suggest that BM-MNCs secrete proangiogenic and anti-apoptotic 
factors beneficial for the heart in the early stages postinjury.
In an attempt to specify the secreted factors involved in these processes in vivo, Shintani 
et al investigated the expression of a panel of 15 factors and found that the increased neo-
vascularisation after injection of BM-MNCs into the damaged heart was accompanied by 
an upregulation of Fgf2 and Hgf mRNA.14 Li et al studied the impact of individual trans-
planted cells by isolating single green fluorescent protein (GFP)-labelled BM-MNCs from 
cardiac tissue sections, 5 days after their injection into the infarcted mouse heart.15 Inter-
estingly, real-time PCR-array revealed that there is a heterogeneous expression profile 
of growth factors between different cell types. One population (CD45+) appeared to be 
mostly responsible for the production of angiogenic factors including VEGFs, IGF1 and 
TGFβ, while CD45− cells expressed factors that are involved in remodelling of the extra-
cellular matrix (MMP2, MMP9, TIMP1),15 which, as a net result, could lead to a reduction 
in scar volume.
Another mechanism by which cell transplantation can augment cardiac function post-MI 
is by stimulating the endogenous cardiomyocyte progenitor cell pool. An elegant study 
using mice with transgenically labelled cardiomyocytes illustrated that injection of bone 
marrow-derived c-kit+ cells resulted in the formation of new (and thus unlabelled) car-
diomyocytes after MI.16 Whether this effect is maintained when injecting the whole bone 
marrow fraction remains to be investigated.
Mesenchymal stem cells
Since infarct healing requires modulation of the immune response, matrix remodelling 
and cell growth and differentiation (Figure 1), MSCs have been considered a very promis-
ing cell population for cell-based therapy. MSCs are generally isolated from bone marrow 
aspirates by using their ability to adhere to plastic. However, since the number of MSCs in 
human bone marrow is low, MSCs require expansion in culture to obtain sufficient num-
bers for application. In theory, MSCs have the capacity to differentiate into cell types be-
longing to the mesodermal lineage including skeletal muscle, smooth muscle, and poten-
tially cardiomyocytes, depending on the tissue source they were acquired from. Only em-
bryonic or foetal-derived MSCs were shown to differentiate into cardiomyocytes in vitro, 
albeit at low frequency.17 Cardiomyogenic differentiation of hMSCs in vivo is a rare event, 
and since transplantation of MSCs promoted healing of the injured myocardium without a 
high incidence of engraftment,18,19 a direct cellular role of MSCs for cardiac repair post-MI 
is unlikely.20 A potential paracrine contribution during the inflammation phase is under-
scored by in vitro experiments showing that MSCs are able to produce anti-inflammatory, 
anti-apoptotic and proangiogenic cytokines.21 Additional supporting evidence came from 
a study injecting MSC-conditioned medium early post-MI, which showed increased capil-
lary density and preserved cardiac function.22
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During the remodelling phase, MSCs may decrease cardiac fibrosis by producing MMPs,23 
or inhibiting collagen production by cardiac (myo)fibroblasts via secretion of fibrotic 
growth factors like TGFβ.24 In an attempt to further enhance their therapeutic potential, 
several studies have genetically modified MSCs. Transplantation of MSCs overexpressing, 
for example, Akt,25 and IGF-1,26 further improved heart function when compared to MSCs 
in experimental models for MI by stimulating angiogenesis and remodulating the fibrous 
scar.
Compared to clinical trials using BM-MNCs, only a very limited number of patients have 
been treated with MSCs. So far, both intravenous infusion of ex vivo-expanded MSCs or 
intramyocardial injection with, for example, a NOGA catheter to improve delivery and 
prolong retention of MSCs shortly after MI has been shown to be safe and to improve car-
diac function. A 5-year follow up showed that the event-free survival and cardiac function 
are comparable with the control group.27,28
Cardiac progenitor cells
Historically, the heart was considered to be an organ without any intrinsic renewal ca-
pacity; hence, the discovery that new cardiomyocytes are formed during life was remark-
able.29 Concurrence with the identification of cells in the heart bearing markers for stem 
cells, as well as early cardiac myocytes30 resulted in the hypothesis that the heart contains 
cardiac progenitor cells (CPC) that can act as ‘tissue stem cells’. To date, three CPC popu-
lations isolated from human heart tissue are being prepared for clinical application. These 
include cardiomyocyte progenitor cells (CMPC), c-kit+ cardiac stem cells (CSC) and car-
diosphere-derived cells (CDC), of which the latter two have entered phase 1 clinical trials.
Although the specific cell characteristics of these CPC populations are slightly different, 
they all possess the intrinsic capacity to differentiate into the three basic cell types of 
the heart: cardiomyocytes, endothelial cells and smooth muscle cells (reviewed in 31). As 
such, CPCs have a distinct advantage over MSCs and BM-MNCs; they could actually con-
tribute to the damaged myocardium by fully replacing lost contractile tissue. However, 
by contrast with BM-MNCs, isolation of autologous cells from cardiac tissue biopsies is 
labour-intensive, has a low yield, and requires several weeks of amplification to obtain 
clinically relevant amounts of cells.
Human CPCs are the only adult mammalian cells that have shown true differentiation into 
(beating) cardiomyocytes in vitro with upregulation of cardiac proteins and the formation 
of striated sarcomeres. Moreover, stimulating CMPCs with in vitro resulted in sponta-
neous beating and resting membrane potentials nearing that of adult cardiomyocytes. 
CMPCs were shown to couple electrically and metabolically, with surrounding cells32 
which would be an important feature of transplanted cells. 
Preclinical studies injecting human CPCs into the borderzone of an infarcted murine heart 
shortly after the onset of MI showed that CPCs are able to survive, to locally differentiate 
into cardiac cell types, and to have a positive effect on infarct size, vascularisation, scar 
formation and LV function.30,33,34 Interestingly, in the case of CMPCs, in situ differentiation 
into cardiomyocytes appeared to occur beyond 2 weeks postinjection, while a positive 
effect on cardiac function was recorded prior.35 Additionally, although formation of new 
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cardiac tissue was observed, the number of surviving cells at 3 months alone could not ac-
count for the increased EF and vascularisation. In vitro experiments confirmed that under 
hypoxic conditions, CMPCs express many cytokines and growth factors, including VEGF 
and MMPs, that would favour vascularisation and scar tissue remodelling.36
Since isolation and expansion of cardiac-derived progenitor cells for clinical application 
will require several weeks of cell culture, it is important to evaluate the potential of CPCs 
when introduced into an established infarct. Interestingly, in both rat and porcine models, 
transplantation long after MI still resulted in myocardial regeneration with an increase 
in LV function, indicating that there would be a window to amplify autologous cells pre-
transplantation.37,38
Two different phase I clinical trials using injections of autologous CPCs were recently 
initiated, applying either CDCs (CADUCEUS) or c-kit+ CSCs (SCIPIO) transplantation af-
ter at least 1 month post-MI. Both studies show that the therapy is safe, and results in 
reduction in scar mass. In the CDC study, functional analysis after a 12-month follow-up 
showed that in the cell-treatment group, scar size was reduced and the viable tissue mass 
increased.39,40 Local increases in cardiac function were detected in both studies, however, 
the SCIPIO trial also reports a global effect on EF.40 This could potentially be explained by 
the difference in cell type used.
Future perspectives
Never before has the translation from an idea to actual application in patients proceeded 
as quickly as in cardiovascular cell-based therapy. Therefore, it is good to realise that this 
field is still in its infancy. Just a decade ago, proposing to regenerate the injured myocardi-
um would have been considered science fiction. So far, it is evident that administration of 
adult stem cells is safe and promotes healing of the infarcted heart. Although considerable 
strides have been made gaining insight in the biology behind cell based therapy, there are 
still several unanswered questions and important issues to explore, especially since the 
results in patients appear slightly disappointing compared to the outcomes of preclinical 
and in vitro studies.
One of the reasons for the discrepancies between clinical and preclinical studies may be 
because a patient receives his or her own cells, which are likely relatively old and have 
been exposed to diseased circumstances for years. Several studies show that the paracrine 
profile and the composition of the bone marrow change with age or disease. This will have 
a major impact on the efficiency of these cells and the outcome of cell-based repair.41–43
A way to circumvent patient variability and maintain paracrine stimulation during the 
early phase of myocardial healing would be the application of exosomes. Exosomes are 
small lipid-layered vesicles, containing proteins and micro-RNAs capable of stimulating 
growth, migration and angiogenesis.44 Exosomes are secreted by stem and progenitor 
cells; after isolation from conditioned medium, exosomes can be used off the shelf, ex-
ploiting the beneficial paracrine effects of cells in a treatment directly available after MI.
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Another aspect to improve upon, is the low number of transplanted cells that are present 
in the heart after transplantation. Unfortunately, many of the injected cells are immedi-
ately ejected out of the heart after the first heartbeat. Moreover, when they do settle in the 
heart, the cells are exposed to a hostile environment, which may not benefit their surviv-
al. Therefore, combining cells with biomaterials that can enhance retention and provide 
a nourishing environment before injection into the heart wall may provide the heart 
with a larger number of cells that can participate in repair. For any cell to improve con-
tractility, a relatively large number of cells need to integrate and differentiate in the dam-
aged LV wall.
Finally, the most promising population for cardiac repair is CPCs, but their isolation and 
amplification are time consuming. A better approach might be to stimulate the CPCs lo-
cally within the cardiac niche to proliferate, migrate and differentiate in situ. Identifying 
small molecules able to stimulate the endogenous regenerative potential of the heart may 
have significant therapeutic potential.
In conclusion, cell-based therapy is an exciting and very promising field to explore for 
treating cardiovascular disease, but investigating the processes that underlie potential 
repair is crucial to understand how to optimise treatment.
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Transforming growth factor-β (TGF-β) is a multifunctional cytokine with important roles 
in embryogenesis and maintaining tissue homeostasis during adult life. There are three 
isoforms of TGF-β, i.e., TGF-β1, -β2, and -β3, which signal by binding to a complex of 
transmembrane type I and type II serine/threonine kinase receptors and intracellular Smad 
transcription factors. In most cell types TGF-β signals via TGF-β type II receptor (TβRII) 
and TβRI, also termed activin receptor-like kinase 5 (ALK5). In endothelial cells, TGF-β 
signals via ALK5 and ALK1. These two type I receptors mediate opposite cellular response 
for TGF-β. The co-receptor endoglin, highly expressed on proliferating endothelial cells, 
facilitates TGF-β/ ALK1 and inhibits TGF-β/ALK5 signaling. Knockout of TGF-β receptors 
in mice all result in embryonic lethality during midgestation from defects in angiogenesis, 
illustrating the pivotal role of TGF-β in this process. This chapter introduces methods for 
examining the function and regulation of TGF-β in angiogenesis in in vitro assays using 




Angiogenesis, the growth of new blood vessels from existing vessels, is an important pro-
cess during development but also plays a role in pathological situations such as tumor 
progression and metastasis. At a certain point during tumor growth, the existing blood 
vessels do not provide sufficient nutrients and oxygen to the tumor, and tumor cells will 
start to produce and secrete proangiogenic factors and reduce the expression of antiangi-
ogenic factors to stimulate the formation of new blood vessels: the “angiogenic switch”.1 
Besides the major factor known to stimulate angiogenesis, vascular endothelial growth 
factor (VEGF), many other growth factors such as transforming growth factor-β (TGF-β), 
bone morphogenetic protein-9 (BMP-9), basic fibroblast growth factor (bFGF), and an-
giopoietin-2 (ANG-2) are also involved in the angiogenic switch.2 Of these, TGF-β plays 
an ambiguous role, either stimulating or inhibiting the formation of new blood vessels.3,4
In part the mechanism underlying these differential effects is that TGF-β signals in en-
dothelial cells via distinct receptors. In most cell types TGF-β exerts its cellular effects via 
TGF-β type I receptor (TβRI), also termed activin receptor-like kinase5 (ALK5), and TβRII. 
TGF-β signaling via the TβRII/ALK5 complex induces the phosphorylation of Smad2 and 3, 
which form heteromeric complexes with Smad4. The Smad complex translocates into the 
nucleus and regulates target gene expression.5,6 Endothelial cells selectively express ALK1, 
another TGF-β type I receptor, and the co-receptor endoglin. Endoglin favors TGF-β/ALK1 
signaling, which induces the activation of Smad1, 5, and 8. TGF-β regulates the activation 
state of endothelial cells by differentially signaling via ALK1 and ALK5; in general, ALK5 
inhibits endothelial cell proliferation and migration, and ALK1 induces opposite respons-
es.4 Depending on the culture conditions and cell types involved, the responses down-
stream of ALK1 may differ.
To study the complex role of TGF-β signaling or other potential regulators during angi-
ogenesis and the effect of for example proangiogenic or antiangiogenic therapies, many 
different assays are available that focus on the different phases of angiogenesis. We dis-
cuss the endothelial cell spheroid sprouting assay, fetal bone metatarsal explant assay, 
and the angiogenic differentiation of embryoid bodies from embryonic stem cells, which 
cover different aspects of the angiogenic process. With the spheroid assay, the capacity of 
endothelial cells to invade, migrate, and form tubular structures can be studied. Endothe-
lial cells are allowed to adhere and form small balls, “spheroids”, which will be embedded 
in collagen. The embedded collagen spheroids will form sprouts when proper stimuli are 
given. This encompasses the basic components for angiogenesis and can therefore provide 
a complete picture. The spheroid assay is very suitable to be used as a screening tool for 
investigating for example the effect of inhibitors and stimulators of the TGF-β pathway.7,8 
However, these spheroids only contain endothelial cells. When investigating the involve-
ment of mural cells other assays, like the metatarsal and embryoid body assay, are more 
suitable. For the metatarsal assay the primary outgrowth of an endothelial plexus from 
metatarsals is analyzed, and the organization of the endothelial cells and the coverage 
by pericytes can be investigated. Interestingly, genetic effects, studying metatarsals iso-
lated from a knockout mouse, as well as the effect of various extracellular physiological 
cues and compounds can be studied.9 The metatarsal assay mostly focuses on endothelial 




the other hand encompasses most processes involved in angiogenesis, because embryonic 
stem cells (with or without genetic alteration) are allowed to differentiate into endothelial 
cells and supporting mural cells. When EBs embedded in a 3D collagen gel are stimulated 
with angiogenic factors, the endothelial cells will invade the surrounding matrix and form 
endothelial sprouts. Besides these endothelial cells, perivascular cells are also present and 
provide a supportive network to the endothelial cells, like the in vivo situation.8,10,11 Using 





• Endothelial cell culture, e.g., human umbilical vein endothelial cells (HUVECs).
• Trypsin–ethylenediaminetetraacetic acid (EDTA).
• 1.2 % methocellulose (Sigma) in M199.
• Endothelial cell growth media (EGM)2: EBM-2 with supplemented growth factors 
(Lonza).
• U-bottom 96-well plates (Greiner Bio-One, Cat. No. 650185).
• Collagen Embedding
• 96-well plate.
• PureCol (Advanced Biomatrix).
• NaOH (1 M).
• EGM-2.
• Vascular endothelial growth factor (VEGF).
Metatarsal Assay
• Metatarsals from mouse embryo day 17 or 18.
• 0.1 % gelatin in phosphate buffered saline (PBS).
• Plastic foil.
• Medium: alpha MEM with 10 % FBS.
• 24-well tissue culture plate.
• Zink Macrodex Formalin: 1 mL of formaldehyde solution with 9 mL of Zink Macrodex 
solution.
• mQ water.
• 40 % methanol/1 % H2O2 solution.
• 0.5 % Boerhringer Milk Powder (BMP)/TBS with Tween (TBST).
• Antibody of choice, e.g., ERMP12 for CD31 staining.
• 1 % 3-amino-9-ethylcarbazole (AEC) stock solution.
• 0.1 M acetate-acetic acid, pH 5.0.




EB Formation by Hanging Drops
• ES cell culture (e.g., R1-ES cells)
• Trypsin–EDTA.
• 0.1 % gelatin in PBS.
• ES medium: Dulbecco’s Modified Eagle’s Medium (DMEM) (high glucose 4.5 g/Land 
l-glutamine, Gibco Invitrogen) supplemented with 15 % fetal bovine serum, 25 mM 
HEPES, 1 mM sodium pyruvate, 0.1 mM β-mercaptoethanol, 1× penicillin/streptomy-
cin.
• Multichannel pipette p200.
• Bacterial dishes.
• Sterile mQ water.
2D and 3D Culture of EBs
• Collagen solution: PureCol with 34.65 % HAM’s F12, 6.25 % NaOH (0.1 M), 6.25 % 
10× F12, 1.25 % 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (1 M), 
0.975 % sodium bicarbonate 7.5 % and 0.625 % GlutaMAX.
• Tissue culture plates: 6, 12, and 24 wells.
• VEGF, PeproTech 100 ng/μL.
•	 Staining of EBs
• 4 % paraformaldehyde in PBS.
• PBS.
• Blocking buffer: 3 % BSA in TBST.
• TBST.
• Antibody of choice.




1. Detach HUVECs by trypsinization and count cell number.
2. Dilute cells to a concentration of 7500 cells/mL in EGM-2 with 0.24 % methylcellu-
lose (1:5 solution of stock methylcellulose) (see Note 1).
3. Pipette 100 μL of cell suspension into suspension U-bottom 96-well plates.
4. Culture cells overnight in humidified incubator at 37 °C and 5 % CO2.
5. Collagen Embedding
6. Make cold collagen solution containing 2/3 EGM-2 with 0.5 % 1 M NaOH (e.g., 2 mL 




7. Keep collagen mixture on ice.
8. Pipette 50 μL of collagen mixture in wells of 96-well plate.
9. Incubate for 1 h at 37 °C to solidify collagen.
10. Gently collect spheroids with p1000 multichannel and collect in 9 cm tissue culture 
dish.
11.  Transfer spheroids to 15 mL tube and centrifugate for 5 min at 170 × g.
12. Slowly remove supernatant and gently resuspend spheroids in collagen mixture: 10–
12 spheroids per 50 μL.
13. Pipette 50 μL of spheroid/collagen mix on collagen coated wells.
14. Incubate for 1 h at 37 °C to solidify collagen.
15.  Add 100 μL of EGM-2 to wells with 50 ng/mL VEGF (final VEGF concentration is 25 
ng/mL).
16. Culture for 2 days at 37 °C, 5 % CO2.
17. Sprouting of HUVECs can be assessed by microscopy (Fig. 1) (see Note 2).




1. Isolate metatarsals from a mouse embryo at day 17 or 18 of gestation (see Note 3).
2. Coat plates with 0.1 % gelatin for 15 min.
3. Add 180 μL of medium (alpha MEM with 10 % FBS) to each well and place the meta-
tarsals in the middle of the well (one metatarsal per well). Make sure metatarsals do 
not float by adding a glass coverslip on top of the metatarsal to push the metatarsal 
down.
4. Wrap the plates with plastic foil and incubate at 37 °C and 5 % CO2 for 3 days (see 
Note 4).
5. On day 3, gently remove the coverslips and old medium and add 250 μL of new me-
dium with desired stimuli.
6. Incubate plates for 7 days.
7. At day 7, remove the medium and gently wash the wells twice with PBS.
8. Fix the bones in Zink Macrodex Formalin for 15 min.
9. Wash twice with mQ water.
10. Preserve the plates with 500 μL of PBS per well for 2 days.
11. Add 500 μL of 40 % methanol/1 % H2O2 per well to block endogenous peroxidase 
activity and incubate at RT for 30 min.
12. Wash twice quickly with PBS and once with TBST for 5 min while gently shaking.
13. Add 245 μL of 0.5 % BMP/TBST and incubate for 1 h at 37 °C.
14. Add first antibody to the well, wrap plates to avoid evaporation of the liquid with 
plastic foil and incubate overnight at 4 °C (see Note 5).
15. Wash twice with TBST for 5 min while gently shaking.
16. Add 250 μL of secondary antibody to each well in 0.5 % BMP/ TBST and incubate at 
37 °C for 45 min.
17. Wash twice with TBST and once with mQ water for 5 min while gently shaking.
18. Add 250 μL of Streptavidin HRP 1:200 in 0.5 % BMP/TBST per well and incubate at 
37 °C for 30 min.
19. Repeat step 18.
20. Add 500 μL of AEC stock solution + 4500 μL 0.1 M acetateacetic acid, pH 5.0, mix 
well.




22. To start staining add 2 μL of H2O2 30 % to the AEC solution and incubate for 10 min 
at room temperature.
23. Stop staining reaction by washing three times with mQ water.
24. Add 500 μL of PBS per well and store at 4 °C for max 14 days (wrap well in plastic foil 
to avoid evaporation). EC outgrowth can be assessed by microscope analysis (Fig. 2).
Figure 2: Outgrowth of endothelial cells from metatarsals cultured with or without VEGF.
EB Assay
EB Formation by Hanging Drops
1. Trypsinize ES cells and wash once with medium. Make sure you have a single cell 
suspension (see Note 6).
2. Seed ES cells ±45 min in a gelatin coated 6-well tissue culture plate in ES medium to 
allow mouse embryonic fibroblasts (MEFs) to adhere to the plate while leaving the 
ES cells unattached.
3. Collect supernatant containing ES cells and count number of cells.
4. Dilute cell suspension to a concentration of 60 × 103 cells/mL.
5. Use multichannel pipette to pipette drops of 20 μL of the cell suspension onto lid of a 
10 cm bacterial dish.
6. Fill bottom dish with sterile water to prevent evaporation.
7. Invert lid and place on top of dish, resulting in hanging drops (Fig. 3a).




1. EBs can be embedded either as single or multiple EBs per well. Single EBs are usually 
cultured in 24-well plates while 12 plates are used for culturing multiple EBs.
2. Coat tissue culture plate with collagen: 750 μL for 12-well plate, 400 μL for 24-well 
plate and allow to polymerize overnight.
Embedding single EB culture
1. Invert lid containing hanging drops carefully.
2. Pick up EB from drop with 200 μL pipette (tip shortened 2–3 mm in order not to 
damage EB).
3. Place EB in wells of the 24-well plate with a minimum amount of medium.
4. Remove excess medium.
5. Put 350 μL of collagen on top.
6. Allow to solidify for 3 h (see Note 8).
7. Add 750 μL of ES medium containing 60 ng/mL VEGF on top (final concentration 30 
ng/mL).
Embedding multiple EB culture
1. Take lid of the dish and keep upside down.
2. Harvest EBs by ticking lid at 45° angle in a clean 9 cm tissue culture dish, thereby 
collecting EBs and medium in dish.
3. Collect EBs with P1000 (tip shortened 2 mm in order not to damage EBs) and put in 
15 mL tube.
4. Allow EBs to settle at the bottom and remove supernatant.
5. Add collagen to the EBs (10–15 EBs per 750 μL), resuspend carefully and plate EBs 
in the 12-well plate; 750 μL EB/collagen suspension per well, resulting in 10–15 EBs 
per well.
6. Allow to solidify for 3 h.
7. Add 1.5ml ES-medium containing 60ng/ml VEGF on top (final concentration 30ng/
ml).
8. Culture EBs for 8–14 days, depending on sprouting of EBs and desired end-stage. 
Medium should be changed every 4 days (Fig. 3c).
2D Culture




2. Harvest EBs by ticking lid at 45° angle in a clean 9 cm dish, thereby collecting EBs 
and medium in the dish.
3. Collect EBs with P1000 (tip shortened 2–3 mm in order not to damage EBs) and put 
in 15 mL tube.
4. Allow EBs to settle at the bottom and remove supernatant.
5. Resuspend in ES-DMEM containing 50 ng/mLVEGF (10–13 EBs per mL).
6. Add 2 mL of EB suspension to gelatin coated 6-well plate resulting in 20–25 EBs per 
well.
7. Culture EBs for up to 21 days, depending on desired endstage. 2D cultures can be used 
for RNA, DNA, and protein isolation as well as FACS analyses and stainings.
Staining 3D Culture
1. Remove medium completely.
2. Wash collagen three times with PBS for a total of 20 min at room temperature.
3. Fix with 4 % paraformaldehyde for 30 min at room temperature.
4. Wash with PBS.
5. Cut collagen loose of rim of well.
6. Remove collage carefully from well and place in lid of petri dish.
7. Localize EBs under a microscope and cut away excess collagen without disrupting EBs 
and sprouts.
8. Put the (clusters of) EBs in a 24-well plate containing PBS.
9. Block with blocking buffer for 2 h or overnight at room temperature.
10. Add primary antibody in blocking solution (concentration depending on antibody) 
and incubate overnight at 4 °C.
11. Wash four times with TBST.
12. Add secondary antibody in blocking solution and incubate overnight at 4 °C.
13. Wash two times with TBST.
14. Stain with Hoechst for 10 min.
15. Wash two times with TBST.
16. Store at 4 °C with PBS.




Figure 3: (A) Schematic overview of the EB assay, from hanging drops till 2D and 3D culture. 
(B) EB after 4 days of hanging drop culture.  (C) Sprouting  of an EB from R1-ES cells after 8 
days of stimulation  with VEGF, bright- field picture. (D) EB of R1-ES cells after 8 days  of VEGF 




1. In the spheroid assay, the methocellulose solution should be free of any contaminat-
ing particles, which will interfere with the formation of spheroids.
2. The spheroid assay protocol is optimized to ensure best sprouting and is very useful 
to study inhibition of angiogenesis. When investigating stimulation of angiogenesis, 
sub-optimal conditions should be used.
3. It is important to isolate the embryos for the metatarsal assay from the uterus and 
keep them in PBS with calcium and magnesium on ice until isolating the metatarsals. 
It is better to do one mouse at a time for optimal condition of the bones, max 2.
4. It is best to place the plate with the metatarsals in the back of the incubator and espe-
cially the first 2–3 days. Do not slam the door, otherwise the bones will float.
5. Staining for CD31 on the metatarsals should be done using the ERMP12 antibody to 
get the best results.
6. The ES cells should be in optimal condition before making embryoid bodies, i.e., all 
colonies should be undifferentiated.
7. Make sure that the hanging drops are not disturbed during the 4 day culture, other-
wise the EBs might not form tight clusters. Ideally the EBs should have a compact, 
round appearance.
8. The second layer of collagen with the EBs should contain no air bubbles and should 
polymerize at least 3 h, to ensure the layers will not be split when the medium is 
added to the wells. It will result in reduced sprouting if the layers are not properly 
attached.
9. The extent to which the EBs sprout varies with the genetic background of the ES cells 
used. This is important to take into account and test when using this assay. Specifi-
cally great care should be taken when knockout ES cells are compared to wild type ES 
cells. This should always be compared to wild type cells with the same background, 
preferentially isolated in the same procedure as the mutant ES cells.
10. Besides angiogenesis, the EB assay encompasses the differentiation from ES cell to 
endothelial cells. Genetic alterations, e.g., knockdown or overexpression, that inter-
fere with the differentiation of ES cells can result in aberrant angiogenesis and con-
found the results.
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ENDOGLIN Is Dispensable for Vasculogenesis, 





ENDOGLIN (ENG) is a co-receptor for transforming growth factor-b (TGF-β) family 
members that is highly expressed in endothelial cells and has a critical function in the 
development of the vascular system. Mutations in Eng are associated with the vascular 
disease known as hereditary hemorrhagic telangiectasia type l. Using mouse embryonic 
stem cells we observed that angiogenic factors, including vascular endothelial growth 
factor (VEGF), induce vasculogenesis in embryoid bodies even when Eng deficient cells 
or cells depleted of Eng using shRNA are used. However, ENG is required for the stem 
cell derived endothelial cells to organize effectively into tubular structures. Consistent 
with this finding, fetal metatarsals isolated from E17.5 Eng heterozygous mouse embryos 
showed reduced VEGF-induced vascular network formation. Moreover, shRNA-mediated 
depletion and pharmacological inhibition of ENG in human umbilical vein cells mitigated 





During development of the embryo, blood vessels evolve de novo from hemangioblasts 
that differentiate into endothelial cells and form a primary vascular plexus. This pro-
cess is defined as vasculogenesis.1 Angiogenesis refers to the remodeling and maturation 
of this primitive vascular network into a branched vascular network.2 Angiogenesis is a 
dynamic and carefully balanced process involving an activation phase associated with 
increased vascular permeability, basement membrane degradation, endothelial prolifera-
tion and migration, and a resolution phase accompanied by inhibition of endothelial cell 
proliferation and migration, in parallel with basement membrane reconstitution.3 In the 
maturation phase the recruitment of pericytes and vascular smooth muscle cells is needed 
to maintain vessel stability and protect endothelial cells from apoptosis.4,5 
Vascular endothelial growth factor (VEGF) plays a very prominent role in vasculogenesis 
and angiogenesis. VEGF represents a family of related cytokines, of which the VEGF-A 
isoform is a potent endothelial mitogen strongly induced by hypoxia.6 Mice lacking one 
Vegfa allele die at embryonic day (E)8.5 as a result of vascular malformations.2,7 VEGF-A 
signaling occurs via the high affinity tyrosine kinase receptors VEGFR1 (FLT-1), and VEG-
FR2 (FLK-1);8,9 VEGFR2 is the important endothelial VEGF receptor during angiogenesis. 
Vegfr2 knockout mice die at E8.5 from impaired development of hematopoietic and en-
dothelial cells10 and closely resemble VEGF-A deficient embryos.
Endoglin (ENG or CD105) is a transmembrane glycoprotein essential for angiogenesis and 
vascular development, which is predominantly expressed in vascular endothelial cells.11 
Mice lacking Eng die at E10.5-E11.5 from angiogenic and cardiovascular defects. The early 
steps of vasculogenesis appear to be normal but the primary endothelial network fails to 
remodel into a mature circulatory system.12–14 ENG functions as a co-receptor for trans-
forming growth factor-b (TGF-β) family members, and interacts with their signaling ser-
ine/threonine kinase receptors.15,16 TGF-β relays its signal via Type I receptors (TbRI), 
also termed as activin receptor-like kinases (ALKs). TbRI acts downstream of type II re-
ceptors (TbRII)17 and mediates the activation of intracellular SMAD effector transcription 
factors.18 In endothelial cells, TGF-β can signal via two different TbRIs, ALK1 and ALK5.3,19 
Activation of ALK1 induces SMAD1 or 25 phosphorylation and mediates endothelial cell 
proliferation and migration, whereas ALK5 induces SMAD2 and -3 activation leading 
to vascular quiescence.3,20 ENG promotes ALK1/Smad1/5 signaling and inhibits ALK5/ 
SMAD2/3 signaling.21–23 ENG and ALK1 have also been shown to bind other TGF-β family 
members. Bone morphogenetic protein (BMP) 9, in particular, can bind directly and with 
high affinity to ENG and ALK1.24,25
In humans, mutations in Eng lead to hereditary hemorrhagic telangiectasia type I (HHT1, 
also known as Rendu-Osler-Weber syndrome), while HHT2 is associated with mutations 
in the type I receptor, ALK1.26,27 HHT is an inherited autosomal- dominant vascular dis-
order that affects the blood vessels of many organs. Characteristic symptoms include 
epistaxis (nosebleeds), skin and mucosal telangiectases associated with hemorrhage, as 
well as pulmonary, cerebral and hepatic arteriovenous malformations.28,29
During the differentiation of mouse embryonic stem cells (ESCs) in vitro, hematopoietic 
commitment within Vegfr2+ precursor populations are characterized by Eng expression.30 
ENDOGLIN in VEGF induced angiogenesis
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In particular, Eng is expressed during the progression from the Vegfr2+Cd45- to Vegfr2-Cd45+ 
stage, marking the hemangioblast.31 In Eng deficient ESCs, the number of hemangioblast 
precursors were reduced and myelopoiesis and definitive erythropoiesis were severely 
impaired, suggesting that the regulated expression of ENG functions to support lineage-
specific hematopoietic development from VEGFR2+ expressing precursors.30,31 Additional 
studies with forced expression of ENG in ESCs and transcriptional profiling studies on 
ENG+ and VEGFR2+ expressing cells from E7.5 embryos further supported an important 
role for ENG in hematopoietic development.32,33
In the present study, we examined the role of ENG in vasculogenesis and angiogenesis 
using aggregates of ESCs known as embryoid bodies (EBs). We found that endothelial cell 
differentiation was not affected by a lack of ENG, but that VEGF-induced angiogenesis was 
severely impaired. The effects were dependent on the level of Eng. heterozygotes exhib-
ited an intermediate phenotype, reminiscent of features in HHT1 patients. These results 
were validated and consolidated by shRNA-mediated Eng depletion and pharmacological 
ENG inhibition studies in endothelial cells. The impaired VEGF- induced endothelial cell 
sprouting in the absence of ENG might provide a suitable cell model to screen for drugs 
that can rescue this phenotype, which might lead to novel treatment modalities.
Results
Absence of Eng impairs organization of vascular structures in 15-day-old embryoid 
bodies
To elucidate the role of ENG in blood vessel morphogenesis we examined the effect of 
Eng gene dosage using the established assay of differentiation of ESCs into EBs.34 When 
induced to differentiate, Eng+/- or Eng-/- ESC lines13 were found to form EBs of similar 
size and compactness to those of wild type EBs (Fig. 1A). Next, the assembly of vascular 
structures was analyzed by platelet endothelial cell adhesion molecule (PECAM)-1 stain-
ing of sections of ESC-derived EBs with different Eng gene dosage (Eng+/+, Eng+/- or Eng-/-) 
obtained after 15 days of differentiation embedded in plastic and sectioned (Fig. 1B). Mor-
phology of the vasculature formed in wild type ESC-derived EBs was very similar to that 
of the yolk sac in wild type mouse embryos (Fig. 1B). Multiple blood islands, lined with a 
single layer of thin elongated endothelial cells, were found between the outer endoderm 
and the inner ectoderm layers (Fig. 1B), as reported previously by Wang et al.35 The num-
ber of blood islands in Eng-/- ESC-derived EBs appeared less numerous than in the wild 
type ESC-derived EBs and endothelial cells were found in clusters rather than in elongated 
single cell layers, confirming the defective formation of vessel-like structures in Eng2/2 
ESC-derived EBs (Fig. 1B). Vascular structures also developed in Eng+/- ESC-derived EBs, 
but their frequency and organization were markedly reduced compared to those in wild 
type ESC-derived EBs, indicating a dose dependent effect of Eng on vascular organization 
(Fig. 1B).
ENG does not affect endothelial cell differentiation
Two processes are responsible for the formation of blood vessels during embryonic 
development: (i) vasculogenesis, the primary in situ differentiation of endothelial pre-
cursors from mesoderm, and their organization into a primary capillary plexus and 
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Figure 1: Impaired vasculature in Eng null-mutation ESC-derived 11-day-old EBs. (A) Eng +/-or 
Eng -/-  ESC lines form EBs with no difference when compared to EBs derived from wild type ESCs 
(B) PECAM-1 whole mount immunohistochemistry of representative wild type, Eng +/-, and Eng 
-/-  ESC-derived 11-day-old EBs. Wild type ESC-derived EBs form a primitive vascular plexus. In 
contrast, Eng-/-  ESC-derived EBs form irregular vascular structures with endothelial cell clusters. 
Light microscopy of serial plastic sections of wild type, Eng+/- and Eng -/-  ESC-derived 11-day-
old EBs stained as whole mount for PECAM-1. Black arrowhead indicates vessel like structures. 
Asterisk indicates endothelial cell clusters.
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(ii) angiogenesis, the formation of new vessels by a process of sprouting from pre-existing 
vessels.1,36 RT-PCR analysis of endothelial cell specific markers on ESC-derived EBs col-
lected from days 0 to 20 were used to define the role of ENG during endothelial cell dif-
ferentiation. Distinct gene expression patterns were induced as differentiation proceeded. 
Vegfr1 was rapidly upregulated at day 3 and Vegfr2, Tie-1 and Tie-2 more prominently at 
day 5 (Fig. 2A). The expression patterns of the different EC markers were similar in Eng-
/- ESC-derived EBs. In addition, we determined the number of PECAM-1 positive cells in 
dissociated 11-day-old EBs by FACS analysis and found no differences between wild type, 
Eng+/- or Eng-/- ESC-derived EBs (Fig. 2B). Analysis of the expression of multiple peri-
cyte-vascular smooth muscle markers by RT-PCR also did not reveal striking differences 
between ESC-derived EBs with different Eng gene dosage (Fig. 2C). Taken together, our 
results show that ENG is not required for endothelial and mural cell differentiation.
Endothelial cell organization is disrupted in Eng-/- ESC-derived EBs plated on gel-
atin
EBs plated on a gelatin-coated substrate can develop branching vascular structures in-
dicative of vascular morphogenesis.37 Endothelial cells are initially aggregated in dense 
clusters but when plated, rapidly form thin branching tubes, in a process resembling an-
giogenesis. To determine the role of ENG in this process, we plated 11-day-old EBs derived 
from Eng+/+, Eng+/- and Eng-/- ESCs and maintained them in culture for four additional 
days before staining them with an antibody to PECAM-1 and hematoxylin to reveal the 
vascular network. Three different phenotypes could be identified in the EBs: (i) those 
with an extensively branched vascular network without endothelial cell clusters catego-
rized as ‘‘organized’’, (ii) those forming some vessels and still containing endothelial cell 
clusters referred to as ‘‘intermediate’’, (iii) those with endothelial cells clusters only; these 
were designated as ‘‘dispersed’’ (Fig. 3A). Of around 90 EBs scored in each case in two 
independent experiments, on average about 63% of Eng+/+ EBs showed an organized phe-
notype, ~26% an intermediate phenotype and only ~11% a dispersed phenotype (Fig. 
3B). By contrast, in the Eng-/- EBs, ~39% lacked cord-like structures entirely and were 
classified as dispersed, whereas ~59% had an intermediate phenotype. Furthermore, the 
length of the vessel sprouts that did form was greatly reduced compared to those of the 
Eng+/+ EBs and vessels appeared often wider. Quantitative analysis also showed that an 
intermediate vascular phenotype predominated in the Eng+/- EBs with ~20% dispersed 
and ~60% intermediate phenotypes (Fig. 3B). When EBs were embedded into a collagen 
gel and allowed to form vascular sprouts in 3D, we observed a reduction in both number 
of sprouts and sprout length in the Eng-/- EBs (Fig. S1).
To validate the data obtained with the Eng-/- ES cell line we depleted Eng by shRNAs tar-
geting Eng in ESCs. Essentially we obtained the same results as for ESCs in which gene 
dosage was reduced (Fig. 4). Partial knock down of Eng in ESC in differentiated EBs (Fig. 
4B, 4C) interfered with efficient VEGF- induced sprouting (Fig. 4D), whereas expression 
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Figure 2: Expression of endothelial-specific markers during vascular development in EBs. 
(A) RT-PCR analysis of endothelial cell markers was performed on ESC and EBs cultured for the 
indicated number of days. Abbreviations: PECAM, platelet endothelial cell adhesion molecule; tie, 
tyrosine kinase with immunoglobulin-like loop and epidermal growth factor homology domain; 
VEGF, vascular endothelial growth factor receptor (B) The number of PECAM-1 positive cells was 
quantified by FACS analysis of the cell suspension of wild type, Eng +/−, and Eng −/− ESC-derived 
11-day-old EBs. (C) RT-PCR analysis of pericyte-smooth muscle cell markers was performed on 
ESC and EBs cultured for the indicated number of days. PCR primers used in this Figure are 
available upon request. Abbreviations: Aebp, adipocyte enhancer binding protein; Axl, a receptor 
tyrosine kinase; Smooth; Smoothelin B; Cspr, cysteine- and glycine-rich protein; Cspg, chondroitin 




Figure 3: Eng −/− ESC-derived EBs plated on gelatin coated plates lack organized vessel 
structures. (A) PECAM-1 immunohistochemical staining of ESC-derived 11-day-old EBs plated 
on gelatin for 4 days displayed “organized”, “intermediate” or “dispersed” phenotype. (B) 
Quantification of wild type, Eng +/−, and Eng −/− ESC-derived 15-day-old EBs vascular phenotypes 
as they were defined in A.
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Figure 4: shRNA-mediated knock down of Eng inhibits VEGF-induced endothelial cell 
sprouting of EBs. ES cells were transduced with either scrambled or endoglin targeting shRNA. 
ES cells formed EBs during 4(30 ng/ml). Sprouting EBs were analyzed after 8 days of VEGF 
stimulation. A) Control EBs and EBs with incomplete endoglin knockdown stained for endothelial 
marker PECAM-1 (green) and DAPI (blue). Control EBs have large and many outgrowing sprouts 
of endothelial cells, which form extensive networks. EBs with incomplete Eng knockdown show 
less sprouts, which do not seem to form as extensive networks as control EBs. Sheets of cells that 
are mostly PECAM-1 negative have formed between the sprouts. B) Control EBs and EBs with 
incomplete Eng knockdown stained for ENG (green) and nuclear marker hoechst (blue). ENG is 
present in the entire sprout in the control EBs, with the highest expression towards the tip of the 
sprout. In the EBs with incomplete knockdown showed expression of ENG mainly in the tips of 
the outgrowing sprouts. The cellular sheets hardly had ENG expression. C) qPCR analysis of Eng, 
PECAM-1 and VE-cadherin expression during differentiation of the control and Eng knockdown 
ES cells. Endoglin expression is reduced by approximately 85% in the ES cells, but during 
differentiation, at day 7 and 9, expression is restored to half of the normal levels. Expression of 
Vegfr2 and VE-cadherin did not significantly differ between control and endoglin knockdown 
EBs at the ES cell state or at day 7 and 9 of differentiation. D) Analysis of number of tips per EB. 
Endoglin knockdown EBs exhibit significantly less sprouts than the control EBs (p<0.01).
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VEGF-induced angiogenesis is reduced in fetal metatarsals from Eng+/- mice
In the studies above, VEGF was provided as the angiogenic stimulus. VEGF is a potent mi-
togen for endothelial cells and elevated ENG expression has been associated with activat-
ed endothelial cells in tumor stroma.38 To investigate a possible interplay between VEGF 
and ENG in angiogenesis, we compared the VEGF-induced angiogenic response in fetal 
mouse metatarsals derived from wild type and Eng+/- mice. After adherence of the fetal 
bones to the culture dish, fibroblast-like cells migrate from the bones to form a monolayer, 
on which a tubular network of endothelial cells is formed.38,39 Staining of this endothelial 
cell network with an antibody to PECAM-1 showed that the VEGF- induced angiogenic re-
sponses, as measured by the number and the length of capillary sprouts were significantly 
reduced in the Eng+/- metatarsals (Fig. 5). This result suggests that ENG is required for 
efficient VEGF-induced angiogenesis.
Inhibition of ENG expression or function mitigates VEGF- induced sprouting of HU-
VECs
To elucidate the role of ENG in VEGF-induced endothelial sprouting, we used a 3D-en-
dothelial cell spheroid-sprouting assay, an established model for studying early in vitro 
angiogenic responses.40 Non-stimulated spheroids of human umbilical vein endothelial 
cells (HUVECs) in collagen remain quiescent, and mimic the quiescent endothelial cells 
in the vessel wall. When stimulated with VEGF, tube-like protrusions emerge from the 
HUVEC spheroid within one day. We observed that shRNA- mediated depletion of Eng 
Figure 5: VEGF-induced angiogenesis is impaired in Eng +/ − fetal metatarsal bones. 
Metatarsals of 17-day-old mouse fetuses were prepared from wild type and Eng +/− mice, 
transferred to cell-culture plates, allowed to adhere, and then stimulated with VEGF (50 ng/
ml). (A) Cultures were fixed and vessel-like structures were visualized by anti-PECAM-1 staining. 
Six bones were stimulated per experimental group and one representative picture of each group 
is shown. (B) VEGF addition stimulated the formation of vessel-like structures. No significant 
difference in the baseline vascular network formation was observed between wild type and Eng 
+/− metatarsals. The induction of the vascular network of wild type metatarsals is significantly 
stronger than the network of Eng +/− metatarsals. P≤0.05.
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in HUVECs significantly reduced the VEGF-induced response in this assay (Fig. 6A, B). 
In addition, treatment of HUVECs with the ENG neutralizing antibody TRC105 also mit-
igated this response (Fig. 6C), confirming that inhibition of ENG function attenuates the 
VEGF-induced angiogenic response.
Direct VEGF-induced signaling is not affected in Eng deficient cells
The data above suggest an involvement of ENG in the VEGF signaling pathway or cross-
talk between ENG and the VEGF pathway. We therefore further investigated the effect of 
ENG on VEGF signaling. The first event in the VEGF signaling cascade is binding of VEGF 
to its receptor, VEGFR2. However, specific depletion of Eng in HUVECs using shRNA did 
not affect VEGF binding to VEGFR2 as measured by affinity crosslinking with radiolabeled 
VEGF (data not shown). After VEGF-VEGFR2 interaction, VEGFR2 autophosphorylates 
itself at amino acid 1175, and thereafter initiates activation of the ERK kinase pathways. 
However, analysis of VEGF-induced VEGFR2, phospho-ERK pathways did not reveal any 
significant changes upon Eng knock down (Fig. 6D). These data indicate that ENG defi-
ciency does not affect VEGF-induced ERK signaling directly.
Discussion
In the present study, we examined the role of ENG in vasculogenesis and angiogenesis 
using aggregates of mouse ESCs known as EBs that were challenged with angiogenic sup-
porting factors, including VEGF. Under appropriate conditions, both vasculogenesis and 
angiogenesis take place in EBs.41–45 We compared EBs from wild type mouse ESCs with 
those from mouse ESCs with heterozygous or homozygous deletions in Eng (Eng+/- and 
Eng-/-, respectively). We found that the endothelial cell differentiation program in ESC-de-
rived EBs is not affected by homozygous deletion of Eng. However, homozygous mutant 
endothelial cells were severely inhibited in their ability to form organized vascular struc-
tures either following plating of EBs on gelatin in 2D or in 3D collagen gels, supporting 
evidence for an essential role of ENG in VEGF-mediated angiogenesis. This is consistent 
with reports by Bourdeau et al.13, Li et al.14 and Arthur et al.12, and more recently by Park 
et al..46 However these data are different from earlier reports on the Eng-/- ESCs claiming 
no effect on endothelial cell organization in differentiating embryoid bodies. However, dif-
ferent methods were used, which might have contributed to the different outcomes.47 To 
validate the defect in sprouting of Eng-/- ESC lines compared with control Eng+/+ ESC, we 
depleted Eng by shRNA. Essentially we were able to confirm the results obtained using the 
knock out cells in that they are also defective in VEGF-induced endothelial cell sprouting, 
albeit not as dramatically as knock out cells. shRNA-mediated depletion has the advantage 
of looking at the effects of Eng depletion at an early stage, before any long term adaptation 
responses occur. Thus, we conclude that ENG is responsible for the lack of VEGF-induced 
endothelial vascular organization.
We observed interdependence for ENG in VEGF-induced angiogenic responses. Genetic 
depletion of Eng from endothelial cells and pharmacological inhibition using TRC105 
ENG antibody severely affected VEGF-induced endothelial cell sprouting. These results 
are in line with previous studies, which demonstrated that ENG is essential for normal 
growth, migration and cord formation of endothelial cells.21,48,49 In addition, our results 
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are consistent with a recent report that showed that TRC105 inhibited VEGF and FGF-
induced HUVEC endothelial tube formation when co-cultured with dermal fibroblasts.50 
Moreover, soluble ENG has been shown to inhibit tumor angiogenesis,51,52 and elevated 
placental expression of ENG results in high serum levels of soluble ENG that contribute to 
vascular dysfunction in pre-eclampsia.53
Remarkably, mouse embryonic endothelial cells (MEECs) isolated from Eng-/- embryos 
have been described as exhibiting enhanced proliferation.54 The basis for the differences 
between our findings here and these studies is not clear. One explanation may be adaptive 
mechanisms that take place in endothelial cells in order to compensate for reduced ENG 
expression in vivo.21,54–56
Analysis of yolk sac vasculature in Eng mutant mice has shown previously that vascu-
lar smooth muscle cells are sparse in the vicinity of vessels lacking endoglin and it was 
striking that immunodetectable TGF-β1 was reduced in the smooth muscle cells although 
TGF-β1 mRNA levels in the adjacent endothelial cells were unaffected.55 The impaired 
ability of endothelial cells to secrete or activate TGF-β1 was believed to explain the lack of 
phosphorylated Smad2 in the adjacent mesothelium and the subsequent failure of these 
cells to differentiate into vascular smooth muscle cells. In the EB vasculogenesis assay 
used here, vascular smooth muscle cells did form and organize to some extent, albeit 
abnormally, in the absence of Eng in contrast to the observations in vivo. However, the 
culture conditions used included the use of fetal bovine serum as a medium supplement, 
which could provide active TGF-β and facilitate partial rescue. Since the EB vasculogene-
sis assay closely models aspects of vascular development and includes both the differenti-
ation and organizational aspects of EC and vascular smooth muscle cell components, it is 
potentially useful in screening anti- or pro-angiogenic drugs as well as in understanding 
the underlying molecular mechanisms.
In conclusion, our results provide insights into the molecular mechanisms that underlie 
vascular defects reminiscent of those in HHT1 patients and opens new avenues for inhibi-
tion of VEGF signaling by interfering with ENG function.
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Figure 6: Eng deficiency inhibits VEGF-induced sprouting of HUVEC spheroids. (A) Effect 
of shRNA-mediated depletion of Eng on VEGF-induced endothelial cell sprouting. HUVECs 
were transduced with lentivirus expressing endoglin shRNA overnight. HUVEC spheroids with 
deficient endoglin expression were embedded in collagen and stimulated with VEGF (50 ng/ml). A 
representative experiment is shown. (B) Quantitation of effects seen in (A). (C) Effect of TRC105 
ENG antibody on VEGF-induced endothelial cell sprouting. HUVEC spheroids were embedded 
in collagen and stimulated with VEGF (50 ng/ml), TRC105 (10 µg/ml), or both overnight. As 
control antibody for experiments using TRC105, the Fc domain (MOPC-21) from Bio Express, West 
Lebanon, NH, was used. Pictures were taken by phase-contrast microscopy. Quantitative analysis 
of the mean total sprout length was performed on 10 spheroids per experimental group. P≤0.05. 
(D) VEGF-induced VEGFR2 phosphorylation at site 1175 and extracellular regulated kinase (ERK) 
mitogen activated protein (MAP) kinase phosphorylation was examined in shRNA-mediated 
Eng knockdown cells. Two bands were detected with the phosphor ERK MAPK antibodies with a 
molecular weight of 44 and 42 kDa; they represent ERK1 and ERK2 isoforms, respectively. Number 
sign (#) represents a background band, indicating the even loading for the experiment. Asterisks 
indicate the protein bands with expected size.





HUVECs. Human umbilical vein endothelial cells (HUVECs) cells were cultured in Me-
dium 199 with Earle’s salt and L- glutamine (Gibco), 10% FCS, heparin (LEO pharma), 
bovine pituitary extract (Gibco) and penicillin/streptomycin (PS) on plates coated with 
1% gelatin, at 37oC and 5% CO2. HUVECs were used up to passage 4. Experiments were 
confirmed with HUVECs from different donors.
HUVECs were isolated from umbilical cords. The LUMC has the policy that umbilical cords 
are considered as ‘‘rest material’’ and collection can be performed without permission of 
the ethical committee, provided that the donor of the umbilical cord has signed a written 
consent and that collection and processing of the umbilical cord is performed anonymous-
ly. At the LUMC obstetric unit, where the umbilical cords were collected, the donor of the 
umbilical cord was asked to sign a formal waiver. The written consents are archived at 
the department of Obstetrics at LUMC and collection of the umbilical cord was performed 
anonymously. 
Embryonic stem cell lines and culture. Two independent R1 ESC lines were used as 
controls. Eng+/- mouse embryonic stem cells (ESCs) were generated by gene targeting of 
the parental wild-type 129/Ola-derived E14 ES cell lines, deleting 609 base pairs (bp), 
including Eng exon 1 and its initiation codon and leaving the Eng promoter intact.13 Eng-
/- ESCs were derived in vitro from Eng+/- ESCs by selection with high concentrations of 
G418.30 Genomic DNA was isolated from ESC lines using standard techniques.57 Primers 
MEFI and MERl amplify normal Exon 1 (300 bp) and primers MEFR1 and MEZR amplify 
the recombinant product (476 bp), as previously described.13 ESC lines were cultured in 
the presence of mouse embryonic fibroblasts (MEFs) in DMEM, supplemented with 20% 
heat- inactivated fetal bovine serum (FBS), 0.1 mM [3-Mercaptoethanol, lx non-essential 
amino acids and 1000 U/ml recombinant Leukemia Inhibitory Factor (LIF).
Lentiviral transduction
HUVECs were infected with lentivirus encoding an shRNA sequence against human Eng 
(TRCN0000003273, TRCN0000003276) selected from the MISSION shRNA library (Sig-
ma) and a third lentivirus encoding shRNA was generated in our lab.58 R1-ES cells were 
infected with lentivirus encoding an shRNA targeting mouse Eng (TRCN0000094355, 
MISSION shRNA library Sigma). As a control, a non-targeting shRNA sequence (SHC002) 
(Sigma) or empty vector pRRL was used. Virus transduction was performed overnight, 
and the infected cells were selected using culture medium containing puromycin (1 mg/ 
ml) for 48 h. The efficiency of Eng knockdown was verified by qPCR.
In vitro differentiation of embryonic stem cell clones
Two different methods were used to differentiate ES cells in vitro. Method 1: ESC lines 
were cultured in hanging drops to form EBs, as described previously.59 Briefly, 800 cells 
were cultured in 20 µl of DMEM, supplemented with 20% FBS, 25 ng/ml VEGF, 50 ng/
ml bFGF-2, hanging from the lid of the culture dish for 5 days, which allows the forma-
tion of cell aggregates (EBs). This makes it possible to control the size of the EBs and 
circumvents paracrine stimulation between EBs, and therefore allows a very high degree 
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of reproducibility. Subsequently, EBs were either (i) cultured in suspension on bacterial 
dishes coated with 1% agar for 11 or 15 days. EBs were then washed with PBS and fixed 
in methanol (MeOH)-dimethyl sulfoxide (DMSO) in a ratio of 4:1, overnight (o/n) at 4oC 
before staining; or (ii) 11-day old EBs were plated on gelatin coated coverslips for 4 days 
and then fixed in Zinc fixative o/n at 4oC before staining. 
Method 2: Mixed Feeder-ES cell cultures were trypsinized and subsequently cultured for 
45 minutes on gelatin-coated plates before the experiment in order to deplete the MEFs, 
which adhere faster to the plate. The ES cells were harvested and plated in suspension as 
hanging drops of 20 µl in complete ES-medium, containing 1200 cells/drop, for four days.
Embryoid body maturation in 2D culture
Four-day old EBs obtained with method 2 were plated in gelatin-coated 6 well-plates with 
15–20 EBs per well. EBs were cultured in ES medium without LIF and supplemented with 
50 ng/ml hVEGF-165 (PeproTech, Rocky Hill, USA). After 7 or 9 days, EBs were washed 
with PBS and RNA was isolated for qPCR analysis.
Embryoid body maturation in 3-D Collagen matrix
Method 1: All the ingredients of the collagen medium (DMEM, 20% FBS, 25 ng/ml VEGF, 
50 ng/ml bFGF-2) with the exception of collagen were mixed and stored on ice before 
harvest of the EBs to avoid prior polymerization of the medium. Prior to use, rat tail type 1 
collagen was added and mixed to a final concentration of 1.25 mg/ml. 11-day-o1d EBs were 
immediately incorporated into the collagen medium at a final concentration of 50 EBs/ml. 
12 ml was poured into a 35 mm bacterial grade Petri dish and cultures incubated for 3 days 
at 37oC in a 5% CO2 atmosphere.30,42 For further analysis of sprouting vessels, the 35 mm 
gel dish was inverted over a 50 mm x 75 mm glass slide. The collagen gel was gently laid 
out on the slide and excess liquid around the gel removed by pipetting with a dispenser. 
The gel was then dehydrated using nylon linen and absorbent filter cards. The slide was 
air-dried for 12 hours and incubated in zinc fixative o/n at 4oC before staining as previ-
ously described.42 The EBs were stained for PECAM-1 (Clone MEC13.3, BD Biosciences).
Method 2: Collagen solution was made as following: Purecol (Advanced Biomatrix, San 
Diego, USA) with 34.65% HAM’s F12 (Gibco), 6.25% NaOH (0.1M), 6.25% 10x F12, 1.25% 
4-(2- hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (1M), 0.975% Sodium bi-
carbonate 7.5% and 0.625% Glutamax. Four-day old EBs were suspended in 350 µl colla-
gen and transferred to a 24-well collagen pre-coated plate (one EB per well). EBs were cul-
tured in complete ESC-medium without LIF and supplemented with 30 ng/ml hVEGF-165. 
The EBs were cultured for eight days in collagen and the medium was changed every four 
days. Afterwards, EBs in collagen were washed with phosphate buffered saline (PBS) and 
fixed with 4% paraformaldehyde in PBS for 30 min at room temperature.
RNA isolation and quantitative PCR
Total DNA-free cellular RNA was extracted with Trizol reagents, according to manufacturer’s 
protocol (Invitrogen). Samples were DNase I treated to eliminate genomic DNA and 1 
mg RNA was reversed transcribed as described.60 All PCR analyses of the endothelial cell 
and SMC specific markers were as previously described.61 RNA from ESCs and EBs from 
method 2 was isolated with the NucleoSpin RNA II kit according to manufacturer’s protocol 
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(Bioké, Leiden, Netherlands). qPCR was performed with SYBRGreen reagent (Roche) for 
Eng, Vegfr2 and VE-cadherin. See Table 1 for sequences. The ΔΔCt method was applied for 
the expression profiling. Gene expression is normalized to house-keeping gene GAPDH 
and wild type ES cells as the reference sample.
Table 1: qPCR primer sequence.
Target Forward primer Reverse primer
Eng GGTCATGACTCTGGCACTCA AGGCGCTACTCAGGACAAGA 
Vegfr2 ACCAAGGCGACTATGTTTGC GGGCAAGTCACTTCAATGGT 
VE-cadherin ATTGAGACAGACCCCAAACG TGTTTTTGCCTGAAGTGCTG 
GAPDH AACTTTGGCATTGTGGAAG ACACATTGGGGGTAGGAACA
Immunofluorescence staining
For cryosections, ESC-derived l5-day-old EBs were processed as previously described62 and 
subsequently sectioned at 7 mm before acetone fixation for 10 minutes at 4uC, followed 
by 30 minutes air drying at RT. Next, slides were permeabilized for 5 minutes with 0.2% 
Triton X-100 in PBS, followed by blocking with 2% BSA in PBS at RT for 1 hour. The slides 
were then incubated with rat anti-mouse PECAM-1 (Clone MEC14.7, Santa Cruz) o/n at 
4oC. The slides were then washed four times in PBS and incubated for 1 hour with goat 
anti-rat Cy3 (Jackson ImmunoResearch Laboratories) at RT. The slides were then washed 
four times in PBS and mounted in Mowiol before confocal laser microscope analysis. Slides 
containing EBs cultured in 3D- collagen gel and zinc fixed were permeabilized for 15 min-
utes with 0.2% Triton X-100 in PBS, followed by blocking with TNB blocking solution for 
1 hour at RT, as described above. EBs were stained with rat anti-mouse PECAM-1 (Clone 
MEC13.3, BD Biosciences). The slides were then washed in TBS and incubated 1 hour 
with donkey anti-rat FITC (Jackson ImmunoResearch Laboratories) and goat anti-mouse 
(Jackson ImmunoResearch Laboratories) secondary antibodies diluted in TNB. The slides 
were then washed four times in TBS and mounted in Mowiol before confocal laser mi-
croscope analysis. EBs matured in 3D according to method 2 were excised from collagen. 
The EBs were blocked in blocking solution (Tris-Buffered Saline Tween (TBST) with 3% 
BSA) for 2 hours or overnight at room temperature. Staining with primary and secondary 
antibodies was done overnight. The EBs were stained with Hoechst to visualize the nuclei. 
The following antibodies were used: rat anti-mouse PECAM-1 (BD Pharmingen) and rat 
anti-mouse ENG (CD105 MJ7/18, BD Pharmingen). Secondary antibodies: donkey anti-rat 
Alexa 488 (Invitrogen) and goat anti-rabbit Alexa 594 (Invitrogen). EBs were stored at 
4uC in PBS until analysis with fluorescence microscopy. Endothelial cell sprouting from 
the EBs was quantified by counting the number of sprouts per EB.
Flow Cytometric analysis
To obtain single cell suspensions for FACS analysis, 15-day-old EBs were collected from 
agar coated-dishes and washed twice with PBS before being incubated for 30 minutes 
in a dissociation solution containing 0.2% collagenase B (Roche Diagnostics). EBs were 
gently washed every 5 minutes using a one ml tip. After centrifugation, the cell pellet was 
washed twice with 2% FBS in PBS and then incubated for one hour at 4oC with a FITC 
conjugated anti-mouse PECAM-1 before FACS analysis.
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Western blot analysis
HUVECs were seeded in six-well plates and allowed to grow to 90% confluence. Cells 
were washed with PBS and serum-starved for 5 hours. Cells were stimulated with VEGF 
50 ng/ml for 5 minutes, washed with PBS and lysed in SDS sample buffer. Samples were 
boiled for 10 minutes and subjected to SDS-PAGE and western blotting. Phospho-VEGFRII, 
phospho-ERK anti- bodies were purchased from Cell signaling Technology. ENG was ana-
lyzed with an antiserum recognizing human ENG.63
3D-culture spheroid assay
HUVECs (400 cells per spheroid) were suspended in Medium M199 containing Earle’s 
salt and L-glutamine, 10% FBS, methylcellulose, heparin, bovine pituitary extract, PS and 
seeded in non-adherent round-bottom 96-well plates. After 24 hours, spheroids were em-
bedded into collagen and stimulated with corresponding stimuli in the presence or ab-
sence of inhibitors or neutralizing antibodies for another 24 hours. As control antibody for 
experiments with ENG neutralizing antibody TRC105, the Fc domain (MOPC-21) from Bio 
Express, West Lebanon, NH, was used. EC sprouts were measured by Olympus Analysis 
software.
Ex vivo fetal mouse metatarsal angiogenic assay
Metatarsals from 17-day-old mouse fetuses from Eng+/+ and Eng+/- mice12 were dissected 
as described previously.64 Six metatarsals per experimental group were transferred to 
24-wells tissue-culture plates containing α-MEM (Gibco), 10% FBS and penicillin/strep-
tomycin (PS), and allowed to adhere for 4 days. Then, medium was replaced by fresh me-
dium containing 50 ng/ ml VEGF. Cultures were fixed 7 days after stimulation and vessel 
formation was visualized by anti-PECAM-1 staining.39 Vascular density was quantified by 
automated image analysis with Image J. Animal experiments were approved by the Insti-
tutional Committee for Animal Welfare of the Leiden University Medical Center (LUMC) 
and were performed according to the regulatory guidelines.
Statistics
All results are expressed as the mean ± s.d. Statistical differences were examined by two-
tailed Student’s t-test and P≤0.05 was considered to be statistically significant (in the 
figures, *P≤0.05 and **P≤0.01).
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Figure S1: Eng-/- ESC derived EBs have impaired endothelial cell-derived vessel structures. 
A) Bright field image and PECAM-1 staining of EBs from Eng+/+ and Eng-/- ESCs. Both bright field 
image and the PECAM-1 staining show that the Eng-/- EB has less endothelial sprouts than the 
Eng+/+ EB. B) Quantification of the number of sprouts per EB and length of the sprouts.
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To date, cellular transplantation therapy has not yet fulfilled its high expectations for car-
diac repair. A major limiting factor is lack of long-term engraftment of the transplanted 
cells. Interestingly, transplanted cells can positively affect their environment via secreted 
paracrine factors, among which are extracellular vesicles, including exosomes: small bi-li-
pid-layered vesicles containing proteins, mRNAs and miRNAs. An exosome-based therapy 
would therefore relay a plethora of effects, without some of the limiting factors of cell 
therapy. Since cardiomyocyte progenitor cells (CMPC) and mesenchymal stem cells (MSC) 
induce vessel formation and are frequently investigated for cardiac-related therapies, we 
investigated the pro-angiogenic properties of CMPC and MSC-derived exosome-like ves-
icles. Both cell types secrete exosome-like vesicles, which are efficiently taken up by en-
dothelial cells. Endothelial cell migration and vessel formation were stimulated by these 
exosomes in in vitro models, mediated via ERK/Akt-signaling.  Additionally, these ex-
osomes stimulated blood vessel formation into matrigel plugs. Analysis of pro-angiogenic 
factors revealed high levels of extracellular matrix metalloproteinase inducer (EMMPRIN). 
Knockdown of EMMPRIN on CMPCs leads to a diminished pro-angiogenic effect, both in 
vitro and in vivo. Therefore, CMPC and MSC exosomes have powerful pro-angiogenic ef-
fects, and this effect is largely mediated via the presence of EMMPRIN on exosomes. 
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Introduction
Cardiac cell therapy aims to replace lost cardiomyocytes and vessels after cardiac is-
chemia.1 Different stem- or progenitor cell populations have been used for cardiac cell-
based therapy, and so far mesenchymal stem cells (MSC) and cardiomyocyte progenitor 
cells (CMPC) are thought to be the most efficient candidates either for their beneficial 
paracrine effects,2 or their intrinsic capacity to differentiate towards cardiac lineages in 
vitro and in vivo,3,4 respectively. In many (pre-) clinical studies,5,6 beneficial effects have 
been observed on cardiac function of cell transplantation after myocardial infarction 
(MI).  Strikingly, a positive effect on cardiac function can be observed while the number 
of transplanted cells present in the myocardial wall is very low. This suggests that other 
mechanisms than cellular differentiation and contractile contribution are involved.4,7 One 
of the suggested mechanisms by which the transplanted cells mediate their effects is via 
the secretion of paracrine factors.8 Here, the injection of CMPCs after MI had already 
positive effects on cardiac function after two days, pointing at a paracrine effect of the 
CMPCs.4,9 More evidence pointing at a paracrine effect is the increase in capillaries found 
two weeks after transplantation without direct differentiation of the transplanted cells.10 
This increase persisted up to 3 months, even though at this point only 3% of the injected 
cells survived.4 Although the composition of the secreted factors, including growth fac-
tors, chemokines, and cytokines has been extensively studied,11 a successful translation for 
their use in a clinical setting is still lacking.12,13 Therefore, several research groups injected 
the conditioned medium (CM)  from (progenitor) cells and have shown successful reduc-
tion of acute injury after MI.14,15 In the CM from progenitor cells, exosomes were identified 
as the active compound and suggested to play an important role in the beneficial effect 
of transplanted cells.16 Exosomes are small membrane vesicles, released from many dif-
ferent cell types,17 characterized by size  (30 - 150 nm), density (1.10 - 1.20 g/ml), and 
the presence of exosomal markers, such as flotilin-1 and CD9.18 Furthermore, these small 
vesicles have been shown to provide a linear transfer of both proteins and RNA molecules 
between cells and  represent another dimension in cell to cell communication due to their 
ability to carry multiple messenger molecules thereby affecting various biological pro-
cesses.19,20 The use of exosomes might be more effective to induce angiogenesis in ischemic 
situations, since exosomes would allow to give a high concentration of pro-angiogenic 
signals at once, without several drawbacks of cell transplantation therapies, such as cell 
survival. Previously, we have shown that extracellular matrix metalloproteinase inducer 
(EMMPRIN) is present on exosomes-like vesicles and might be an important factor in en-
dothelial activation.21 Here, we characterized in detail the vesicles secreted by both CMPC 
and MSC, their effect on both in vitro and in vivo angiogenesis assays, and the role of 
EMMPRIN in these processes. 
Results
Characterization of CMPC and MSC derived extracellular vesicles (EVs)
To determine the distribution of the extracellular vesicles present in the CM of CMPCs 
and MSCs, the CM was investigated using Nanoparticle Tracking Analysis (NTA with Na-
nosight). This analysis showed that 44,13% ± 6.11% of the CMPC derived vesicles (n=3) 
and 45.60% ± 11.41% of the MSC derived vesicles (n=3) are smaller than 100 nm with a 
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Figure 1: MSC and CMPC exosomes characteristics. A) Nanoparticle tracking analysis (NTA) 
of CMPC and MSC derived conditioned medium (CM) centrifuged at 2000 x g (n = 3). The most 
abundant vesicles within the CMPC and MSC derived CM are 84.4 ± 5.2 nm and 86.9 ± 7.0 
nm in size, respectively. B) Electron microscopy analysis of CMPC and MSC derived exosomes 
isolated from the CM via differential centrifugation. C) Western blot analysis for the expression of 
exosomes enriched markers flotillin-1 and CD-9 on sucrose gradient purified exosomes, displays 
the protein presence around 1.12 g/ml (1.10-1.14 g/ml). Scale bar = 100 nm.
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peak at size 84.40 nm ± 5.24 nm and 86.87 nm ± 6.96 nm, respectively, suggesting the 
presence of exosomes-like vesicles (Figure 1A). A comparison of vesicle content of normal 
medium versus cleared FBS can be seen in Figure S1A. After differential centrifugation of 
the CM, EM analysis confirmed bi-lipid membrane vesicles within the size range of 100 
nm in size (Figure 1B). Centrifugation of the isolated EVs using a sucrose gradient showed 
the presence of exosomal markers flotillin-1 and CD9 in the fractions with a density of 
1.09 g/ml to 1.17 g/ml, with a peak density at 1.12 g/ml (Figure 1C). Thereby further 
suggesting the presence of exosomes-like vesicles in the secretome by CMPCs and MSCs. 
Analysis of the EVs after ultracentrifugation shows a population of vesicles with a mean 
size of 100nm (Figure S1B).
Exosomes from CMPCs and MSCs are taken up by endothelial cells
To determine the uptake of exosomes by endothelial cells, exosomes were labelled with 
the lipid binding dye PKH26. PKH26 labelled exosomes or PKH26 alone were loaded at the 
bottom of a sucrose density gradient (Figure 2A, left panel). PKH labelling did not affect 
exosome characteristics, since PKH26-labelled exosomes still floated (middle panels) to a 
density of 1.12 g/ml after centrifugation on a sucrose gradient. Unbound PKH26 remained 
Figure 2: PKH26 labelled exosomes are taken up by endothelial cells. A) PKH26 labelling of 
CMPC and MSC derived exosomes before (left) and after (right) sucrose gradient. PKH-26 labelled 
exosomes float in sucrose gradient, whereas PKH26 without the presence of exosomes does not. 
B) CFSE labelled human micro vascular endothelial cells (HMECs; green) take up PKH-26 labelled 




in the bottom fraction (Figure S2A). To investigate if labelled exosomes are taken up by 
endothelial cells, the twelve fractions that were collected from the sucrose gradient were 
incubated with HMECs and HUVECs (Figure S2B). Only the fractions that contained the 
exosomes, ranging from 1.11-1.15 g/ml, became red (Figure 2B, Figure S2B), but remain 
PKH26 negative in the absence of exosomes (Figure S1B). Staining in the last obtained 
fraction was due to unbound PKH26 (Figure S1B). Analysis of the stained exosomes re-
vealed that the PKH labelling is equally efficient in both exosomes-types. The fluorescence 
present in the cells after exposure to the exosomes therefore correlates to the relative up-
take. Live-imaging over the course of 24 hours showed that the first exosomes are being 
internalized within an hour, with increasing cell numbers becoming positive over the next 
3 hours (Figure S3).  Conclusively, exosomes derived from CMPCs and MSCs are readily 
taken up by different endothelial cells. 
To verify exosomal quality after isolation, pAkt and pErk1/2 levels in HMECs stimulated 
with exosomes were analyzed at several time-points during stimulation. As indicated in 
Figure S4, pAkt and pErk levels were increased up to 60 minutes after exosomes addition, 
with no difference in total Erk1/2 and Akt levels. Altogether, this demonstrated that ex-
osomes from CMPCs and MSCs can activate the endothelial cells relatively fast.
CMPC and MSC exosomes enhance the angiogenic capacity of endothelial cells in 
vitro
The pro-angiogenic effect of exosomes on endothelial cells was studied in different angi-
ogenic in vitro assays. In a scratch assay, we observed that the wound closure of HMECs 
was increased in the presence of CMPC and MSC exosomes, compared to non-stimulated 
HMECs (closure: exosomes CMPCs 46.6% and exosomes MSCs 42.91% vs no exosomes 
9.82% (p<0.05)) (Figure 3A & Figure S5A). Moreover, HMEC spheroids efficiently in-
creased in sprouting when stimulated with medium conditioned by CMPCs or MSCs (Fig-
ure 3B & Figure S5B). Depletion of exosomes from the CM reduced the relative cumulative 
sprouting length per spheroid to 0.45 ± 0.21 for CMPC (p<0.05) and 0.65 ± 0.18 for MSC 
(p<0.05) compared to whole CM. Reintroducing exosomes to this assay resulted in the 
rescue of the pro-angiogenic effect. Addition of exosomes from CMPCs or MSCs to a tubule 
formation assay with HMECs resulted in longer tubules than basal medium alone (CMPC: 
1.27 ± 0.06 fold increase and MSC: 1.33 ± 0.18 fold increase, Figure 3C). Finally, network 
formation was stimulated as the number of junctions was increased by 1.51 ± 0.11 fold 
(CMPC) and 1.48 ± 0.24 fold (MSC) (Figure 3C). 
Exosomes from CMPCs and MSCs are equally potent in stimulating the angiogenic poten-
tial of HMEC in several angiogenesis assays. Interestingly, when using HUVECs, tubule 
formation demonstrated an increase in tubular length (29.64% ± 7.09%; p<0.05) upon 
stimulation with CMPC derived exosomes only (MSC: 4.50% ± 6.44%, Figure S5C), sug-
gesting that the angiogenic response of CMPC exosomes is more robust and affects mul-
tiple endothelial cell types. Moreover, 106 MSC produce approximately 4.5μg of exosomes 
whereas CMPC produce 2μg within 72h.  
In vivo angiogenesis is stimulated by exosomes from CMPCs and MSCs
Next, we investigated the angiogenic capacity of MSC and CMPC derived exosomes in 
vivo using a matrigel plug assay. To determine the angiogenic effect, infiltration of cells 
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Figure 3: CMCP and MSC derived exosomes stimulate angiogenesis in vitro.  A) Scratch 
wound migration assay: CMPC and MSC derived exosomes lead to a 46.6% ± 4.9% (n > 4; 
p<0.01) and 42.9% ± 2.8% (n = 4; p<0,01) closure of the wound. B) Spheroid assay: conditioned 
medium (CM) diminished for exosomes (by 100,000 x g centrifugation) lead to reduced sprouting 
by 0.45 fold (n=3; p<0.05) and 0.65 fold (n=4; p<0.05) for CMPC and MSC derived, respectively. 
Reconstitution of the CM with the exosome pellet restored the sprouting stimulating capacity of 
CM on endothelial spheroids (p<0.05). C) Matrigel assay: stimulation of HMECs with CMPC and 
MSC derived exosomes increased tubular lengths with 1.27 ± 0.06 fold (CMPC, n > 5; p<0.05) 
and 1.33 ± 0.18 fold (MSC, n = 5; p<0.05) and number of junctions with 1.51 ± 0.11 fold (CMPC, 
p<0,05) and 1.48 ± 0.24 fold (MSC, p<0.05). Scale bar = 200 μm.
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Figure 4: CMPC and MSC exosome enhance the influx of vascular cells into the matrigel plug 
in C57/Bl6 mice. A) Representative pictures of in vivo matrigel plug assay in C57/Bl6 mice  (left) 
lead to enhanced cell infiltration into the matrigel plug, CMPC (n = 9) and MSC (n = 8) derived 
exosomes lead to 439.01 ± 53.7 and 437.5 ± 94.9 cells per hpf, respectively, compared to 118.7 
± 7.1 cells per hpf in empty matrigel plugs (right, n = 5, p<0.05). B) Representative pictures of 
CD31 and SMA staining in matrigel plugs (top) demonstrated that more CD31+ cells infiltrate the 
matrigel plug (bottom left) in the presence of CMPC (202.4 ± 72.7 cells per hpf) and MSC (198.3 ± 
31.3 cells per hpf) exosomes compared to empty matrigel plugs (58.0 ± 21.5 cells per hpf, p<0.05). 
The number of SMA+ cells seems higher in the presence of exosomes (bottom right), although not 
significant (no exosomes; 10,7 ± 9.8, CMPC; 76.9 ± 72.4, MSC; 60.0 ± 40.0 cells per hpf). Scale 
bar = 20 μm.
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and formation of blood vessels were analyzed. The addition of CMPC or MSC derived 
exosomes to the matrigel plug before subcutaneous implantation, led to a 3.4-fold increase 
of infiltrating cells as compared to matrigel plugs without exosomes (CMPC; 439.01 ± 53.7 
and MSC; 437 ± 94.9 vs no exosomes: 118.7 ± 7.1, p<0.05)(Figure 4A). Furthermore, we 
found that infiltration of cells was dose-dependently related to the amount of exosomal 
protein. Less than 1 μg of exosomal protein present in the plug was not sufficient to induce 
infiltration, whereas more than 2 µg and 4 µg lead to a significant increase in infiltrating 
cells (CMPC; 404.8 ± 66.2 and 439.0 ± 53.7, p<0.05 and MSC; 342.5 ± 34.5 and 437.0 
± 94.9 vs no exosomes 132.1 ± 11.7, p<0.05, Figure 4A and S6A). Interestingly, when 
combining empty matrigel plugs with plugs containing exosomes in a single animal, we 
observed that the cellular influx in the empty plug was enhanced when in the proximity 
of an exosome-containing plug (Figure S6B), suggesting long-range angiogenic potential 
of the injected exosomes.
To identify blood vessels, the cells in the plug were stained for CD31 and αSMA (Figure 
4B). The absolute number of CD31+ cells increased from 58.0 ± 21.5 to 202.4 ± 72.7 and 
198.3 ± 31.3 (p<0.05) for CMPC and MSC exosomes, respectively, evident of the pro-angi-
ogenic effect of the exosomes. The composition of the infiltrating cell population remained 
the same compared to the plug without exosomes, with the percentage of CD31+ cells 
remaining at approximately 50% of the total cell population (Figure S7A). In contrast, 
increase in the number and percentage of SMA+ infiltrating cells in exosome containing 
plugs did not reach significance compared to plugs without exosomes (Figure 4B, Figure 
S7B). More detailed analysis showed co-localization of αSMA with CD31, which is sugges-
tive of mature vessel formation. Additional confirmation of functional vessel formation 
came from the detection of red blood cells in a number of vessels in the exosomes groups, 
but we did not confirm this functional link with the mouse circulation by dye infusion. 
In summary, exosomes from both CMPCs and MSCs are capable of increasing overall cell 
invasion in a matrigel plug and inducing the formation of functional vessels, proving their 
pro-angiogenic capability. 
EMMPRIN is the major pro-angiogenic factor on CMPC and MSC exosomes
We set out to identify the factors that could elicit the pro-angiogenic effect of the ex-
osomes. Previously, we have shown that EMMPRIN and MMPs are abundant in CMPC 
exosomes.21 Now, we found that MSC and CMPC-derived exosomes contained comparable 
levels of VEGF, EMMPRIN and MMP-9 (Figure 5A-C). These three proteins are all well 
recognized for their role in stimulating angiogenesis.22–25 Furthermore, we observed that 
all cells that infiltrated the matrigel plug in vivo expressed these three proteins (Figure 
5D-F).
To unravel the role of EMMPRIN in the exosome mediated pro-angiogenic response, we 
blocked exosomal EMMPRIN. Adding an EMMPRIN neutralising antibody (Figure S8A) 
resulted in a reduction of the in vitro angiogenic responses (Figure S8B). However, this 
effect was not sustained when applying it to in vivo matrigel plugs (Figure S8C and D). 
Since the antibody may only transiently inhibit the angiogenic response, we generat-
ed a lentiviral shRNA-induced knock-down of EMMPRIN. To this end, we used CMPCs 
since they showed a more robust pro-angiogenic response in the previous in vitro assays, 
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Figure 5: Expression of angiogenic growth factors in CMPC and MSC derived exosomes 
and their target cells in in vivo matrigel plug assay. A) Western Blot analysis of exosomal 
expression of EMMPRIN. B) Zymogram on CMPC and MSC derived exosomes to detect MMP-9. 
C) VEGF expression in CMPC and MSC derived exosomes detected by Western Blot. D-F) Immuno 
histochemistry on matrigel plugs demonstrated the expression of EMMPRIN (D), MMP-9 (E) and 
VEGF (F) in infiltrated cells. Scale bar = 20 μm.
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Figure 6: Effect of EMMPRIN knockdown on in vitro and in vivo angiogenesis. A) 
Representative images of control CMPCs and EMMPRIN KD (EM KD) CMPCs, Relative expression 
of EMMPRIN after KD and Western Blot analysis. B) Migration of endothelial cells in a scratch 
assay. Control exosomes induced a closure of 58.9% ± 3.1, while EM KD exosomes induced a 
closure of 39.4% ± 4.6. C) Representative images of a spheroid sprouting assay. Sprout length 
and number of sprouts was reduced with EM KD exosomes. D) Matrigel tubule formation assay 
showed a decrease in closed networks and branchpoints in the presence of EM KD exosomes 
compared to control exosomes (E) In vivo matrigel plug assay. Stimulation of cell invasion was 
diminished with EM KD exosomes. (F) In vivo matrigel plug assay. EM KD exosomes failed to 
stimulate vessel formation. (Green: CD31, Blue: DAPI; M= matrigel plug, T= surrounding tissue)
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are more susceptible to lentiviral transduction, and can be better maintained in a 
long-term culture as compared to the MSC. Lentiviral mediated knockdown of EMMPRIN 
in CMPCs led to a decrease in mRNA and protein levels of EMMPRIN in both cells and 
exosomes (Figure 6A). 
In vitro, EMMPRIN-KD exosomes were unable to stimulate the migration of endothelial 
cells in a scratch (Figure 6B). Furthermore, spheroid sprouting length was significantly 
reduced compared to control exosomes (138.8±7.0 vs 165.7±6.5, respectively, p<0.05; 
figure 6C)) while the increase in number of sprouts was significantly reduced (8.7±0.5 vs 
14.9±1.2, p<0.05). EMMPRIN KD exosomes were also unable to stimulate network forma-
tion in a matrigel tubule assay to the same extend as control exosomes, demonstrated by 
the number of closed networks and number of branching points (12.1±1.8 vs 28.3±2.5 and 
76.75±5.6 vs 170±4.8 respectively, p<0.05, Figure 6D). 
In an in vivo matrigel plug assay, overall cell invasion was significantly reduced with EM-
MPRIN KD exosomes (19358±2057 vs 27983±3412 cells with control exosomes, p<0.05, 
see Figure 6E). Moreover, vessel formation in the matrigel plug was almost completely 
abolished with the loss of exosomal EMMPRIN (see Figure 6F, 1.0±0.4 vs 6.3±2.0, p<0.05, 
respectively). In summary, EMMPRIN knockdown in CMPCs results in a significant loss of 
EMMPRIN on exosomes and subsequently to a drastic reduction in the angiogenic effect 
of CMPC exosomes both in vitro as in vivo.
Discussion
More evidence is emerging that secreted paracrine factors play a major role in the benefi-
cial effects of cell therapy after myocardial infarction.4,8,31–35,14–16,26–30 Here, we show that ex-
osome-like vesicles from CMPCs and MSCs are capable of eliciting a strong pro-angiogenic 
effect in endothelial cells, and that this effect is mediated via exosomal-bound EMMPRIN. 
Exosomes have been widely studied especially in the field of immunology and cancer biol-
ogy were they are involved in the progression and formation of metastasis from tumors, 
suppression of the immune system, and pro-angiogenic effects.36–39 Here, we have shown 
that both CMPC and MSC release exosomes, since an exosome-like morphology and en-
riched expression of exosome markers could be observed by EM and western blot anal-
ysis. Previously, Lai et al. identified exosomes as the active component within MSC-CM, 
suppressing acute ischemia reperfusion injury.16 Exosomes from MSC, CPCs and embry-
onic stem cells have been shown to increase angiogenesis after brain damage, hind limb 
ischemia and MI.16,32,40–42 Since this increase can also be caused via exosomal activation of 
other cell types in the heart, like pericytes or fibroblasts, the real effect on endothelial cells 
remains unknown.43,44 Furthermore, in vitro data show indeed that these exosomes can 
induce some aspects of angiogenesis.16,32,35,45 Therefore, we hypothesized that exosomes 
from CMPCs and MSCs have all-round pro-angiogenic properties by directly activating 
endothelial cells in vitro and in vivo.  
We have previously reported that CMPC exosomes stimulate angiogenesis in vitro and 
here we show that MSC exosomes have a similar effect.21 When attempting to understand 
their pro-angiogenic effect, we observed that these exosomes are efficiently taken up by 
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different endothelial cells (HUVECs and HMECs).  Cellular sprouting, tubular formation, 
and network organization are enhanced after exosome stimulation, but interestingly our 
observations suggest some variations in effectiveness in different endothelial cell origins. 
Thereby this suggests that there is some level of uptake specificity between target cells.46,47 
Activation of the endothelial cells as a result of exosomes stimulation is demonstrated 
by an increase in ERk1/2 and Akt signaling, the latter was also observed in the myocar-
dium by Arslan et. al.,29 although cellular specificity remained undefined. Besides these 
stimulatory effects in vitro, in vivo angiogenesis is enhanced upon CMPC and MSC ex-
osome stimulation. We also observed an increase in vascular cell invasion and blood filled 
capillary formation after two weeks in vivo when exosomes were applied in a matrigel 
plug, although we did not confirm this functional link with the mouse circulation by dye 
infusion. Similar to our finding, Sahoo et al. described the pro-angiogenic stimulating 
capacity of CD34+ cell derived exosomes in a matrigel plug assay and in corneal angio-
genesis assays.48 Since no cells were present in the matrigel plug, one might speculate that 
exosomes not only stimulate endothelial cells by activating the cells themselves, but also 
have a chemo-attractant effect. Exosomes are tiny membrane vesicle and we have found 
that they rapidly diffuse out of the matrigel in vitro. Furthermore, it has been reported 
that exosomes have the potential to elicit their effect over long distances.49,50 We have also 
observed that infiltration in empty matrigel plugs is increased when these plugs were 
surrounded with exosome-containing matrigel plugs. Thus, the angiogenic effect of CMPC 
and MSC exosomes can also be transferred over long distances.37 The fact that exosomes 
can be used in higher concentration as a single therapy compared to their production by 
transplanted cells is an advantage in effectivity. However, one could speculate that the 
continuous release of exosomes from remaining cells can be more effective than a single 
injection of exosomes. In our current research, we have focused purely on the angiogenic 
effect of MSC and CMPC exosomes with established in vitro and in vivo models. Since 
we have shown their angiogenic potential, follow-up research would entail examining 
their angiogenic effect in clinical related settings. In the provided dataset here, we did 
not include the effects of MSC and CMPC themselves since these cells will provide a con-
tinuous production of angiogenic factors, including exosomes, but moreover, will partic-
ipate directly in vessel formation themselves as well. A future step in exosome research 
for cardiac repair is to investigate how effective the pro-angiogenic responses are in the 
heart, such as vessel growth into the border zone and infarcted area. Moreover, a com-
parison of exosomes with cell therapy might provide insight in effectivity between the 
two treatments. In addition to the pro-angiogenic effects, cells might contribute directly 
as well by differentiation into vascular structures. However, exosome injection would face 
some similar problems as cell transplantation therapies, such as retention problems in a 
beating heart and a severely damaged environment.51 Therefore, further developments of 
local delivery systems are needed that will allow a slow release of exosomes in the affected 
myocardial area.
Although we cannot exclude a loss of vesicle integrity via our isolation approaches, we 
feel that we do not have any evidence for this by visualizing intact exosomes via EM, since 
exosomes retained their density in a sucrose gradient and maintained their functionality 
in stimulating target cells, but further testing and optimizations are essential to move 
this field forward. Additionally, although we started our in vitro work with exosomes 
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from 10^6 cells, which reflects cell numbers that have demonstrated paracrine effects in 
cardiac transplantation, recent suggestions from the international working group suggest 
to rapport actual amount of obtained vesicles.52
Exosomes are able to convey their pro-angiogenic signals through transfer of miRNAs 
and proteins. Studies showing in vitro and in vivo angiogenesis after exosome stimulation 
have shown that among others pro-angiogenic miR-132,32 miR291,42 miR17 and miR210,53 
are present in the exosomes. However, the contribution of angiogenic proteins to the in-
crease in vascularization is less known. Here, we show  that CMPC and MSC-derived 
exosomes contain pro-angiogenic proteins, like EMMPRIN, MMP-9 and VEGF, and we and 
others have observed that migration of endothelial cells after exosome or microvesicle 
stimulation  is dependent of EMMPRIN.21,54 We hypothesized that blocking EMMPRIN, a 
transmembrane protein that activates angiogenic cells via e.g. EMMPRIN-EMMPRIN in-
teraction,55 would reduce the pro-angiogenic activity of exosomes in vivo., Blocking EM-
MPRIN on CMPC and MSC exosomes led to reduced endothelial network formation in 
vitro, but not in vivo, which might be caused by a transient effect of the antibody.
By lentiviral-knockdown of EMMPRIN in the CMPCs, we successfully created cells that 
secreted exosomes with reduced EMMPRIN protein levels. These EMMPRIN deficient ex-
osomes were unable to elicit the same angiogenic response in vitro and in vivo, thereby 
showing the essential role of EMMPRIN in exosome mediated angiogenesis. It is known 
from tumor biology that EMMPRIN is a mediator in cell migration and angiogenesis 
through activation and upregulation of MMPs and VEGF.56–59 Recent research has shown 
that EMMPRIN also functions as a coreceptor for VEGFR2, thereby positively mediating 
VEGF signaling.60 Increased levels of EMMPRIN on the recipient endothelial cells by ex-
osomal uptake could therefore increase the levels of pro-angiogenic proteins, enhance 
VEGF signaling and thus induce angiogenesis. The increase in Akt and Erk signaling cor-
roborates these findings. 
Conclusion
In the context of an angiogenic paracrine effect of myocardial cell therapy, future clinical 
therapies using MSC and CMPC exosomes are very promising as a pro-angiogenic off-the-
shelf therapy in ischemic disease, even more since MSC exosomes have been described to 
bear little immunogenicity.61,62 Additionally strategic manipulation of the important miR-
NAs and proteins in exosomes could improve their therapeutic effects  exploiting the pow-
er of exosomal communication and enhance cardiac regeneration.27,32,33 Overall, CMPC and 
MSC derived exosomes have a strong pro-angiogenic potential by stimulating endothelial 
cells. They are capable of eliciting capillary formation both in vitro as well as in vivo, 
which is dependent on the presence of EMMPRIN on the exosomes. 
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Experimental Section
The complete description of methods is available in the Supplementary Material online.
Cell culture
All procedures were carried out in accordance with the principles set forth in the Helsinki 
declaration. Standard informed consent procedures and prior approval of the ethics com-
mittee of the University Medical Center Utrecht and Leiden University Medical Center 
were obtained. Human fetal CMPCs and MSCs (bone marrow derived) were isolated as 
previously described by MACS or  by Ficoll-Paque density separation followed by plastic 
adherence, respectively.2,63 Both cell types were cultured in the designated culture medium 
in the presence of exosome depleted serum.21 Human umbilical vein endothelial cells (HU-
VECs) and human microvascular endothelial cells (HMEC-1) were isolated and cultured 
as previously described.21,64,65 Conditioned medium was collected after 3-4 days of culture 
when the cells reached confluency. 10^6 MSC produce approximately 4.5µg of exosomes 
whereas CMPC produce 2µg within 72h.
Lentiviral mediated EMMPRIN knockdown
Human fetal CMPCs were transduced with lentivirus containing a shRNA construct tar-
geting EMMPRIN (MISSION Library Sigma, TRCN0000006734) or luciferase (SHC007V) 
as control. Cells were transduced with shRNA lentivirus for 16h and selected with puro-
mycin (1μg/ml) for 8 days during 2 passages. EMMPRIN knockdown was confirmed by 
qPCR (see supplemental Methods).
Exosomes 
Conditioned medium and exosome isolation
Conditioned medium from both CMPC and MSC was analyzed by nanoparticle tracking 
analysis (NanoSight) as described before.66 Exosomes were isolated by differential cen-
trifugation with a final centrifugation step at 110,000xg (adapted from Thery et. al., see 
Figure S9).18 
Electron microscopy
Isolated exosomes were resuspended in phosphate buffer containing 1% glutaraldehyde 
(Polyscience) and subsequently loaded onto formar/carbon-coated electron microscopy 
grids. Samples were treated with uranyl acetate (SPI) to enhance contrast. Images were 
captured using a transmission electron microscope JEOL 1200EX.21,67 
Western blot and zymography
The expression of flotillin-1, CD-9, VEGF and EMMPRIN on exosomes was determined 
by Western blot. Proteins were detected via immune labelling with the appropriate anti-
bodies and chemiluminescent peroxidase substrate. For zymography, proteins were sep-
arated in a gelatin (Sigma) 8% bisacrylamide gel (Bio-Rad). The gel was washed in 2.5% 
Triton-X100 solution (Sigma) and activated in 0.05% Brij35 solution (Sigma). The bands 
were visualized via Coomassie blue counterstaining.21
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PKH labelling of exosomes and uptake by endothelial cells
CMPC- and MSC derived exosomes were stained with PKH26 (Sigma; 050M0730), as pre-
viously described.68 Excess PKH26 was separated from the exosomes by a sucrose gradi-
ent. PKH-26 labelled exosomes were incubated for three hours with HMECs and HUVECs 
to determine the uptake of the exosomes.
Scratch assay
A scratch was made in a confluent monolayer of HMECs. Floating cells were removed and 
the medium was replaced with MCDB131, with or without the addition exosomes from 10 
million cells. After six or twenty-four hours the closure of the wound was determined.21,64 
Matrigel assay
HMECs or HUVECs (10,000 cells) were cultured in a μ-slide for angiogenesis (Ibidi), coat-
ed with growth factor reduced (GR) matrigel (BD Biosciences), and incubated with basal 
endothelial medium with or without exosomes from 10 million cells. After 14h, the total 
length of the network and the number of junctions were measured.64 Additionally, ex-
osomes were treated with an αEMMPRIN antibody as described before.21
Spheroid assay
HMEC spheroids were prepared in 0.1% methyl cellulose (Sigma) in DMEM followed by 
embedding in collagen.64 The spheroids were stimulated with CM, exosome diminished 
CM, or isolated exosomes resuspended in exosome diminished CM. After 24-48 hours, 
sprouting was quantified by measuring the cumulative and average length of the tubular 
outgrowth.
In vivo matrigel plug assay
Animal experiments
The animal experiments were approved by the Animal Ethical Experimentation Commit-
tee of Utrecht University and Leiden University Medical Center and carried out in accord-
ance with the Guide for the Care and Use of Laboratory Animals. Male mice (C57bl/6) 
were anesthetized with an intraperitoneal (ip) injection of a mixture of fentanyl (0.05 mg/
kg), midazolam (5 mg/kg), and medetomidine (0.5 mg/kg) or via isoflurane inhalation 
of 2-4%. The animals were divided in the following groups: matrigel plug, matrigel plug 
with exosomes (CMPC/MSC), matrigel plug with exosomes (CMPC/MSC) and EMMPRIN 
neutralizing antibody, matrigel plug with EMMPRIN knockdown exosomes (CMPC). Ex-
osomes (20 μg exosomal protein) were resuspended in 50 μl PBS and 950 μl GR matrigel, 
of which 200 μl was subcutaneously injected in the abdomen of mice. For the knockdown 
experiments, 300 µl of GR matrigel was injected. To recover, the mice received i.p. a mix-
ture of atipamezole (2.5 mg/kg) and flumazenil (0.5 mg/kg) or isoflurane was removed. 
After 14 days all mice were sacrificed using a cocktail of ketamine (100 mg/kg) and me-
detomidine (8 mg/ml, ip) or CO2 and the matrigel plugs were collected. 
Immunohistology 
Matrigel plugs were fixated in formaldehyde and processed for paraffin sectioning. 
Seven μm paraffin tissue sections were obtained and stained by haematoxylin and eosin. 
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For the detection of CD31 and SMA positive cells, slides were stained with the appropriate 
antibodies and counterstained with Hoechst 33342 dye (Invitrogen). Total cell infiltration 
was quantified in the plugs at three levels and at three random areas per level, as well 
as the number of CD31+ and SMA+ cells. In addition to the detection of vascular cells, 
infiltrated cells were analyzed for pro-angiogenic proteins, EMMPRIN, MMP-9 and VEGF. 
The analysis of the knockdown experiments were done at three levels per plug and the 
entire section was analyzed using whole section scanning.
Statistical analysis
Data are presented as mean ± SEM. Differences between groups were analysed by Stu-
dent’s t-test for 2 samples. For three or more groups, one-way ANOVA (equal variances) 
or Kruskal-Wallis (non-equal variances) was used. Significance level was set at P<0.05.
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Figure S1A: Comparison of FBS before and after clearance of exosomes. Medium containing 
10% normal FBS contains approximately 45% more vesicles than 10% FBS in PBS, cleared for 
exosomes. Medium without serum contains a minimal amount of vesicles. B) NTA characterization 
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Figure S2: PKH26 labeled exosomes are taken up by endothelial cells. A) PKH26 labeling of 
CMPC and MSC derived exosomes before sucrose gradient (left) and after collection of twelve 
different fractions (1.06 – 1.27 g/ml) after sucrose gradient (right). PKH-26 labeled exosomes float 
in sucrose gradient to a density of 1.12 g/ml. B) CFSE (in green) labeled human micro vascular 
endothelial cells (HMECs) and human umbilical vein endothelial cells (HUVECs) incubated with 
all different fractions of the sucrose gradient demonstrate uptake of PKH-26 labeled CMPC and 
MSC exosomes (red) (approximate density 1.12 g/ml). Scale bar = 10 μm. C) Labelling efficiency of 




Figure S3: Live imaging of exosome uptake. PKH26 labeled exosomes are visibly taken up by 
endothelial cells within 1 hour, with increased cell numbers labeled the next 3 hours after which it 
remained stable. Scale bar = 500 µm.
Figure S4: Western Blot of HMECs stimulated with exosomes. Stimulation of HMECs with 
exosomes up to 60 minutes resulted in increased pERK1/2 and pAkt levels, whereas total levels of 
ERK1/2 and Akt remain stable. 
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Figure S5: CMPC and MSC derived exosomes stimulate angiogenesis in vitro. A) Scratch 
wound migration assay with HMECs stimulated with CMPC and MSC derived exosomes. 
Representative pictures of the closure of the wound at t = 0h and t = 6h. B) Spheroid assay; 
representative pictures after stimulation of HMEC spheroids with CMPC and MSC derived 
exosomes. C) Matrigel assay: stimulation of HUVECs with CMPC-derived exosomes increased 
tubular lengths with 29.6% ± 7.1% (n>5; p<0.05) and number of junctions with 33.53% ± 
14.22% (ns). MSC stimulation of HUVECs does not lead to a longer tubular length (n=5; 4.50% ± 
6.44%, ns) or increase in the number of junctions (0.45% ± 9.63%). Scale bar = 200 μm
100
Chapter 5
Figure S7: Percentage of vascular cells 
infiltrating the matrigel plug. A) CMPC 
and MSC derived exosomes in the matrigel 
plug (n = 3-5) does not lead to a significant 
increase in the percentage of CD31+ cells (no 
exosomes; 61.8% ± 29.3%, CMPC exosomes; 
48.3% ± 12.0%, MSC exosomes 54.1% ± 
11.0%, ns) or B) SMA+ cells (no exosomes; 
9.5% ± 4.0%, CMPC exosomes; 14.2% ± 
12.7%, MSC exosomes 14.8% ± 11.6%, ns).
Figure S6: Dose dependent effect of CMPC and 
MSC exosomes on influx of cells into matrigel 
plug. A) Less than 1 μg of CMPC (n = 9) and MSC 
(n = 3) exosomes did not lead to a significant 
increase in the number of cells per hpf infiltrating 
the plug (respectively: 159.5 ± 32.7 and 161.6 ± 
38.9) as compared to empty matrigel plugs (n = 10, 
132.1 ± 11.7), whereas more than 2 μg of exosomes 
do (CMPC derived exosomes; n = 5; 404.8 ± 66.2, 
MSC derived exosomes; n = 10, 342.5 ± 34.5). B) 
CMPC and MSC derived exosomes in a matrigel 
plug can influence the influx of cells in neighboring 
empty matrigel plugs. In the matrigel plug 
without exosomes, without surrounding matrigel 
plugs 105.7 ± 6.8 cells per hpf could be detected, 
whereas in the empty matrigel plug surrounded by 
two matrigel plugs with a low dose of exosomes 
(derived from 1*107 cells) 161.2 ± 25.2 or with a 
high dose of exosomes (derived from 1*108) 248.7 ± 
46.3 cells per hpf could be detected.
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Figure S8: CMPC and MSC derived exosome stimulation of angiogenesis in vitro is 
dependent on exosomal EMMPRIN expression, but not in vivo. A) Blocking exosomal 
EMMPRIN with anti-EMMPRIN antibody (Fitzgerald; 10R-CD147aHU, 20 μg/ml). Western 
blot analysis of antibody treated CMPC exosomes (top: isotope control antibody, middle: anti-
EMMPRIN antibody) after sucrose gradient purification, probed with goat anti-mouse secondary 
antibody (top and middle) or flotillin-1 antibody (bottom). B) Matrigel assay with anti-EMMPRIN 
treated MSC exosomes lead to 22.1% ± 7.2% reduced total tubular length (top) and 39.3% ± 7.9% 
less junctions (bottom). C) In vivo matrigel plug assay with anti-EMMPRIN treated CMPC and MSC 
exosomes did not lead to reduced influx of cells (CMPC: 451.1 ± 97.8, MSC: 491.02 ± 151.3 cells per 
hpf) compared to isotype control antibody treated exosomes (CMPC: 404.8 ± 66.2, MSC: 348.17 ± 
36.4 cells per hpf) (D) nor did it lead to reduced expression of EMMPRIN (top), MMP-9 (middle) 
and VEGF (bottom) in infiltrated cells. Scale bar = 20 μm
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Figure S9: Schematic overview of exosome isolation. Exosomes are isolated from the 
conditioned media using differential centrifugation. The CM is centrifuged at increasing 








Human fetal CMPCs are isolated from the heart based on MACS separation using a Sca-1 
antibody, as previously described1. CMPCs are cultured in 0.1% gelatin coated flasks in 
a mixture (1:3) of EGM-2 (Lonza; CC3156 and CC4176) and M199 (Lonza; BE12-119F), 
supplemented with 10% fetal bovine serum (FBS; Gibco; 10270), penicillin and strep-
tomycin (P/S; Gibco; 15140-122), and non-essential amino acids (Lonza; BE13-114E).1–3 
Human fetal MSCs are isolated from human bone marrow cells, from which mononuclear 
cells are separated by Ficoll-Paque (GE Health care; 17-1440-03) density gradient and 
subsequently plastic adherence.4 HF-MSCs are cultured in 0.1 % gelatine coated flasks 
in culture medium, consisting of alphaMEM (Gibco, 22561-021) supplemented with 10% 
FBS, P/S, Vitamin C (35.2 μ/ml; Sigma; A4544) and basic fibroblast growth factor (bFGF, 
1ng/ml, Sigma; F0291).4 Human umbilical vein endothelial cells (HUVECs) are isolated as 
previously described and propagated in EGM-2 culture medium on uncoated flasks.5 Hu-
man micro vascular endothelial cells (HMEC-1) are cultured on fibronectin coated flasks 
(10 μg/ml) in MCDB131 (Gibco; 10372-019), supplemented with 10%FBS, P/S, hydronic 
acid (50 nM, Sigma ; H6909-10), and human endothelial growth factor (EGF, 10 ng/ml, 
Peprotech/Invitrogen 016100-15-A) and L-glutamine (200 nM, Gibco; 25030-024).6,7 All 
cells are grown to confluence in 3 to 4 days, in a humidified 37°C incubator at 5% CO2. 
Standard informed consent procedures and prior approval of the ethics committee of the 
University Medical Center Utrecht were obtained. All procedures were carried out in ac-
cordance with the principles wet forth in the Helsinki declaration.
Conditioned medium and exosome isolation
For the isolation of exosomes, MSCs and CMPCs were cultured to confluence in exosome 
free medium. Hereto, all serum components are cleared from exosomes via centrifugation 
for 1h at 164,000 x g using Optima™ LE-80K Ultracentrifuge (Beckman Coulter), followed 
by filter sterilization (0.2 µm before use. Comparison of vesicle content of normal medium 
versus cleared serum is shown in Figure S1. Conditioned medium (CM) was collected 
from the cells and centrifuged 15 minutes at 2,000 x g. Exosomes were isolated from the 
CM, as described previously,7,8 via differential centrifugation in two additional steps; 30 
min at 10,000 x g and 70 min at 110,000 x g at 4°C. After the last step, the supernatant 
(exosome diminished CM) was removed and the pellet (exosomes) was washed once 
in PBS and centrifuged again for 70 min at 110,000 x g.7 The final exosome pellet was 
resuspended in PBS or subjected to a sucrose gradient for further purification. For the 
sucrose gradient, exosomes were resuspended in 2.5 M sucrose 20 mM TRIS (pH 7.4) 
solution and a linear gradient was created by layering 15 fractions (2.0 M – 0.4 M Sucrose) 
on top. This gradient is subsequently centrifuged for 14-16 hours at 230,000 g at 4°C and 





Total RNA was isolated using the Nucleospin RNA isolation kit (Bioké, The Netherlands) 
according to manufacturer’s protocol. Subsequently cDNA was synthesized with 1 µg of 
RNA using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). Quantitative 
real-time was performed for expression levels of EMMPRIN, β-actin and ARP (primer 
sequences available on request), using Sybr-green mastermix (Bio-Rad Laboratories). 
Expression was normalized for the housekeeping genes β-actin and ARP.
Exosome characterization
NanoSight analysis
The size distribution of all vesicles, including exosomes, within the CM was analyzed 
based on Brownian motion using the NanoSight LM10SH equipped with a 532-nm laser 
(NanoSight, Amesbury, United Kingdom and NTA software version 2.2). The conditioned 
medium was centrifuged at 2,000 x g to remove cell debris and was diluted at least 500 
times with PBS. From each sample five recordings were made for 90 seconds at 22°C with 
equal shutter and gain adjustments.9
Electron microscopy
Isolated exosomes were resuspended in phosphate buffer containing 1% glutaraldehyde 
and subsequently loaded onto formar/carbon-coated electron microscopy grids. The sam-
ples were contrasted with uranyl acetate. Images were captured using a transmission 
electron microscope JEOL 1200EX.7,10
SDS-PAGE, Western blot and zymography
The expression of exosomal markers was analyzed by Western blot. In preparation isolat-
ed and sucrose gradient- purified exosomes were resuspended in PBS and 4x laemli buffer 
and subjected to SDS-PAGE under denaturating and non-reducing conditions using pre-
cast gels (Novex; NP0335BOX). Proteins were transferred to PVDF membranes (Millipore; 
IPVH00010), which was subsequently blocked in 5% milk (BioRad; 170-6404) dissolved 
in PBS-T20 (0.1%). Membranes were incubated with appropriate antibodies, diluted in 
5% milk-PBS-T20; flotillin-1 (0.4 μg/ml; Santa-Cruz Biotechnology; SC25506), CD9 (0.5 
μg/ml, Santa-Cruz Biotechnology; SC53679), VEGF (1 μg/ml; Santa Cruz Biotechnologyl 
SC-152), EMMPRIN (10 μg/ml; Fitzgerald; 10R-CD147aHU), Vinculin (Sigma V9131) Goat 
anti-Rabbit-horse radish peroxidase (HRP) (0.12 μg/ml, Dako; P0448), and Goat-anti-
Mouse HRP (0.5 μg/ml, DAKO; P0447). The proteins were detected with chemilumines-
cent peroxiase substrate using a Chemi Doc™ XRS+ system (Bio-Rad) and Image Lab™ 
software.
For zymography, proteins were separated in a gelatine (2 mg/ml, Sigma) 8% bisacryla-
mide gel (Bio-Rad, 210004678). The gel was subsequently washed in 2.5% Triton-X100 
solution (Sigma; T8787) and activated in 0.05% Brij35 solution (Sigma; B4184). The 
gel was counterstained with coomassie blue solution and bands were visualized using a 
Chemi Doc™ XRS+ system (Bio-Rad) and Image Lab™ software.7
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Exosomal stimulation of endothelial cells in vitro
PKH labelling of exosomes and uptake by endothelial cells
CMPC- and MSC-derived exosomes were stained with PKH26 (Sigma; 050M0730), as de-
scribed by the manufacturer. After ten minutes of incubation at RT, 50 μl of exosome-de-
pleted FBS was added and excess and free PKH26-label was washed from the exosomes 
by sucrose gradient. All fractions were subsequently centrifuged at 110,000 x g and the 
pellets were resuspended in 20 μl PBS and incubated for three hours with both HMECs 
and HUVECs.11 Live imaging was performed for 24hours using the Leica AF6000, in a 
climate controlled chamber at 37oC with 5% CO2. Pictures were taken every 20 minutes. 
Scratch wound cell migration assay
HMECs were seeded in a 48 well plate and grown to confluence. A scratch was made 
with the tip of a 200 μl pipet tip as described before and the medium was replaced with 
MCDB131, with or without the presence of CMPC- or MSC derived exosomes from 10 
million cells. The cells were incubated at 37 C and 5% O2 for 6 hours and closure of the 
scratch was measured based on the surface covered in the scratch area between 0 and 
6h/24h using Adobe Photoshop CS5 Software. The area of the scratch after the incubation 
was calculated relative to the initial scratch area, resulting in percentage closure of the 
scratch. 6,7[6,7] 
Spheroid assay
HUVECs and HMECs were used to make spheroids as described before.6 For this, 800 
cells were seeded in a low-binding 96-well round bottom plate in 0.1% methyl cellulose 
in DMEM. After 24 hours, the spheroids were embedded in collagen (1 mg/ml) and stim-
ulated with CM, exosome depleted CM, or isolated exosomes resuspended in exosome 
depleted CM. These were derived from both CMPCs and MSCs and incubated at 37 C, 5% 
CO2. After 24-48 hours, in vitro sprouting was quantified by measuring the cumulative 
length of the tubular outgrowth and the number of branch points using ImageJ software 
(NIH, v1.50c).6,7
Matrigel assay
HMECs or HUVECs (10,000 cells) were cultured in a μ-slide for angiogenesis (Ibidi; 81501), 
coated with growth factor reduced (GR) matrigel (BD Biosciences; 354230), and incu-
bated with basal endothelial medium with or without CMPC- or MSC derived exosomes 
from 1e7 cells. After 14h, the organization of the network was analyzed by comparing the 
total length of the network, the number of junctions, and the length per junction using 
AngioQuant.6 Additionally, exosomes were treated with anti-EMMPRIN antibody as de-
scribed before.7 In short, isolated exosomes were resuspended in PBS and incubated with 
αEMMPRIN antibody (Fitzgerald; 10R-CD147aHU) or isotype control antibody (Fitzgerald; 
31C-CH1004) in a final concentration of 20 μg/ml in 100 μl for 30 minutes at 37°C, fol-
lowed by sucrose gradient. To verify exosomal binding of the antibody, each fraction was 






The animal experiments were approved by the Animal Ethical Experimentation Commit-
tee of Utrecht University and carried out in accordance with the Guide for the Care and Use 
of Laboratory Animals. Mice (C57bl/6) were anesthetized with a mixture of fentanyl (0.05 
mg/kg), midazolam (5 mg/kg), and medetomidine (0.5 mg/kg) through an intraperito-
neal (ip) injection. For knockdown experiments, mice were anesthetized with isofluorane 
inhalation (2-4%). CMPCs- and MSCs-derived exosomes (20 μg exosomal protein; deter-
mined by BCA protein assay, ThermoScientific; 23225) were subjected to sucrose gradient 
and exosome fractions (density 1.07-1.17 g/ml) were pooled and centrifuged before use. 
This pellet was resuspended in 50 μl PBS and 950 μl GR matrigel. As a control 50 μl PBS 
was resuspended in 950 μl of GR matrigel. 200 μl of GR matrigel with CMPC exosomes, 
MSC exosomes, or without exosomes was subcutaneously injected in the flank of the mice. 
To recover, the mice received a mixture of atipamezole (2.5 mg/kg ip) and flumazenil (0.5 
mg/kg ip).  After 14 days, the matrigel plugs were collected and all mice were sacrificed 
using a cocktail of ketamine (100 mg/kg ip) and medetomidine (8 mg/ml). Matrigel plugs 
were fixated in formaldehyde and processed for paraffin sectioning. 
Immunohistology 
From the matrigel plugs, 7 μm paraffin tissue sections were obtained and stained by 
hematoxylin and eosin (H&E). For the detection of CD31 and SMA positive cells, slides 
were stained with anti-CD31 (130 ng/ml, Santa-Cruz Biotechnology; SC-1506R), bioti-
nylated goat anti rabbit IgG (7.5 μg/ml, Vector Laboratories; BA-1000) and streptavidin 
Alexa Fluor® 555 (2 μg/ml, Invitrogen; S21381) or with anti-actin-α-SM-FITC (1:400, 
Sigma-Aldrich; F3777), both counterstained with Hoechst 33342 dye (Invitrogen) and em-
bedded in Fluoromount-G (SouthernBiotech; 0100-01). Images were captured using cellP 
software (Olympus) on an Olympus BX60 microscope and processed with Adobe Photo-
shop CS5. Total cell infiltration was quantified in the plugs at three levels and at three 
random areas per level, as well as the number of CD31pos and SMApos cells.
In addition to the detection of vascular cells, infiltrated cells were analyzed for pro angio-
genic proteins; EMMPRIN, MMP-9 and VEGF. For EMMPRIN, slides were stained with an-
ti-EMMPRIN (Santa Cruz Biotechnology, sc-9753, 2 μg/ml), biotinylated rabbit anti-goat 
(1.6 μg/ml, DAKO, E0466) and streptavidin-HRP. MMP-9 was detected by staining slides 
with anti-MMP-9 (2 μg/ml, Abcam; 38898) and anti-Rabbit-HRP (brightvision; DPV0999). 
Both HRP labeled antibodies were visualized by AEC and all nuclei were visualized via 
Haematoxylin staining. Slides were embedded in entellan (merck Millipore, 107960) and 
images were captured and analyzed.  For the detection of VEGF positive cells, slides were 
stained with anti-VEGF (1 μg/ml; Santa Cruz Biotechnologyl SC-152) and biotinylated goat 
anti rabbit IgG (7.5 μg/ml, Vector Laboratories; BA-1000) and streptavidin Alexa Fluor® 
555 (2 μg/ml, Invitrogen; S21381) and nuclei were stained with Hoechst 33342 dye. Slides 
were embedded in Fluoromount-G and pictures were taken and analyzed. An overview of 
all antibodies used in this study can be found in Table 1.
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Table 1 Overview of antibodies used in this study
Antibody Company Cat Number  Antibody Company Cat Number
Flotillin-1 Santa Cruz SC25506  Goat anti rabbit HRPO DAKO P0448
CD9 Santa Cruz SC53679  Goat-anti-mouse HRPO DAKO P0447
EMMPRIN Fitzgerald 10R-CD147aHU  Goat-anti-rabbit biotinylated
Vector 
Laboratories BA-1000
CD31 Santa Cruz SC1506R  Rabbit-anti-goat biotinylated DAKO E0466
α-SM-FITC Sigma-Aldrich F3777  anti-Rabbit-HRPO Brightvision DPV0999
EMMPRIN Santa Cruz SC9753  Streptavidin Alexa Fluor® 555 Invitrogen S21381
MMP9 Abcam 38898  Donkey-anti-Mouse HRP Abcam ab98771
VEGF Santa Cruz SC152  Donkey-anti-Rabbit HRP Abcam  ab98493
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Cell transplantation studies have shown that injection of progenitor cells can improve 
cardiac function after myocardial infarction (MI). Transplantation of human cardiac pro-
genitor cells (hCPCs) results in an increased ejection fraction, but survival and integration 
is low. Therefore, paracrine factors including extracellular vesicles (EVs) are likely to con-
tribute to the beneficial effects. We investigated the contribution of EVs by transplanting 
hCPCs with reduced EV secretion. Interestingly, these hCPCs were unable to reduce infarct 
size post MI. Moreover, injection of hCPC-EVs did significantly reduce infarct size. Anal-
ysis of EV uptake showed cardiomyocytes and endothelial cells primarily positive and a 
higher in Ki67 expression in these cell types. Yes associated protein (YAP), a proliferation 
marker associated with Ki67, was also increased in the entire infarcted area. In summary, 
our data suggest that EV secretion is the driving force behind the short term beneficial 
effect of hCPC transplantation on cardiac recovery after MI.
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Introduction
Cardiovascular disease is one of the most prevalent causes of mortality in the world and 
myocardial infarction (MI) attributes to almost one-third of its deaths.1 Though many 
of the risk factors leading to MI can be treated to prevent recurrence, the tissue damage 
remains untreatable to date. The loss of cardiomyocytes is permanent, reducing cardiac 
output, and ultimately leading to end-stage heart failure. To prevent heart failure, ther-
apies aiming to reduce damage to the injured myocardial wall and/or replace the lost 
cardiomyocytes have been explored. One approach to repair cardiac tissue was to inject 
human heart derived cardiac progenitor cells (hCPCs) into the border zone of the in-
farction.  Since hCPCs are able to differentiate into cardiomyocytes, endothelial cells and 
smooth muscle cells in vitro,2,3 they are likely candidates to replenish the infarcted heart 
with new cardiovascular cells. Transplantation of hCPCs into the infarct border zone has 
indeed been shown to lead to a sustained stabilization in cardiac function up to 3 months 
post-MI, and was accompanied with a significant increase in the number of murine ves-
sels in the infarct border zone.4 However, only a small percentage of the injected hCPCs 
remained in the mouse heart 3 months after transplantation.4 Two weeks after transplan-
tation, an increase in vessel density was already discerned, with no evidence of vascular 
differentiation yet of the injected progenitor cells.5 Most interestingly, an effect on cardiac 
function was observed as early as 2 days post-MI 4. These observations suggest that hCPCs 
positively influence the post-MI environment through the secretion of paracrine factors, 
instead of direct differentiation into cardiovascular cells that rebuild the myocardial wall. 
This is further supported by our observation that extracellular vesicles (EVs) isolated 
from hCPCs have a great pro-angiogenic potential in vitro and in vivo,6,7 due to presence 
of several pro-angiogenic factors in and on these EVs, of which extracellular matrix met-
alloproteinase inducer (EMMPRIN) is a major determinant.6,7
EVs form a population comprising a multitude of microvesicles, of which the smallest, 
termed exosomes, range from 50-150nm in size. Exosomes have a lipid bilayer membrane 
and their content includes mRNAs, miRNAs and proteins.8–10 EVs are able to influence 
many aspects of cell behavior, such as migration and proliferation, modulate the immune 
response and can signal over both short and long distances.6,11–13 These influential char-
acteristics make EVs promising as therapy after MI, since after injection, they potentially 
can affect the cardiovascular cells in the damaged and ischemic area.
Another effect of hCPC transplantation is an increase in the number of PCNA expressing 
cells in the mouse myocardium.5 Inducing proliferation of the surviving endogenous car-
diomyocytes can also lead to restoration of cardiac contractility. Unfortunately, although 
proliferation of cardiomyocytes is observed in neonates, this capacity reduces dramat-
ically shortly after birth.14 Until recently, the adult mammalian heart was considered a 
post-mitotic organ,15 but Bergmann et.al. showed that cardiomyocyte turnover was pres-
ent in the adult heart, albeit at only 0.3-1% per year.16,17 The transcription factor Meis1 
has been shown to be involved in the decrease in cardiomyocyte proliferation after birth,18 
while other studies have shown the involvement of the Hippo pathway in cardiomyocyte 
proliferation.19,20 Inhibition of Hippo pathway components lead to activation of YAP, which 
induces proliferation of cardiomyocytes.21,22 
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Since hCPC transplantation after MI improves cardiac function within 48 hours after in-
jection,4 which is too early to be the result of hCPC differentiation.5 hCPC transplantation 
do increase the number of PCNA expressing cells in the mouse myocardium,5 and hCPCs 
secrete EVs that are pro-angiogenic,6,7 the aim of this study is to determine if hCPC secret-
ed EVs are responsible for the early beneficial effects after hCPC transplantation.
Materials and methods
Cell culture
hCPCs were isolated and cultured as previously described.23,24 For the isolation of EVs, 
hCPCs (fetal CPCs, HFH17.1) were cultured for 4 days in medium containing EV depleted 
serum as described before 7. Human microvascular endothelial cells (HMEC-1), used for 
functional assessment of the hCPC-EV activity,6 were isolated as previously described25,26 
and cultured on fibronectin coated flasks in MCDB131 medium (without L-Glutamine) 
with 10% fetal bovine serum (FBS), 10ng/mL Epidermal Growth Factor (EGF), 1 μg/mL 
Hydrocortisone, 10 mM Glutamine and 1% penicillin/streptomycin. All cells were cultured 
at 37oC with 5% CO2. 
EV isolation and labelling
After culturing hCPCs for 4 days, conditioned medium was harvested, and hCPC-EVs were 
isolated by differential centrifugation with a final step at 110,000xg, as described previ-
ously.7 Density separation was performed by sucrose gradient. EVs were mixed into the 
bottom layer containing 2.5M sucrose, followed by a layered gradient ranging from 2M to 
0.4M sucrose. The gradient was centrifuged for 16 hours at 190,000xg, divided in 12 frac-
tions, washed with phosphate buffered saline (PBS), centrifuged 70 minutes at 110,000xg 
and used for Western blot analysis. To label EVs, PKH26 or PKH67 (Sigma) was incubated 
with isolated EVs according to the manufacturer’s protocol. After a 10-minute incubation, 
labelling was stopped by adding FBS (ultra-EV free, centrifuged overnight at 160,000xg), 
and EVs were isolated by a sucrose gradient as described above. The fraction containing 
EVs was washed with PBS and centrifuged for 70 minutes at 110,000xg. Pellet was resus-
pended in PBS and diluted to a concentration of 0.8μg/μl based on EV protein, assessed 
by BCA assay (Thermo Fischer).
Characterization of EVs
EV characterization was performed by loading 10μl of EV-isolate, corrected for equal cell 
numbers,  onto a 10% SDS-PAGE gel and Western Blot analysis for Flotillin-1 (rabbit, SC-
25506, Santa Cruz), CD9 (sc-53679, Santa Cruz), CD63 (CBL-553, Millipore), CD81, ALIX, 
TSG101, EMMPRIN (10R-CD147alphaHu, Fitzegerald).27 Purity of EV isolates was con-
firmed by absence of Calnexin (mouse, SC-80645, Santa Cruz) and underrepresentation 
of AGO.  EV size was analyzed with qNano (Izon) to confirm size distribution and concen-
tration, and TEM was used to visualize the vesicles. EV functionality was confirmed using 
a scratch assay.7 A scratch was made in a monolayer of HMEC-1 cells and any floating cells 
were removed. Medium was replaced by basal MCDB131 with or without the addition of 
5μg/ml EVs (determined by BCA assay (Thermo Fischer), or equal volumes of EV-isolate 
(corrected for equal cell numbers). Percentage closure was determined after 24 hours. 
113
6
EVs from hCPCs reduce infarct size
Rab27A and Rab27B knockdown
Knockdown of Rab27A and Rab27B was established via lentiviral mediated shRNA 
(TRCN0000380306, TRCN0000294016, MISSION library, Sigma). As a control, cells were 
transduced with a shRNA targeting luciferase (SHC007, MISSION library). Medium was 
changed after 16 hours and the cells were subjected to puromycin selection for 48 hours. 
Knockdown was verified by qPCR. RNA was isolated using TriPure (Sigma), according 
to manufacturer’s specifications. cDNA was synthesized with the RevertAid First Strand 
cDNA Synthesis Kit (Thermo Scientific) using 1μg of RNA. Expression levels of Rab27A 
and Rab27B were assessed by quantitative real time PCR using SYBR-green mastermix 
(Bio-Rad Laboratories). Housekeeping genes GAPDH, β-actin and ARP were used to nor-
malize expression levels. For further EV analysis (Western Blot, qNano, scratch analysis), 
volumes of EV isolates were corrected for number of cells.
Myocardial infarction by ligation of the left anterior descending artery (LAD)
All animal experiments were approved by the Animal Ethical Experimentation Committee 
of the Leiden University Medical Center and carried out in accordance with the Guide for 
the Care and Use of Laboratory Animals. Male NOD-SCID mice, 10-12 weeks old, were 
anesthetized by intraperitoneal injection (i.p.) injection of 200 μl anesthesia mixture 
(0.05 mg/ml dexmedetomidine, 0.01 mg/ml fentanyl and 1 mg/ml midazolam) and sub-
sequently intubated. The LAD was permanently ligated as described previously.28 After 15 
minutes, PBS, 0.5*106 hCPCs or 8 μg of purified EVs were injected into the border zone 
of the infarction, with two injections of 5μl on each side of the ligation. Injections were 
randomly assigned. The mice were awakened by i.p. injection of an antagonist mixture 
(100 μl, 0.08 mg/ml flumazenil, 0.4 mg/ml atipamezole, 0.025 mg/ml buprenorfine). 
PBS injected mice were used as control group for all experimental conditions to reduce 
animal numbers. Mice were excluded from further analysis in case of irregularities during 
surgery that could affect infarct size including lack of blanching of the cardiac tissue after 
ligation, or when the location of the suture was incorrect. Number of animals per experi-
ment is shown in figure legends.
TTC staining
After two days the animals received a lethal dose of anesthesia, after which the hearts 
were flushed with Evans-blue to identify the transfused area. Subsequently the hearts 
were collected, sliced into 1 mm slices and stained with 1% TTC in Sorensen buffer. Slices 
were imaged with AxioCamICc3 and infarct size was analyzed with ImageJ (v1.50f). In-
farct size was analyzed by measuring total left ventricular area and infarcted area, and 
calculating the infarct as a percentage of total left ventricular area. Analyses were per-
formed blinded.
Immunostaining
Hearts destined for immunohistochemical analysis were incubated overnight in 15% 
sucrose solution, embedded in optimal cutting temperature (OCT) compound and stored 
at -80oC. Cryosections of 7μm were cut transversally from apex to the site of ligation, 
with 280μm intervals after every 33 sections. Sections were dried and fixed with 4% 
paraformaldehyde before staining. The following antibodies were used for staining the 
sections: α-Ki67 (rabbit, AB9260, Millipore), α-MF20 (mouse, DSHB), α-αSMA (mouse, 
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A2547, Sigma), α-cTNI (goat, 4T21/2, HyTest), α-CD31 (goat, SC-1506, Santa Cruz), 
α-YAP (rabbit, 4912, Cell Signaling), α-Endoglin (goat, AF1097, R&D systems). The α-YAP 
antibody was amplified using TSA amplification (Thermo Fisher). After incubation with 
the appropriate secondary antibody, the section were counterstained with DAPI and 
mounted with Fluoromount (Sigma). The sections were imaged using a Leica microscope 
and scanned with Pannoramic Slide Scanner (3D Histech). Analysis was performed with 
ImageJ software. 
Quantification of proliferative markers
To determine the where in the heart EVs induce proliferation markers, the total number of 
Ki67 and YAP expressing cells was determined in sections at levels 3 till 8 of a pilot group 
(see Figure 3A). The total number of positive nuclei was counted in the infarct area plus 
border zone, corrected for infarct size. Since levels 5 and 6 showed the highest uptake 
of EVs and numbers of positive cells, quantification of proliferating cell types in sections 
of level 5 and 6 was performed in all hearts. An area of 1.2 mm2 in the border zone was 
analyzed, spanning the entire width of the ventricle. Cells with Ki67 positive nuclei were 
categorized based on co-staining with cell type specific markers and morphology into car-
diomyocytes, endothelial cells and other/interstitial cells. Endoglin was analyzed as total 
area of endoglin signal in the sections corrected for total cardiac area. All analyses were 
performed blinded for treatment.
Statistical analysis
All data are presented as mean ± SEM. The statistical difference between two groups was 
analyzed using an unpaired Student’s t-test, with Welch’s correction in case of unequal 
variances. For three or more groups, one-way ANOVA was used, with Bonferroni as post-
hoc test. Level of significance was set at p<0.05.
Results
Infarct size is not affected after injection of hCPCs with reduced vesicle secretion
Transplantation of hCPC resulted in beneficial effects on the heart after MI.4 Interestingly, 
EVs secreted by hCPCs were shown to possess pro-angiogenic activity,7 hence paracrine 
factors may represent an important component of the beneficial effects of cardiac progen-
itor cell transplantation on the heart after MI. Therefore our first aim was to examine to 
what extend the secretion of EVs by hCPCs contributes to this effect. Rab27A and Rab27B 
are part of the EV secretion pathway and loss of these proteins has been documented 
to affect EV secretion.29 To this end, we transduced hCPCs with lentiviruses expressing 
shRNA for Rab27A and Rab27B or a scrambled control (sControl). qPCR analysis revealed 
efficient knockdown of Rab27A and Rab27B (Figure 1A). To determine if the knockdown 
influenced the EV secretion of hCPCs, conditioned medium of sControl-hCPCs, Rab27A 
KD-hCPCs and Rab27B KD-hCPCs were processed for EV isolation by ultracentrifugation. 
EV-isolates were resuspended in equal volumes and corrected for the number of cells 
the conditioned medium was derived from. We confirmed the presence of extracellular 
vesicles in the conditioned medium of sControl-hCPCs with Western blot for EV markers 
and by determining the density of vesicles (Supplemental Figure 1A, B). qNano tech-
nology revealed a population of vesicles within a size range of 50-150nm, with a mean 
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diameter ±100nm (Supplemental Figure 1C), suggesting the presence of exosome-like 
vesicles, which could be confirmed by EM (Supplemental Figure 1D).10,27 In the EV-iso-
lates of Rab27A KD-hCPCs, the number of secreted vesicles was decreased, while Rab27B 
knockdown did not affect vesicle secretion (Figure 1B). Although Rab27A knockdown in-
creased the mRNA levels of Rab27B, this did not restore the number of secreted EVs to 
sControl-hCPC levels (Figure 1A, B). Western Blot analysis for exosomal-enriched protein 
Flot-1 confirmed a drastic reduction of the amount of EVs in the EV isolates upon Ra-
b27A knockdown, while no difference was seen in the EV isolates from Rab27B KD-hCPCs 
compared to sControl-hCPCs (Figure 1C). We have previously reported that migration 
of endothelial cells was increased after stimulation with EVs from hCPCs.7 Therefore, we 
examined whether migration of HMEC-1 cells was attenuated when subjected to EV-iso-
lates from the Rab27A KD-hCPCs, compared the sControl-hCPCs. Indeed, isolations from 
Rab27A KD-hCPCs were unable to stimulate the migration of HMEC-1 cells in a scratch 
assay to the same extend as sControl-hCPC (Figure 1D). 
To determine if the EV secretion is responsible for the cardioprotective effect of hCPCs 
after myocardial infarction, we injected either sControl-hCPCs or Rab27A KD-hCPCs into 
the infarct border zone after induction of MI. Immunohistological analysis after 48 hours 
showed the presence of both sControl-hCPCs (Figure 1E) and Rab27A KD-hCPCs (Figure 
1F) in the heart. To determine the effect on infarct size we performed a TTC staining 
and observed that sControl-hCPCs significantly reduced the infarct size when compared 
to PBS injections (Figure 1G,H). This effect was not present upon injection of Rab27A 
KD-hCPCs, suggesting that the vesicles secreted by hCPCs are a major contributor to the 
reduction of infarct size by hCPCs.
hCPC derived EVs reduce infarct size
Since Rab27A KD-hCPCs did not reduce infarct size, suggesting a role for the extracellular 
vesicles, we next sought to directly analyze the effect of hCPC derived EVs upon injection 
into the infarcted myocardium. Prior to injecting the EVs we confirmed that the pres-
ence of a population of EVs of ± 120nm in size with a density of approximately 1.12g/ml 
(data not shown). Furthermore, functional activity of EVs was evaluated by performing a 
scratch assay, which revealed that these EVs stimulated the migration of HMEC-1, as we 
previously reported6 (Figure 2A). EVs were subsequently injected into the border zone of 
the infarction, 15 min after permanent ligation of the LAD, and the infarct size was analyz-
ed after 48 hours (Figure 2B). As shown by TTC analysis (Figure 2C), PBS injected hearts 
displayed a mean infarct size of 42.9% ±4.4, while the infarct size in hearts injected with 
EVs was 26.75% ±2.2 (Figure 2D), indicating that hCPC-EVs reduce the extent of damage 
shortly after MI.
EV uptake by cardiovascular cells post MI in the myocardium
To understand how EVs could exert their effect shortly after MI, we determined which of 
the cardiovascular cells present within the injured myocardium internalize EVs. There-
fore, we injected EVs labelled with PKH67 or PKH26 into mouse hearts that underwent 
MI and analyzed the distribution of the fluorescently labelled EVs in combination with 
cell type specific immunofluorescent analysis (Figure 3A). After EV labelling, sucrose 
gradient separation was used to prevent free label injections into the myocardium. As can 
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Figure 1: Rab knockdown reduces the secretion of EVs as well as their positive effect in 
vitro and in vivo. (A) Rab knockdown analysis by qPCR. Both Rab27A and Rab27B are effectively 
knocked down after lentiviral shRNA transduction. (B) qNano analysis of vesicles in the EV-isolate 
by sControl-hCPCs, and hCPCs with Rab27A and Rab27B knockdown. Only Rab27A KD reduces the 
number of EVs compared to sControl-hCPCs. (C) Western Blot for Flotillin-1 confirms reduction 
of EVs by Rab27A knockdown, while no effect is seen with Rab27B knockdown. (D) Effect of 
EV-isolate on migration of endothelial cells after scratch assay. EV-isolate from Rab27A KD has 
reduced capacity to induce migration compared to sControl-hCPCs EV isolate (EV isolates of equal 
cell numbers. (E, F) Both sControl-hCPCs (E) and Rab27 KD-hCPCs (F) are observed in the heart 
after 48 hours (Blue: DAPI, Green: human Lamin A/C, Red: PECAM-1, yellow: cardiac troponin 
I (cTNI). (G) Representative pictures of TTC analysis after injection of PBS, sControl-hCPCs and 
Rab27A KD-hCPCs. (H) Quantification of the infarcted area in hearts injected with PBS, sControl-
hCPCs and Rab27A-KD hCPCs (PBS: n=9, control-hCPC: n=4, Rab27A KD-hCPC: n=5).
Figure 2: hCPC-derived EVs reduce infarct size.  (A) EVs stimulate wound closure in a HMEC-1 
scratch assay. Percentage of closure of the wounded area was determined after 24h. (B) Timeline 
of in vivo procedures. (C) Representative images of TTC stained hearts injected with PBS or 
exosomes, 48 hours after MI. White area represents the infarcted region. (D) Quantification of the 
infarcted area as a percentage of the total area of the left ventricle (n=9).
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Figure 3: EV distribution in the heart (A) Schematic representation of the analysis of infarcted 
heart. Blue arrows indicate the EV injection site. (B) Analysis of the entire heart showed the 
uptake of PKH67 from the loaded EVs in the heart from level 3 to 7/8. White arrows point at 
positive cells. (C) Higher magnification of insert in B, showing uptake of EVs in the infarct zone. 
(D) Higher magnification of insert in C, which shows uptake of EVs by cardiomyocytes (arrows) 
and endothelial cells (arrowheads). 
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showing a large area of EV uptake from levels 3 to 8 (Figure 3B). The total area of EV dye 
uptake extended to over 2,700μm. Most EVs were taken up by cells in the border zone, 
close to the anticipated sites of injection (levels 5 and 6). To determine which cell types 
contained EVs, we analyzed high magnification images (Figure 3C). The dominant target 
cells for hCPC-derived EVs were endothelial cells and cardiomyocytes, although some in-
terstitial cells also seemed to be positive for EV uptake (Figure 3D, single channel pictures 
in Supplemental Figure 2). Thus, EVs are effectively taken up by cardiomyocytes and 
endothelial cells after injection into the ischemic left ventricle.
EVs increased the number of Ki67 and YAP expressing cells in the left ventricle
Since EV injection reduced infarct size, we analyzed the EV positive area in more detail. 
We first assessed proliferation of cells within the infarcted area by determining the num-
ber of Ki67 positive cells. Interestingly, we found Ki67 expression not only within the PKH 
positive cells, but it was also more present in cells in the vicinity of the EV signal (Figure 
4A). Quantification of these cells, by counting the number of positive nuclei in relation 
to the infarct area, showed a significant increase in the number of Ki67 positive nuclei in 
hearts receiving hCPC-derived EVs compared to PBS injected heart (Figure 4B). Number 
of positive cells was corrected for infarct size in order to correct for differences in cardiac 
size. Next, we analyzed which of the cell types found in the border zone of the infarct were 
Ki67 positive. As shown in Figure 4C, we found Ki67 positive nuclei in cardiomyocytes, 
endothelial cells, and other/interstitial cells, which is in agreement with the cell types 
we identified before. Since the largest increase in proliferation was seen in layers 5 and 
6 (Supplemental Figure 3), we quantified the specific number of different cell types 
in the border zone of the infarct in these levels. As can be seen in Figure 4D, hCPC-EV 
injection resulted in a significant increase in Ki67 positive cardiomyocytes compared to 
PBS control (mean ±st.dev: 226,5±74.31 vs 94.17±43.20, p<0.05). A similar effect was 
seen for endothelial cells, where EV injection increased the number of Ki67 positive cells 
from 36.17±17.88 to 177.0±110.9 (p<0.05) (Figure 4E).  The difference in Ki67 positive 
cells in other cell types did not reach statistical significance (PBS: 215.2±56.53 vs EV: 
411.7±228.4) (Figure 4F). 
In order to investigate how EVs can increase Ki67 after MI, we looked into the association 
with activation of YAP. In tumor- and progenitor cells it is shown that Ki67 correlates to 
YAP expression and furthermore, a decrease in YAP causes a decrease in Ki67 levels and 
a decrease in proliferation.30–32 Therefore, we explored whether EV treatment affects YAP 
levels. Interestingly, we observed an increase in nuclear YAP in the border zone in the 
vicinity of the EV signal (Figure 5A, single channels Supplemental Figure 4), and a sig-
nificant increase of total YAP in the infarcted area (Figure 5B). In summary, injection of 
hCPC-EVs increases Ki67 and YAP signaling in the heart, of which the former is predomi-
nantly increased in cardiomyocytes and endothelial cells.
Endoglin level in the heart is influenced by EVs
Since we observed an increase in endothelial cell proliferation, we next questioned wheth-
er hCPC-EV treatment affected endothelial activation. We have previously shown that EVs 
from hCPCs are a very potent stimulant of angiogenesis.7 Since changes in vascular den-
sity are not yet measurable at this short-time point post-MI, we turned to endoglin as a 
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Figure 4: hCPC-derived EVs induce Ki67 expression in de left ventricle after MI (A) Ki67 (red) 
in the heart in the presence of EVs (green). Nuclei are stained with DAPI (Blue). (B) Quantification 
of Ki67 positive cells in the infarct and border zone, relative to the area of the infarct, shows 
that EVs increase the number of Ki67 positive cells (n=3) (C) Ki67 staining in the heart after EV 
injection show proliferation in various cell types (Arrows: positive cardiomyocytes; arrowheads: 
positive endothelial cells; circled arrowheads: other cells). Smaller pictures show examples of 
individual cell types. Cardiomyocytes were identified through autofluorescence. (D-F) Graphs 
depicting the number of proliferating cardiomyocytes (D), endothelial cells (E) and other cells 
(F) in the heart, in layers 5 and 6, after EV and PBS injection. A significant increase was found in 
cardiomyocyte proliferation (n=3).
Figure 5: YAP expression after MI. (A) Representative pictures of YAP expression in the 
borderzone of PBS and EV injected hearts. (B) Quantitative analysis shows that the number of 
YAP positive cells is higher in the infarct zone of hearts injected with hCPC-EVs compared to PBS 
injected hearts. Numbers of positive cells are normalized for infarct size and shown as number of 
cells per percentage infarct.
122
Chapter 6
Figure 6: Endoglin levels in the heart (A) Endoglin is present in EVs from hCPCs, two individual 
isolations are shown. (B) After injection of PKH labeled EVs, areas positive for EV uptake are also 
highly positive for endoglin, compared to PBS injection. (C) Quantification of endoglin levels in the 
entire heart after PBS or EV injection. (D) Endoglin signal is mainly found in endothelial cells and 
cells positive for EV uptake. 
and determined whether endoglin expression was changed after hCPC-EV injection. As 
shown in Figure 6A, endoglin is clearly present in hCPC-EVs, confirming their pro-an-
giogenic profile. Next, we analyzed if endoglin expression was increased in the injured 
myocardium after hCPC-EV injection. We observed an increase in endoglin expression in 
the infarct border zone in the area of EV uptake, when compared to control. (Figure 6B, 
C). Higher magnification showed mainly endothelial cells and small vessels with a strong 
endoglin signal. Endoglin staining also partially colocalized with EV uptake, suggesting 
delivery of endoglin by EVs (Figure 6D). Although the difference in endoglin levels did not 
reach significance, it does suggest that EVs, through delivery of endoglin itself and other 
pro-angiogenic stimuli, cause an increase in endoglin levels.
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Discussion
Cell transplantation has been extensively studied over the last decade as a regenerative 
therapy for the heart. The transplantation of hCPCs has been shown to increase cardiac 
function, induce neovascularization and, in some cases, provide new cardiomyocytes.3,4,34 
However, in the last few years it has become clear that this beneficial effect on heart 
performance is mainly due to the paracrine factors secreted by these cells.35 In this study, 
we show that EVs from hCPCs can decrease infarct size by inducing proliferative markers 
and by altering the angiogenic state of the tissue, as shown by the presence of endoglin 
positive activated blood vessels. 
Several studies have shown that injection of hCPCs exert beneficial effects after MI, and 
that hCPCs are able to differentiate to cardiomyocytes and endothelial cells in the mouse 
heart.3,4,34 Even as soon as 2 days post-MI, when hCPC differentiation is still absent, a 
positive effect is already seen, suggesting the effect of paracrine factors.5 Therefore we 
set out to discern between the effect of hCPCs and their secreted EVs on short term car-
diac regeneration and infarct size. Knockdown of Rab27A in hCPCs, previously shown to 
affect EV secretion in tumor cells,29 also reduced the number of EVs secreted from hCPCs. 
The observed increase in Rab27B was not sufficient to rescue the EV secretion, showing 
that Rab27A is crucial in the secretion pathway in hCPCs. This dependence on Rab27A 
has also been seen in other cells.36 The in vitro effect on endothelial cell migration was 
reduced when stimulated with the EV isolate from Rab27A knockdown cells, confirming 
a loss of paracrine effects. Injection of the cells into the murine heart after MI showed 
that normal hCPCs can decrease the infarct size after two days, which confirms the effect 
on cardiac function seen before.4 In contrast, we could not find a decrease in infarct size 
with RAB27A KD-hCPCs, showing that on the short term the paracrine factors are a major 
contributor to the cardioprotective effect.
It has been shown that paracrine factors from e.g. mesenchymal stromal cells (MSCs) 
and cardiac progenitor cells have beneficial effects after MI. Injection of the conditioned 
medium from MSCs has confirmed this hypothesis by showing a decrease in infarct size 
and increase in cardiac function.37,38 Since hCPCs are part of the cardiac cell lineage, their 
paracrine factors could be more tailored towards cardiac regeneration. For example, 
conditioned medium of hCPCs has been shown to induce angiogenesis and migration of 
hCPCs.39 Following this, multiple studies have shown that injection of EVs - of several cell 
sources - are capable of reducing cardiac infarction in mice and rats more than one week 
after MI induction.40–49 The first large animal experiment using cardiosphere derived EVs 
revealed a reduction in infarct size in an acute MI setting; however, it failed to show an 
improvement in cardiac function in a chronic model.50 A short term effect on infarct size, 
within 48 hours, has only been illustrated with EVs from human MSCs.51 Arslan and col-
leagues observed that the decrease in infarct size coincided with an increase in pAkt and 
pGSKβ signaling, known mediators in survival pathways of the cells. Here, we demon-
strate that EVs from hCPCs are also capable of reducing the infarct size after 48 hours. 
This is in corroboration with the results on cardiac functions after injection of hCPCs and 
supports the theory that paracrine factors are a major effector of cell therapy.4,5  
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Proliferation of cardiac cells after MI can prevent the extent of the damage and result in a 
preservation and regeneration of contractile force. So far, proliferation has only been seen 
after treatment with ES derived EVs and hypoxic MSC EVs.45,52 Khan et al. have shown an 
increase in proliferation of resident c-kit positive cells, via phospho-histone 3 staining,45 
upon EV injection. Zhu et. al. showed that MSC EV treated hearts had an increase in over-
all proliferation by Ki67 staining, but could not find a significant increase in cardiomyo-
cyte proliferation.52 We show here that injection of EVs from hCPCs leads to stimulation 
of expression of proliferative markers in the heart after MI and that this effect is already 
present after 48 hours. After EV injection an overall increase in proliferation could be 
observed in the infarcted and border zone area of the hearts. In particular around the 
area of EV uptake, the increase in proliferation, shown by Ki67 staining, was striking. 
Moreover, detailed analysis showed a specific increase in cardiomyocyte and endothelial 
cell proliferation, suggesting that these cell types are mainly being affected by the injected 
EVs. Interestingly, Ki67 was shown to correlate with YAP levels and a decrease in YAP ex-
pression levels caused a reduction in Ki67.30–32 In corroboration with the increase in Ki67 
we observe in our EV injected hearts, we also observed an increase in YAP in the vicinity 
of EV uptake. This is in line with reports showing that YAP is involved in cell growth21,53 
and that EVs are able to activate YAP signaling.54,55 Interestingly, Yap is part of the Hippo 
pathway and deficiencies in Hippo signaling have shown to be beneficial in heart failure.19 
Moreover, analysis of miRNAs involved in cardiomyocyte proliferation showed that the 
majority inhibit the Hippo pathway and lead to nuclear YAP localization.56 The increase in 
YAP we see therefore implies a link to proliferation and cardiac regeneration. However, to 
establish a direct correlation between cardiomyocyte proliferation and hCPC-EVs with re-
gards to YAP signaling, in depth in vitro experiments will be required. Since the Hippo-Yap 
pathway is also related to angiogenesis,57 and we observe an increase in ki67 expressing 
endothelial cells, the increase in Yap after EV-treatment could also affect endothelial func-
tion and neo-vascularization. Altogether, our results indicate that hCPC-EVs are capable 
of increasing proliferative markers in the cardiac tissue. 
Since we have observed the increase in Ki67 also in endothelial cells, we raised the ques-
tion whether angiogenesis was also affected by the hCPC-EVs here, since we have shown 
previously that hCPC-EVs are very potent inducers of angiogenesis.6,7 This increase in an-
giogenesis was seen in vitro as well as in vivo, and shown to be dependent on EMMPRIN. 
Therefore, since we analyzed the effects after 48 hours, we investigated the activation of 
endothelial cells after hCPC-EV injection through endoglin. Endoglin, a co-receptor for 
the TGF-β/ALK1 signaling pathway, is a known pro-angiogenic factor and is present on 
activated endothelial cells.33,58 We found that endoglin is present on the hCPC-EVs and that 
the endoglin signal was increased in and around the area of hCPC-EV uptake after hCPC-
EV injection. This signal was mainly seen in endothelial cells and small vessels, suggesting 
primarily endothelial activation of the smaller capillaries. Although the quantification did 
not reach statistical significance, probably due to the already activated post-MI responses, 
the observation of the increased endoglin signal indicates more local and small vessel ac-
tivation. This suggests that hCPC-EVs can activate endoglin in the cardiac cells and could 
thereby increase the activation of endothelial cells.
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The intricacy of their content, consisting of several (mi)RNAs and proteins, and the effec-
tiveness of EVs make them interesting potential therapies. Their ability to convey several 
signals and to be taken up by virtually any cell is an indispensable quality for an effective 
regenerative therapy, and makes them very suitable as an off-the-shelf treatment. We show 
that hCPC secreted EVs likely contribute to the reduced cardiac deterioration observed in 
pre-clinical cell transplantation studies. They increase proliferation in the left ventricle 
and promote cardiomyocyte proliferative markers in the border zone. Furthermore, they 
can influence angiogenesis by stimulation pro-angiogenic factors such as endoglin. Fur-
ther research into the mechanisms by which the EVs exert this effect would provide better 
insight into the therapeutic range of the EVs. Altogether, hCPC-EVs exert cardioprotective 
effects shortly after MI, making them promising novel therapeutic agents.
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Figure S1: Quality control of hCPC EVs. (A) Western Blot for known EV and exosomal markers, 
and AGO, which is underrepresented in vesicles. (B) EV isolation by sucrose gradient was collected 
in 12 different fractions that were individually analysed for the presence of EV. Western blot 
analysis is shown for CD9, ALIX, TSG101 and Flotillin-1. The triangle above the Western Blot 
represents the density of the numbered fractions, ranging from 1.06 g/ml (left, fraction 1) to 1.25 
g/ml (right, fraction 12). EVs are specifically present at 1.12 g/ml. (C) qNano analysis of vesicles 
secreted by hCPCs. The main population of vesicles is found at 120nm. (D) TEM picture of vesicles 




Figure S2: EV uptake by cardiomyocytes and endothelial cells. Single channel views of Figure 
3D, showing the distribution of the EV signal (PKH67) compared to stainings for DAPI, endothelial 
cells (PECAM-1) and cardiomyocytes (MF20).
Figure S3: Distribution of proliferation. 
Analysis of proliferating cardiomyocytes, 
endothelial cells and other/interstitial cells 
from level 4 through 8 in the heart. Increase in 
proliferation starts at level 5 and peaks at level 6.
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Figure S4: Yap signal after EV injection. Single channel representation of Figure 5A, showing 






Myocardial infarction leads to a long and complex interplay of processes within the cardi-
ac tissue. In short, ischemia in the cardiac wall results in cell death, which triggers an in-
flammatory reaction, necessary for the removal of cell debris, but also affecting the cardi-
ac ECM structure. In order to compensate for the loss in cardiomyocytes and to strengthen 
the cardiac wall, (myo) fibroblasts migrate to the infarcted area and form collagen rich 
scar tissue. New blood vessels are formed in an attempt to restore blood flow. Lastly, the 
unaffected myocardium compensates for the loss in contractile force by, for example, hy-
pertrophic remodelling.1 Even though this does not result in repair of the myocardial wall, 
it encompasses the best efforts of a tissue under strain to maintain its function. Regener-
ative therapy for the heart involves a treatment that should alter these processes in such 
a way that the injured area regains its functionality, without loss of cardiac output. The 
aim of my thesis was to explore different processes involved in cardiac repair and develop 
a possible therapy for cardiac regeneration. 
Regenerative processes for cardiac repair
The different cellular responses after MI each serve an important role to regenerate the 
heart. However, the balance between these cellular responses should be precisely tuned, 
otherwise complete repair is not possible. Cell death is an immediate consequence of is-
chemia and reperfusion, and is the major factor for the loss in cardiomyocyte numbers.2 
Protecting cells from apoptosis and necrosis by inducing survival pathways would there-
fore reduce the initial infarct size. However, in order to completely heal the infarct, new 
cardiomyocytes are needed within the myocardium via stimulation of proliferation of en-
dogenous cells and/or transplantation of exogenous cells. The heart was long thought to 
be a post-mitotic organ, but the research by Bergmann et.al. showed that the mature heart 
was capable of self-renewal, albeit only a very low rate of 0.3-1% per year.3,4 Following 
this finding, multiple means were explored to induce cardiac proliferation,5–7 among which 
also affecting YAP (Yes-associated protein) in the Hippo pathway.8,9 Besides proliferation 
of cardiomyocytes, cardiac progenitor cells are also able to replace the lost cardiomyocytes 
by their ability to migrate to the infarcted region, expand and differentiate. However, their 
number is not sufficient to produce the necessary number of new cardiomyocytes. 
Since an MI also leads to the deterioration of blood vessels, neo-angiogenesis is an impor-
tant process for restoring the blood flow to the infarcted area. Without new blood vessels, 
any newly formed cardiomyocytes is unable to survive. Even though a hypoxic environ-
ment already induces angiogenesis, via production of e.g. VEGF, further stimulation of 
this process might lead to complete neovascularization of the affected area.10
The extracellular matrix also undergoes extensive remodelling throughout the healing 
process of the infarcted ventricle. Firstly, inflammatory cells that homed to myocardium 
in response to the hypoxia and cell death, not only clear cell debris, but also release 
proteases such as e.g. MMPs.11 These proteases break down parts of the ECM, which on 
the one hand makes it easier for migrating cells to enter the tissue, but on the other 
hand leads to weakening of the cardiac wall. Myofibroblasts that migrated to the site of 
injury produce new ECM, which helps to stabilize the cardiac wall and prevent rupture.12,13 
However, without new cardiomyocytes being incorporated, the production of new matrix 




organization. Therefore, the remodelled matrix does not provide a suitable environment 
for cardiomyocytes to form new contractile tissue. 
Paracrine signalling after MI
Cell-based therapy after MI has shown in the past that injection of cells can stimulate 
the regenerative process of the injured myocardium at multiple levels. Besides directly 
contributing cells to the newly formed tissue – e.g. endothelial cells and cardiomyocytes 
– they also influence the resident cells during the different phases of wound healing after 
MI. Although large numbers of cells are injected, only a small percentage of the initial 
cells injected can be found in the heart 3 months post-MI.14 The lack of cell retention 
contradicts the beneficial effects on cardiac function, angiogenesis and fibrosis.14,15 This 
supports the theory that the paracrine factors secreted by the transplanted cells are a an 
important contributor to the beneficial effect seen after MI. Paracrine factors, such as 
cytokines and extracellular vesicles (EVs), are able to influence cellular processes that will 
enhance tissue survival after MI, such as apoptosis and proliferation. Using conditioned 
medium from stem and progenitor cells, especially the vesicle fraction, demonstrated that 
this was sufficient to reduce infarction size, stimulated angiogenesis, and improve cardiac 
function to the same extent as injecting the cells. 16,17 These observation make EVs, such 
as exosomes, an interesting factor for future therapies. Cell therapy has several disadvan-
tages in a clinical setting, such as immune response and retention. Utilizing their secreted 
factors can overcome these problems and therefore be an interesting approach for future 
therapy. We do however need to understand which component in this conditioned medi-
um, such as cytokines or EVs, are necessary for this paracrine effect. 
The impact of Endoglin
Angiogenesis
One interesting factor in the aftermath of an MI is endoglin. Endoglin is a co-receptor in 
the TGF-β pathway and thus involved in TGF-β related processes, such as angiogenesis. 
Angiogenesis is an important process for regeneration and understanding the underly-
ing mechanisms to stimulate this is essential in order to improve therapies. Although 
VEGF is the key regulator of angiogenesis, many other signalling pathways, like TGF-β, 
modulate the growth and stabilization of new vessels. TGF-β has a biphasic effect on 
angiogenesis, depending on the receptor that transduces the signal: binding of TGF-β 
to ALK5/TGF-β receptor 2 (TGF-βRII) inhibits angiogenesis, while signalling via ALK1/
TGF-βRII is pro-angiogenic. Endoglin is a coreceptor for ALK1 and signalling via this path-
way leads to Smad 1/5/8 phosphorylation, while it inhibits the anti-angiogenic signal via 
Alk5/TGF-βRII and Smad2/3.18 Inhibition of endoglin by neutralizing antibodies reduces 
neo-vascularization19, which underlines the importance of endoglin in angiogenesis, and 
makes it an attractive strategy for anti-angiogenic therapies.20 Research has shown that 
endoglin can also interact with the VEGF receptor, which resulted in retention of the 
VEGF-receptor on the surface of the cell membrane and thus reduced degradation of the 
VEGF-receptor. A neutralising antibody against endoglin inhibited VEGF signalling and tip 
cell formation.21 These results corroborate our findings, showing that endoglin is a cru-
cial factor in angiogenesis, as shown in chapter 4. Even though vasculogenesis did occur 
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when differentiating endoglin deficient embryonic stem cells using embryoid bodies, the 
reduced endoglin levels prevented the formation of a complex vascular network.22
Because of the strong pro-angiogenic effect of endoglin, it is no surprise that the expres-
sion of endoglin is upregulated after MI. One week post-MI, endoglin is predominantly 
expressed by the endothelial cells in the border zone of the infarction, and not present in 
the scar myofibroblasts, confirming involvement in neovascularization.23Besides endoglin 
upregulation after MI in vivo, expression of endoglin was also increased in endothelial 
cells in hypoxia in vitro. The increase in endoglin resulted in enhanced endoglin/ALK1 
signalling.24 Comparison of the angiogenic response of wild type mice with mice that are 
heterozygous for endoglin (Eng+/-) showed that endoglin expression and the number of 
newly formed vessels was higher in wild type mice after MI, and long term follow-up re-
vealed reduced cardiac function in Eng+/- mice compared to wild type animals.23 
Fibrosis and remodelling
While endoglin is supportive of cardiac repair when taking into account its stimulating 
role in angiogenesis, it can have adverse effects during cardiac remodelling and fibrosis. 
Endoglin is expressed not only on endothelial cells, but also on fibroblasts. As TGF-β is a 
well-known factor in fibrosis, it is not surprising that an increase in endoglin correlates with 
an increase in cardiac fibrosis.25 Interestingly, reduced endoglin levels was also reported to 
limited fibrosis in a cardiac overload model.26 Transplantation of cardiospheres, generated 
from rat heart explants outgrowths, into the myocardium one month after MI showed 
a decrease in hypertrophy and an increase in cardiac function, relating to a decrease in 
TGF-β signalling via Smad 2/3. This change in TGF-β signalling was caused by an increase 
in soluble endoglin, cleaved from the cardiospheres and fibroblasts by MMP14. In vitro 
coculture of cardiospheres with fibroblasts indeed showed that the presence of soluble 
endoglin was able to reduce TGF-β1 induced Smad2/3 signalling.27 Since soluble endoglin 
can interfere with TGF-β1 signalling, this might abrogate the pro-fibrotic effects of 
TGF-β in the remodelling phase of wound repair post-MI. Therefore, increasing endoglin 
is desirable in a time-dependent manner, in order to stimulate only the pro-angiogenic 
effect.
Influence of EVs on regeneration
Angiogenesis
Angiogenesis is not only stimulated by cytokines released by the cells in the infarcted 
area, but also by the proteins and miRNAs present in EVs secreted by the injured cells. 
Studies in tumour research have shown that EVs can play an important role in angio-
genesis. Vessel growth is essential for tumour progression and it is therefore not sur-
prising that tumour cells release EVs that contain factors to stimulate angiogenesis. 
These pro-angiogenic factors include VEGF and microRNAs miR-21 and miR-126-3p.28–31 
EVs from tumour cells containing pro-proliferative mRNA have been shown to 
increase the mitosis of HUVECS.32 Furthermore, uptake of tumour EVs by endothelial cells 
in vivo increases the permeability of the blood vessels, which in turn enhanced the forma-




The composition and content of EVs, i.e. the miRNAs, proteins and receptors present in 
and on the vesicles, is (partly) reflective of the cytoplasmic and membrane composition of 
the donor cell at a certain moment in time. Any change in the physiology and environment 
of the cell, e.g. a drop in oxygen levels, will result in a change in the composition in the EVs 
they secrete. Hypoxia induces stabilization of Hif1-α followed by induction of VEGF and 
Angiopoietin 2 transcription within the hypoxic cell.10 Therefore it is no surprise that this 
increase in angiogenic factors is mirrored within the EVs they secrete. EVs from glioblas-
toma cells, cultured in hypoxic conditions, were shown to stabilize tube structures of ECs 
under hypoxia.34 Moreover, EVs from hypoxic glioma cells induce the secretion of growth 
factors and cytokines by endothelial cells and stimulate pericyte activation and migra-
tion.35 Not only the content but also the number of EVs secreted by cells is influenced by 
hypoxia, for example a two fold increase in exosome secretion by MDA-MB231 cells after 
24 hours of 0.1% O2.
36 
In our studies, we have found that EVs from CPCs are capable of inducing angiogenesis 
both in vitro and in vivo. This pro-angiogenic effect was highly dependent on the presence 
of the extracellular MMP inducer EMMPRIN on the EVs. We demonstrated that EMMPRIN 
was a key player in stimulating angiogenesis, as EVs with reduced EMMPRIN levels failed 
to induce migration and tube formation of endothelial cells. Moreover, the general infil-
tration of cells and the formation of blood vessels in a matrigel plug was decreased when 
EMMPRIN depleted from the EVs (see chapter 5). Other reports have shown that EVs 
from embryonic stem cells, cardiosphere derived cells (CDCs)and MSCs are also able to 
stimulate the proliferation of endothelial cells, corroborating our in vitro results.37–40 EVs 
from embryonic stem cells, human bone marrow cells and human CPCs increased vessel 
density when injected into the myocardial wall after myocardial infarction, demonstrating 
that EVs also induce angiogenesis in a hypoxic and damaged environment in vivo.28,37,40–42 
Analysis of the paracrine effects of CDCs showed that endoglin is one of the factors re-
sponsible for its proangiogenic effect. Knockout of endoglin in CDCs led to a decrease in 
the pro-angiogenic paracrine effect of CDCs in in vitro assays. Moreover, a decrease in 
vessel density was observed in the border zone of the infarction after injection of endoglin 
KO CDCs.43 We have shown that EVs from CPCs have high levels of endoglin in chapter 6. 
Injection of CPC EVs after MI resulted in an increase in the expression of endoglin in the 
myocardial wall, partly overlapping with the uptake of EVs. This suggests that delivery 
and/or upregulation of endoglin is beneficial for the stimulation of angiogenesis.
Cell protection
Protection of cardiac cells from ischemic damage shortly after myocardial infarction helps 
to preserve cardiac tissue and therefore will maintain cardiac function in the long term. 
In the last decade, transplantation of cells, e.g. CPCs, MSCs and ES cells, have shown a 
beneficial effect on cardiac function,14,15,27,28,37,40,41,44–48 but the studies have been ambivalent 
about the influence on infarct size shortly after MI.14,40,48 In order to understand these 
long-term effects, we sought to understand how CPCs and the EVs they secrete affect the 
myocardium shortly after injection. In our experiments (see chapter 6), we have observed 
a decrease in infarct size 48 hours after MI in the animals injected with CPCs. This effect 
is lost when Rab27A is knocked-down in the injected CPCs, Rab27a knockdown severely 
reduces exosome secretion, indicating that the effect on infarct size of transplanted CPCs 
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is due to the vesicles secreted. Although studies have shown that injection of EVs mimics 
the effect of cell injection on infarct size in the long term,37,39,40,42,49–53 we already observed 
a reduction in infarct size 48 hours after injection of CPC-derived EVs. Thus, not only are 
the EVs an important part of the cardioprotective effect of CPCs, the vesicles alone are 
already capable of reducing the infarct size. Differences in EV secretion or effectiveness by 
the different cell types transplanted might explain why not all studies have detected a de-
crease in infarct size after cell transplantation compared to injecting a high concentration 
of EVs directly into the myocardium.
The studies of Ibrahim et.al. and Wang et. al. show that pre-treatment of CDCs or MSCs 
with the exosome secretion inhibitor GW4689 successfully decreased exosome secre-
tion and abrogated their in vitro cardioprotective effects. After cell transplantation, the 
GW4689 cells were unable to reduce infarct size and improve cardiac function.28,39 Param-
eters such as viable cardiac tissue and wall thickness were decreased while scar mass was 
increased .39 Systemic blocking of exosome secretion in HSP-20 overexpressing cardiomy-
ocytes also failed to increase cardiac function in a mouse model of diabetes, compared to 
injection of EVs from the HSP-20 overexpressing cardiomyocytes.54 These results corrob-
orate that the effects seen two days after cell transplantation are due to the secretion of 
EVs by these cells.
Evaluation of the miRNA content of EVs has revealed that multiple cell survival miRNAs 
are present in EVs, of which miR210 and miR21 are mentioned regularly.28,42,48,55 Multiple 
of these miRNAs have targets in the pAkt pathway. This pathway has been documented 
to be involved in cell survival after MI.56 Moreover, one of the earliest studies with MSC 
exosome injection after MI showed an increase in pAkt after 24 hours.53 In vitro analysis 
of the downstream effects of EV uptake resulted predominantly an increase in pTEN-pAtk 
signalling. It was shown that the miRNAs present in the respective EVs were responsible 
when similar results were obtained with transfection of mimics or miRNA. Altogether this 
is indicative of cardioprotective effect of EVs through the pAkt pathway. 28,37,42,48,51,55
Proliferation and migration
Proliferation is essential for complete regeneration after myocardial infarction in order to 
replace the lost cells. New cardiomyocytes can restore contractile units, while prolifera-
tion and migration of endothelial cells provide new blood vessels and fibroblasts help to 
strengthen the cardiac wall and aid in cell alignment. All together, these cells are able to 
restore cardiac function. However, since their endogenous proliferation and regeneration 
is not sufficient to restore the normal cardiac tissue, (myo) fibroblasts populate the infarct 
area and produce a collagen rich scar to strengthen the cardiac wall and replace the lost 
cells. 
Proliferation is known to be influenced by EVs, which is mostly studied using tumour 
cells. EVs from gastric cancer cells are able to induce proliferation of these cells in an Akt 
depending manner.57 Mast cells secrete EVs able to induce proliferation and stimulate the 
migration of lung cancer cells, via activation of the PI3/AKT pathway due to the presence 
of KIT, a growth factor receptor, on the EVs.58 Furthermore, EVs from T cells are able to 
promote the invasion of tumour cells by inducing MMP9 expression and activating the 




stimulated by tumour EVs to induce the expression of pro-angiogenic genes, as seen in 
melanomas. Together with an increase in matrix proteins, this enhances tumour recruit-
ment and growth.60 Vesicles can also influence bone marrow cells to enhance tumour 
growth and increase the vascular density in the tumour mass.33 
Even though these effects on proliferation and migration are detrimental in tumour pro-
gression, it does confirm that exosome signalling is able to influence the proliferation and 
migration of cardiovascular cells needed for cardiac regeneration. EVs for cardiac repair 
can in theory be isolated from any cell type, but all possible (side) effects of these EVs on 
the recipient cells need to be investigated. Although EVs isolated from tumour cells are 
very potent and stimulate many beneficial effects necessary for cardiac regeneration, the 
chance of oncogenic activity makes them less suitable for a potential therapy. Therefore, 
isolating EVs from cardiac specific donor cells such as CPCs reduces the possibility of 
transferring unwanted stimuli. Adverse effects of EVs are often related to their systemic 
administration and can therefore be decreased when EVs are locally delivered. Modifica-
tion of EVs through hypoxia and overexpression or knockdown of specific proteins can 
further increase the effectiveness of the EVs, but any undesirable effects of the modifica-
tion should be thoroughly investigated.
EVs from various cell sources have been studied for their effect on cardiac regeneration 
and an increase in cell proliferation was observed. Endothelial cell proliferation is in-
creased after stimulation with MSC or cardiomyocyte derived EVs.40,61 Both MSC and car-
diosphere derived EVs were able to increase proliferation of cardiomyocytes,39,62 while 
EVs from ES cells and rat MSCs stimulated the proliferation of CPCs.37,47 Studies aiming to 
identify the mediators of cardiovascular cell proliferation showed miRNAs, such as miR-
291, miR146a and miR147 are responsible for this effect.37,39,47 In vivo proliferation has 
only been analysed in two studies. Khan et.al. show that treatment after MI with ES-de-
rived EVs increases the proliferation of cardiac progenitor cells in the heart.37 Zhu et. al. 
also saw a slight increase in CPC numbers as well as proliferating cardiomyocytes, which 
failed to reach significance.63 We have shown that EVs from CPCs are able to increase cell 
proliferation in the infarct border zone of the heart, 48 hours after MI, explaining why 
the infarct size is reduced. In depth analysis of which cells respond to exosome treatment 
reveals that primarily the number of proliferating cardiomyocytes and endothelial cells is 
increased (see chapter 6). These cell types are vital for restoring cardiac tissue contractil-
ity and viability. 
Boundaries and challenges of regenerative therapy
Cardiac regeneration requires an interplay of several processes. We have shown the im-
portance of endoglin and EVs in angiogenesis and the potential of EVs on infarct reduction 
and proliferation, as shown in chapters 4, 5 and 6. Endoglin can be an interesting target 
for a therapy, as its role in angiogenesis and vessel stability is well known. However, 
angiogenesis is not the only process endoglin and the TGF-β pathway play a role in. For 
example, homing of inflammatory cells and tissue fibrosis are also affected by a change 
in endoglin/TGF-β signalling. Therefore, any treatment changing this signalling pathway 
should be applied locally and in a time-specific manner. 
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EVs have the advantage that they are rapidly taken up by cells, not having the problem of 
retention seen with cell transplantation. However, this rapid uptake does imply a short term 
and short range effect of the EVs, which could be circumvented by multiple treatments or 
a slow release delivery system. Though quantification of total EVs uptake is very difficult 
in order to compare to percentage of cells retained in the heart, the spread of the exosome 
uptake clearly shows that a large area of the heart can be targeted. For translation into 
a clinical setting, challenges such as the number of EVs and injection strategies must 
be addressed. Furthermore, patient details such as sex, age and comorbidities may 
also affect EVs dose and effectiveness. One study has compared intracoronary injection 
vs intramyocardial injection of cardiosphere-derived EVs in a large animal model. 
Figure 1: Hypothesized potential of EV treatment after MI. A therapy with EVs has the 
potential to increase the number of cardiomyocytes, promote angiogenesis and reduce scar 




They concluded that only direct injection into the myocardium resulted in preservation 
of cardiac function. They also observed a decrease in scar size one month after MI.64 This 
large animal study shows that intramyocardial injections of EVs are safe and can lead to 
long-term effect on scar size. 
Future perspectives
The ultimate goal is to develop a ready, off-the-shelf, universal therapy able to regener-
ate the heart after MI. The studies done so far have shown that endoglin is a promising 
pro-angiogenic target and that EVs from several cell sources are able to beneficially in-
fluence the heart after MI in preclinical models. Yet several questions remain before the 
leap to the clinic can be made. Ideally, EVs should be used directly after the occurrence 
of an MI, at the time of opening the vessel, to serve as a direct cardiac protection agent 
and deliver the first regenerative stimuli. An overview of the potential implications of EV 
treatment after MI is shown in Figure 1. How EVs can best be isolated and stored in order 
to fulfil this requirement needs to be investigated. Since EVs are sensitive to changes in 
the cells environment, cell culture and exosome isolation needs to be optimised and stand-
ardised. Nevertheless, this also provides possibilities to modify and improve the isolated 
EVs, for example by harvesting more angiogenic EVs from hypoxic cells. Furthermore, 
artificial methods can be used to increase the cardioprotective effect of EVs. Genetic ma-
nipulation of donor cells can increase the levels of beneficial RNAs and proteins in the 
secreted EVs. This type of modification requires a more detailed knowledge about the 
exosomal content and transmembrane proteins in the exosomal membrane, in order to 
find the most suitable targets for modification. An interesting direction for EV modifica-
tion would be to introduce specific cardiac homing proteins to the vesicles, which would 
make intra-venous administration possible for cardiac treatment. Lastly, more knowledge 
is needed about autosomal and autologous application of EVs. EVs from MSCs and CPCs 
are immunosuppressive according to the first reports, but in-depth analysis of their effect 
on the immune system is needed before moving to the clinic.65,66
Conclusion
Complete restoration of cardiac function is the aim of regenerative therapies. An all-en-
compassing therapy might not be attainable yet, but our increasing knowledge of the 
factors involved in regeneration paves the way for smaller, targeted treatments. In this 
thesis, we explored these regenerative processes and different means to enhance them. 
We found that endoglin is a crucial factor for angiogenesis. Reduction in endoglin levels 
is sufficient to prevent correct vessel and network formation, making endoglin an inter-
esting target for pro-angiogenic therapies. Angiogenesis was also stimulated by the EVs 
secreted by our CPCs. Furthermore, these CPC-derived vesicles are able to convey cardi-
oprotective effects leading to a decrease in infarct size and an increase in proliferation of 
cardiac cells. More research into their content and the cellular and systemic consequences 
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Myocardial infarction (MI) results in a permanent loss of function in the heart and thus 
affects these patients for the rest of their lives. Even though fast interventions and med-
ications to reduce recurrence have substantial increased the quality of life, there is no 
therapy available that addresses the heart of the problem: the loss of cardiomyocytes. The 
endogenous regenerative capacitiy of the heart is insufficient to deal with the damage 
after a MI. Even though there are new blood vessels being formed and there is limited 
proliferation of cardiac progenitor cells and cardiomyocytes, in the end the affected tissue 
is not sufficiently perfused and the lost cardiomyocytes are replaced by scar tissue. To 
fully regenerate the heart, an intervention is needed directly after the occurrence of an 
infarction, in order to reduce the damage to the myocardium. Furthermore, new cardio-
myocytes are needed, either through stimulating proliferation of endogenous cells or cell 
transplantation. Lastly, other processes needed in regeneration such as angiogenesis also 
need to be stimulated. A central point in stimulating regeneration is cellular communica-
tion: how do (exogenous)  cells induce survival and how can we alter the communication 
signals to increase regeneration?
Cell transplantation has been a focus of cardiac regenerative studies as it holds the poten-
tial to completely replace any lost cardiomyocytes. In chapter 2, we explored the different 
approaches taken in cell transplantation studies. Several different cell types have been 
used in both pre-clinical and clinical studies, such as bone marrow mononuclear cells 
(BM-MNCs), mesenchymal stromal cells (MSCs), and cardiac progenitor cells (CPCs). Of 
these, only the CPCs have the ability to differentiate to cardiomyocytes, but all three have 
shown to increase cardiac function in preclinical models. More interesting, the results 
from these transplantation studies show an effect on cardiac function and vessel forma-
tion with minimal retention and differentiation in the heart, suggesting that the paracrine 
effect of the cells is a major factor. 
Besides replacing cardiomyocytes, restoring blood flow to the infarcted area is vital. 
Therefore, studying the mechanisms of angiogenesis in vitro can provide relevant insights 
for stimulating this process in vivo. It is important to use the proper assay to answer an 
angiogenesis related question. The methods and uses of a metatarsal assay, spheroid assay 
and embryoid body assay are described in chapter 3. Since angiogenesis is a process that 
is influenced by many signalling pathways, among which TGF-β, we sought out to iden-
tify the role of the TGF-β coreceptor endoglin in chapter 4. Using a variety of methods, 
among which embryonic stem cells from endoglin knockout mice and shRNA mediated 
endoglin knockdown, we showed that vasculogenesis is not hampered by the loss of en-
doglin. However, proper angiogenesis, among which network formation, was impaired 
when the endoglin expression was reduced, showing that endoglin and TGF-β signalling 
are indispensable for angiogenesis. 
Since the effect of MSC and CPC transplantation after MI seems to be partly due to the 
paracrine factors they secrete,  and extracellular vesicles (EVs) are a major part of the 
paracrine factors, we investigated if the EVs from MSCS and CPCs can affect angiogene-
sis in chapter 5. Both in vitro and in vivo angiogenesis was significantly improved in the 
presence of these EVs. In detail analysis showed the presence of several pro-angiogenic 
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factors, among which EMMPRIN. Knockdown of EMMPRIN resulted in a pronounced re-
duction in angiogenesis and cell migration.
The effect of CPC derived EVs after MI is studied in chapter 6. Here, we investigated the 
effect seen short term after MI, after 48 hours, to see if EVs can reduce the initial damage 
and convey survival signals to the tissue. Comparing CPC transplantation and EV injection 
on infarct size reduction showed similar results, concluding that EVs are able to mimic 
their donor cell effects. Furthermore, total proliferation was increase in the border zone 
and infarcted area as seen by an increase in Ki67 and Yap. Interestingly, in depth analysis 
showed that mainly endothelial cells and cardiomyocytes were increased in proliferation.
In summary, this thesis studies various means in which cellular communication, through 
cytokine signalling and EV secretion, plays a role in the regenerative processes after a MI. 
It shows the importance of proper angiogenesis and how the EVs from various cell types 
can stimulate this. Moreover, these EVs have similar effects as their donor cells after MI 
and can stimulate proliferation in the heart. Thus the use of EVs as a therapeutic to restore 
cardiac function is a viable alternative to using cells.
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Nederlandse samenvatting
Een myocard infarct (MI) resulteert in permanent verlies van hartfunctie en heeft daarom 
invloed op de patiënten voor de rest van hun leven. Ook al is de kwaliteit van leven 
aanzienlijk verbeterd door snelle interventies en medicatie om herhaling te voorkomen, 
er is geen therapie beschikbaar die zich richt op het centrale probleem: het verlies van 
cardiomyocyten. De endogene regeneratieve capaciteit van het hart is niet voldoende om 
om te gaan met de schade na een hartinfarct. Ondanks de formatie van nieuwe bloedvaten 
en de gelimiteerde proliferatie van cardiale voorlopercellen en cardiomyocyten, uiteindelijk 
wordt het aangetastte weefsel niet voldoende doorbloed en de verloren cardiomyocyten 
worden vervagen door littekenweefsel. Om het hart volledig te regenereren is een 
interventie nodig direct na het ontstaan van het infarct, om de schade aan het myocard te 
verminderen. Bovendien zijn er nieuwe cardiomyocyten nodig, door het stimuleren van 
proliferatie in endogene cellen of transplantatie van cellen. Andere processen die nodig 
zijn voor regeneratie zoals angiogegenese moeten ook worden gestimuleerd. Een centraal 
punt in het stimuleren van regeneratie is communicatie tussen cellen: hoe induceren 
(exogene) cellen overleving en hoe kunnen we de communicatie signalen veranderen om 
de regeneratie te vermeerderen? 
Cel transplantatie is lang de focus geweest in regeneratief onderzoek omdat het de mo-
gelijkheid heeft om de verloren cardiomyocyten volledig te vervangen. In hoofdstuk 2 
verkennen we verschillende aanpakken die genomen zijn in cel transplantatie studies. 
Een aantal verschillende cel typen zijn gebruikt in (pre-)klinische studies, zoals beenmerg 
mononucleaire cellen (BM-MNCs), mesenchymale stroma cellen (MSCs) en cardiale voor-
loper cellen (CPCs). Van deze cellen hebben alleen de CPCs het vermogen om te differen-
tiëren naar cardiomyocyten, maar alle drie hebben een positief effect op de hartfunctie 
in preklinische studies. Interessant is dat de resultaten van deze transplantatie studies 
hebben laten zien da teen effect op hartfunctie en bloedvat formatie aanwezig is ondanks 
de minimale retentie en differentiatie van de cellen in het hart, wat suggereert dat het 
paracrine effect van de cellen een grote rol speelt. 
Naast het vervangen van cardiomyocyten is het ook het herstellen van de bloedtoevoer 
naar het infarct gebied van groot belang. Daarom kan het bestuderen van de mechanismes 
van angiogenese in vitro belangrijke inzichten geven om dit proces in vivo te stimuleren. 
Het is belangrijk om de juiste analyse te gebruiken om angiogenese gerelateerde vragen 
te beantwoorden. De methoden van een metatarsal assay, spheroid assay en embroid 
body assay zijn beschreven in hoofdstuk 3. Omdat angiogenese een proces is dat door 
vele signaleringsroutes wordt beïnvloedt, o.a. TGF-β, wilden we identificeren welke rol 
de TGF-β coreceptor endoglin speelt in hoofdstuk 4. Met verschillende methoden, zoals 
het gebruik van embryonale stamcellen van endoglin knock-out muizen en knockdown 
van endoglin met behulp van shRNA, hebben we laten zien dat vasculogenese niet wordt 
verminderd door de afwezigheid van endoglin. Verschillende aspecten van angiogenese, 
zoals netwerk formatie, zijn echter aangetast wanneer de expressie van endoglin is 
verminderd, wat laat zien dat endoglin en TGF-β signalering noodzakelijk zijn voor 
angiogenese. 
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Omdat het effect van MSC en CPC transplantatie na MI deels te danken is aan de paracrine 
factoren die ze uitscheiden, en extracellulaire vesicles (EVs) een groot onderdeel zijn van 
de paracrine factoren, hebben wij onderzocht of de EVs van MSCs en CPCs angiogenese 
kunnen beïnvloeden in hoofdstuk 5. Zowel in vitro als in vivo angiogenese was significant 
verbeterd in de aanwezigheid van deze EVs. Gedetailleerde analyse heeft laten zien dat 
verschillende pro-angiogene factoren present zijn op de EVs, waaronder ook EMMPRIN. 
Knockdown van EMMPRIN resulteerde in een opvallende vermindering van angiogenese 
en cel migratie.
Het effect van door CPCs uitgescheiden EVs na MI is bestudeerd in hoofdstuk 6. Hier 
hebben we het effect op de korte termijn, 48 uur na MI, onderzocht, om te zien of EVs de 
aanvankelijke schade kan verminderen en overlevingssignalen kan overbrengen aan het 
hartweefsel. Een vergelijking van CPC transplantatie en EV injectie liet zien dat hun effect 
op de vermindering van infarct grootte vergelijkbaar is, dus de EVs kunnen het effecten 
van hun donor cel nabootsen. Verder was de totale proliferatie in de grenszone en het 
infarct gebied vermeerderd, wat te zien was door een stijging in Ki67 en Yap. Diepere ana-
lyse liet interessant genoeg zien dat voornamelijk de endotheel cellen en cardiomyocyten 
meer prolifereerden.
Samengevat, dit proefschrift bestudeert de verschillende middelen waarmee cellulaire 
communicatie, door cytokine signalering en EV secretie, een rol speelt in de regeneratieve 
processen na een MI. Het laat het belang zien van de gepaste angiogenese en hoe de EVs 
van verscheidene cel types dit kan stimuleren. Bovendien hebben deze EVs vergelijkbare 
effecten als hun donor cellen na een MI en ze kunnen proliferatie stimuleren in het hart. 
Het gebruik van EVs als een therapie om de hartfunctie te verbeteren is een haalbaar al-
ternatief voor cel transplantatie.
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mit mir gefreut über den schöne Sachen und alle Fortschritten. Du hast mein Leben so viel 
schöner gemacht. Danke, für alles.
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